var title_f22_32_23040="Trigger points myofascial pain";
var content_f22_32_23040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trigger points in myofascial pain syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with myofascial pain syndrome have tenderness within the affected muscle and soft tissue. Trigger points arising in the erector spinae muscles, the gluteal fascia, and the presacral fascia are common.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23040=[""].join("\n");
var outline_f22_32_23040=null;
var title_f22_32_23041="Urothelial CIS D";
var content_f22_32_23041=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial carcinoma in situ (CIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 299px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAErAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6jjIYUu3mohlBSpLlqou3YsiikU5pakgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKOtFHegA/CkpeKQ0AFJS0UAJSdaXtRQAnrSUppKQwNJ3paQ0AIaM0vakNAxtIRTqQ0DGmilNNPSqKQwsu7GeaGqssTCbPbNWW6dqY0W3QMMVCIfmzVmilcyUmhAMCloFFIQUUUUAFFFGKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBGIUZNNjkV+VOaWRA6kHoaZBCsKbUGBQBJSmiigBKKU0lAAaQ0tIaACkpe1JSAQ0UtJ3oGJ3o70UUAN7Uhp1NNMYlJ3paSgpCHimmlNIelUUi7RTJJAgyTUIu0JwDmkk2ZJN7FmimowYZBp1IQUUAYooAKKKKACiiigAooooAZJIEFOU7hmo5ULsPQVIowMUxu1hs0mxc1HHPk/NxSXg/dFvSqMM6uMkjFNK6NIQ5o3NVSCMilqtDIBgZ4qyOlJqxm1YKKKKQgooooAKKKKACiiqN9O8R44FNK5UYuTsi9RXI3/iyy0+dEurqONmOACeTXT2d1HdQrJEwKsMjFVKDirsqdKUNyeiiioMwooooAKKKKACiiigA7UGiigBDRS0GgBKSlpDQAfyooNJSADSUppO1ABSH3opD1oGB6U2nUh60xoQ9aaacaaaCkIaYc0/t/Wmt0qikcpD4i+3RfI2cjir9lvPzSHAryfQdUGm20Abc7BQDu9al8T+PrizszINsaL129a7nR1tE9R4VpaaI9oi1GGMAM4/OrC38DfxV8vWvxTSWcLIJgCcZ4ro38YXLhWtH3qcHrSlg2tzB4OLV4yPoE3sAHLimLqNsTjzBXg9x4tubWye5vJNsajPX9K86vPiXq13f4tpDFEWAAHX8aUcE2ZywkYr3mfYkc8Un3HU/jUteYfCw3moxfaLq4IVVU7T1ORmvT65asPZy5TlrU1Tlyp3CjNZt1qKxThDViCYTYINTyvclwaV2WqKKKkgKKoX2oLauFIyTUdtqQuGKgYqlF7mipSa5raEOs3eI2jX0rnHupIYML61qasD5pNVUs1uFGOa3ikkd1PlhE0dKM13ErA4xW/GNqgE5NUtItfs1uBV+sZu7OKrPmloFFFFQZBRRRQAUUUUAFU9ShEsBB9KuUjAEYNNOzHF8rufInxisrzS/FEkzs5hmO9Dmu++B3ji4uk/su8cu6DMRPXHpXafGDwVH4i0IyQssd1bkyKW6EY5Br5t8F6svh/wAURyytJmKTaPL6da9Sm41qVnudkZqa1PtW0uBPGD0OOanrF8NzrdWUNwhysihh9CK1JLiNHCk8+leY42djlnG0rImooByM0VJAUUVF5wDFTQNK5LRUazRsSAwyO1SCgVrBRRQelAB2pKp3eo2loMzzIv41HDq9nKAVmUA8Ak4zT5WWqcmr2NCg1HHNHIuUdWHsc1JSItYSikY4pokU5AYEj3oAdRSbgaXNADaO1KcUn1oGJSHrTu1J9aBjaQ0p60lBSGtjBPpUKTByRUzYwc9DUCRhWJqikfPOrzQWP+lSMEtJl8xGboPauP1rXtJ1w+Qsjg4GSVwM10tzbnxf4OurSAhbq1xLGo/iA6ivEL+KazuniIKshwfrXtUlGSue1XqypPkkjrn8NncnkuNueGHOa6nS7b7FaBXJZwfxzXJeCNVkW5WG4zIhPAPY11V9runwXTxddoydgyAfT61pKMk7F0nTtzrQb4jzqUKWW7yxnduPQn0rl9G0mS21SN54/wB2hBLHoRXSalqVj/ZazQNvdxgMeqn3rlLK+vLpmgjLFQx5Y4AHrThF21MaqjzXep7X4b8YWliI4Le4cT8Dk9favT9L8axSxqLpQrEffFfMWnX2i6ZIoubiSS5zy6JkKc/rXZHxJpkMyRRanHIGUEBlIxn+Vc9XDKeyIcKVX+Jue13Vyt3L5kZyvYirVpdNCQM15to3iX7IxRgskeA3B4IPpXSW2orqOJLJ/mHJQ9a5ZUXHcidLlXdHfW1+CAGNXo5VccVx1vLMsY3qd1aEOoJbR77hwgA7mueVPscU6Kfwl3WrUyfOvJFY63X2CKWRlyUUtj1wKjufG+mb/KWeNn6YBrLuvFNkyy5jLYBGeMZxVxpzS1R0UYTceVrQ4zX/AIgXflvPhIYUJBbGTmuTX4rXFtMAJZAM5JHp9KzPF9nPrEvlQXkKKrFhCGHJrnYfAWqyPukmgSMDduLE/hx1NelCnSS947p3j7sI6Hvfhb4myXMKSTI0kLHG/bg13dt4y0uWHe0pVv7uOtfJ2r+KrnT4Y9NsRsFuNryFcFm+naquh+Nb+2u0N1I00RblT6VlPAqeq0OepSoSfvKz8j7S03VLfUVzAT+NXXdUXc7BR6k1494B8QLcSQSwM/lSHr2rR+JHiCXTLuKPcxMqEpk/KDXF9WbqciOWphEqnKnoelfa4WJCSqT9eKpTavFGdqnc4OMd8+lfPK+O9VtpFHmgxg8iruo+MpLjQpbq2SZJyxVmPT6it/qEky44OPc9yXxNp3meVLOiSg4K5zg1qJdwvEJVkGw96+Op/FkthKzMxd2GQv8A9epIvitq6WzW52GNjkjJ4FXPLv5WTLCw7n1BceL7WK9MRBEPZyPvfSt+zvbe8iWS3lVgRnGeRXy7pHi+bXGkjlsQiqo2SKx49jmuj0vWr3Typjmbb9f5VlUwiWi3Oj6jTqwvTdj6A1CFZ7SWNujAivn64+Dkl34me4tplW1aTeVZeRzXqPg/xO+pRhJ3ByO/BrtIVRV3LjmsFKVB2Rwzpug+WS1KWkWA07To4EP+rTAHpgVxEOqX114keIxSKgbGMYxXo3mJz8y/nUBW1RmmAjz1LCsJXl16lYfEey5nKN21b0J4gRGoPXFPqk+p2iLkzL+FLb6jbT4CSjJ7GnyvexzuEt7Fymsit1FKzBRliAPWo0mjdtqupYdgaknXoZWoQvFIWTIU88VLZXhG1X5X19PrWk5Qg7iPxNZl1BFHlo3UMc/xAVad9DZSUlys1QQRwa5fxz4hXRbBVQjz5jtX/ZHc1q6fLhCd2RjpnP5V4/8AEi5ku9Z5Y4jO0DtWlGnzSszfCYdTq+9sihPrn2sOryM0rHqegrC8b+Mb3SbOC2sdyyBT5jMAQSen4iuJ1PxPeWGsyEQRhVfI8xSc11Wh/YPHlw0V4FjvXGACTj8K9CNHklzz1R69atTceSnoyt4L+IGp3E4gmmkWRBu8xGwDz3HrXq2i/EW8EXlXKq7fwu3Ga87TwrLpV69rY2ikKdpKr8x9zmpTG1m/lyqGYNwQentTnCnU2REaUKkUqmp9B211/bOjx3Nu2wuvOOx7ivn/AMf+PtV8NeILmyhdtyNklu4P9K9E+HWstHdm3LYgcZ8snO01xf7UOi28UFhrEcR82VjA7r04GRmuSjFRq8j6nnyTw83BbMz/AAp8cLqOZBqsYeLoWUn+Ve9+G/EljrtpHNaSDLruCnrivg21YeYAeRmvfvhjfyxabDPE7hIzyB2x2ravQi1dKxaoRrp9z6IkuUVtpYA09JVYZBrlFmN4BPC2SwB9qv6XI8rPH82UOG4OK89xscs6CitzXe6jR9pODUqsGUFTmuX8S3tvpgWa6kCL71a8P6pFeRBo2yp6UrEumuW8XqdAfemmgtVC5vhC2CvFJIzSLppm3BqtFerIMgYqdXDCqL5Wj5k8M3g8OXxupJPl6BfUVvavp3hvxpJ9rs5ILW9kx5kbqAGPr9a8310PHqG+YOY+wNUkvZEuUa1xGAcjDc17iofai7M9OtVc5cx6E3gX+ygSsKgDowAwfxryfxNpd3pOqPFKjBSdyse4NfRPgLV/t2mmy1JSySLt/ecg1d8a+DdMOiLNtEuzkA88CsoV3Tnyz6kOrzpRloz570XTZb/SihYR5kBVm47c1UuhJapPagEeXxgd/evbNL/srUIbeBIVikhXCKq4B9q5bxJ4WibWvtdp8kbD95F0II6n6Vsqt5NSRcouyS3PIWjlfJwc+tMWSSJiG6+9ewS+EftVozQBSmBgKvIrnZvCKCJ/tm+NRkKV65qlNPYxdNoi8N63cy6bHZBV8yHLRv3x6Vo+FPFd3ZasYJ3YfNgZqmYLLwnB50Hm3lw6FSsi4VQfpXP2Grx32pR/aIUUs2Bt4pu0tUVGXLa7Ppd/GtrDo63E7orgYO44GfWvI/G/ji91SRoreU+QG6qcZridd1K4vtSaKMuYoTsVR09zUoglGnhpIyHZ+M8HAFRToRhqU1G7UUNtdUuPtAKs4bNdrrNtrGqaFZfZ1lbr5sa8FvQ+9afwl8J2muTiW5XJjO5s9/QV6drr6dpLfZ4rZSFGNwPIrOpWUZ8qWqFB68qPmTUNJvbOVFmhljcnI3KQTWxpuqarpcAjnWXyGOF35/SvcrpNJ1SGCORPnU5DMckVi+KPB8V8sTpIEt4RkleSxqliVLSaLinF36nimvXkE+qLJJAhYAByT1P+NXvD+nDUrlz9mQRnGMDoa3rPwTa3OozSXUzMC+QBwAPxqlrPiGHQb42mmCNo4mxvHOTVpp6RBq0m5np2l2raBp8NzfXkdlCuAAfX09zWr4t1bRb/AES3utUMM9uozHOrlT+H+FeG654svPEt9biY4hiUIkY6D1P1NQeI57mNLfTbiQ+VAu4J2Bbn+tQsNzNSb1Jck9X0PUtDg8KasPMsh5jrw0ckhGPeu8/4R/TrjT4oVjTylXGF6V4T4Pgj0nTpNSvpDHHIdsfq2K9V8BeKLO/SWOOZ2WMAneMYrGvTlum9CfeM3xL8NvDP2Brm6muYJIyT+6YdPTmvNYvD1gJZBZ2UkiqcLLOc/jivYPE2oQXR8mIeapPI7VxXjq++wWVpaWSqhcbmcDB+lVRlOWjZfs+Vc0kYlvo13NCEgBRE4PljGa0LS5k0+1ZNUcpDFyHbqPasm21K+OnFYrpo5UO4lDgkVZ1OabxD4Ymjc+ZfWx3gjguvv71u09pbGsZW1R0ej6/GYle0myh5Dqeh/pU3i74ga7b6Si2N2eflLqOceteV+G7iYadqenMRAZVzGznbh/8A9Vdt4R0pLHTwupzeemCcHkH2qJU4Rd3qNS9tHY5D/hK/E17cbRqN7I7/AMKsefyr1fwDceLv7LmGoySPEQNiykFgKhs7m0tmZ9Ps7aHAyXKjP1zUh8VS2rYF9ACeoDj8qmpJzXKokRocurZpveXcZO/zcE4YA8f/AFqtWHiT7K4GMsvQVinVri4Rmbynifqy4/pWbq15Y2Vt9pcujjoF7ms+Tm0aOj3be8tDrdS8WTu6tcysyHoC2AKpw+LI43G+6iQ45JfGPauCsdZtNcxbGQw3Ab5N33W9vauP8T2V5Z6lKLgMcnKk9MVpGgn7r0MXOCXuLQ+gYPFwkAWKZbgd9kgOK5D4ga9e295DPEZPLdMKxJ2g+n1ryfSL64tJonjk2SBsjBr08X0Gp6ekV9EsiuvK5wVPqPQ0eyVKSa1JilPZWMzR/HV/ZTwslw+5eSu47Wrrb+5XWbSO/iDlZeWHXY3cVxUfhYLJmO4j2esnBFdHZ6vp+j2BtFuI5SDlueCaKii9YocE4Suzndc0xpyQtoJWBz8wpPDen6jp16lxbafHEwPDheRW5F4iQ3alYPl/vE5BrpF1c3Kj5IkwOgHGKluSVkVK9R3RdiN/fxAwgrdlTvPrVU2Gn2kH+nMz3ZGSqHhP8TWDrHiqGwbymu9hPBWP0rF1jVl17Snt9LkRLkkfOzEEj0qI05fIa00uadn4m0vSNZLtqMQO7BUnnFd54nhi+IHgqS3s54rgx4kXYwOf/r4r5/h+Gms3D+ZJLbopOd2/Ndr4A0i+8KXjPHqcZJIBjVuPyp1KcdJReqMJc9WWsbHGw+BLiDUPLklAjDEHKkEV7J8N9Ijs1WHYTEw2tkZ69zXSeIrKHVrCGcRr5/eWMDOMd/WsZrqSztxbxkoByT3aspVHVia01FxairM9KtobKzCxCaMBR93PStSOaAJ8joRjPFeG6l4kXS7NpbhmyThQOpNc4fiUwuArLKi+qtWKwk56o554NN+9I9y8W+HrfxLaiF3ZQDkEetLoGhDR7dIVYsEHU9a830rx5dPGrxXGQfWuht/HVyw2yxrJ9OD+lZPDSi7kfUZxfNHqegPcqgAJqpK8UzcnmuRh19btjuPlk9AxrSt7kFQwb9e9TyNblfVeXc6BUSKInIqjJdusnykYqrNeFo2j25BGDn0qCCaJYmExAQc5PAAosEKVldngetW8V9seIqXb5Sh9fauams4VkwFeN16g9jSeZcQ3Bbc4O7rXTaPZx3Z8+7Tc2M5PQ176fIi92UtImubNleCaVWcfdGTnmvR4tUvdQ0aCG7Zw4B3A8ZrhL/X4rCXy7eNNoPXHNbmiaot8nmKwB7jPesqi59WiouNzYsrKG1cOwJBOTt4NTa7Fi6F1BIDHIoIzwQQMEGqt9dCCE7iTxwRXIy+IbuCchDvVugYZGKzjBt3NHNJ3O10e7dElAH3V5XtWZ4guFt7aWaaN0G0Ptx1NR+Hy16wkwUJ5OK338Py6taSQNJvjPAyORSdovUFJbnid/rl9PNKY22Rn+FQKSw0cX9zBdRjZtkAcAYycjpXodx8NktFkkku1ATlg4xkVNoOpaBot3G0kkTJESduM5Pr+dbSqRkvcMeW93M8p1u4kGqTlVCguT8owK6PwpDLre2yP+tHzRMf1FdTqz+F/EWqtPbLiSQ/Oq/L+Ndh4B8N6Vp939pt8swU43N/SplVSjqtR8r+JbHoHw68OxaF4bT5VNzLlnYUzxD4cGpozj5JM5BqzaeILbTYjHcP8u4lV6nFZ2rePLNYGS3RhIcgFsAV5tqkpuRywjVjO8Uc/L4dvIoMxhXUckY54p0UN1LpU8TKRIh285FUl8bTQQlJJY2x0bcOTUL+Oft0Pkp5LSL98J9410clRna/aPSR5/wDESV7a3AjcxlzhscZI7V5HeSF5c56GvfdfsbHWIcSbju5I7g+org9Q+HOoTOrWSxtbluJHIB/GuuE1y8r0Jrwk9Ucr4XtZrzUII4lJJYZxXqGreCn1S5W5YkbVAceoFavgbwfH4dR57yWFp8cAHJFbcuoAsypu5PyjPAqJVXe8B06fu6njfjd5F1MWUWVt7ZRGidsY6/ia6n4b2cmn6ddXd1lFnUKgPUqOp+ldTf2On3UiTXttHNcgYUlQTn+tZetaXf3GlahJAWU+WWVBxwB2q3UUoqOwKKjK7MnUPGVgt60PzhFbBZe30pnjG4tdS060urK4E23KkL1x64ryaSRlkZWJyT3qRbqWFQFdguc4Bq+SMbNdDN1nK9z0XwzALyZvvBApUk9zV1oG0AT3W4ttHAB/SuJ0vWrm2CyJIxx7101nrY1O3khvzu8wYJPFKSu79DWEo7dTlL6a81vUyyxtJJI33Yx0rotUupdB0eCyZs3R+Zh12+1ZN3ey6Pq0i2I8lVIAIHLDHXNSam0+vFJI0LSkYYCre67Ga91vuZMus3kysrXD7D1XdgY9KzXuCWzk1pSeHNQiUu8RVRzzVGS2kjVtyNx1Pai76Gb5upa0vXLqxkBgmYeq54Ndkmrxa5YGO42xSj8j7152kR3ZHeuh02NxYszIxUsACKVr7lUpNadCwlhdWt2GVDnOQVr0jUdLfVtH01pxjzUIdj2I6Vm+HD9qtEMqZKnAYdfxra1HWDY2AtpFyM5BHaspyd1bobKCj76OctvCGltu/wBIZJ0PG5wAT6VS1K9j0e8W3kcySDG7b0UVnXJlN48xlJRjuGfWsXxKZmvfMkBIdAR78Y/pWqj1buS5cqujodevp7iFJ7aZmtmXAwcYPoawIRc3DrGqsznrjtU/h1neOeJ+YsBiD0BrsfDUlg8n2aJNshB+bHU0r8uwW59WUNO0u6ugkRmKhB0HWutt7C5tbKdIZI5p1jJVQwPNY3i7UY/D9q62ny3cy4HfA7mvPPDuu31lqiSwytuLcgnIOazs5K9wc1TkaFzZXt5evHIjmfPzo3BWqjLNpk+1i6Sg/lXT+Pru6N7bMu6NJow7FeCfx9q5a7N1f/NJl3Q43dyK1TbVyJJLY9N8M642paS1vIwWccBu5rmdVhuo7hk80pKpyGp2gW8ejQo97Osc8nKoTyB71fvtdtTdhLhNwP8AHWaXK7pGtlKKcnqel+A9b3aJC17lmjG1tx4YVYutZ066ultsRGQ8gZG4ivOo9e09IzZC52KwwCPugntmuPbxFLYa4Z4o1LQkoGPXHSsfq/M29iXanruen+J/Dst/am3L7GDbkc9DXn0vg3VIZCAI2BbOd1epeGvEEGsabEGA8zaSEJ5JHpXEav4yMeovFDb4QMVO7r1p0nV1iuhpeMtZFrw/pD6fGsU7b3Jz64rtLWyjt7KSeaURqi7yW4ArL0XUIdQhSTAVxyRWprifatOmtGyokUqCKym23aRbbslE5O58V6cJiFnfA6kqcVq6ZrshXzLKbeh5POc15TrWh31pK6SRM6E8MvIIrV8GpeR3DAo8dvsO4kHHTj8a2lSg1eLKhVd+WSPZbHxRA6BJ5FV+hBPNaMWsW8nDMSW79a+e9clnhvfOSVhyK7zwZqk19ZoZEBkztyPauedFJaFLlbtY5e+s2eaNogdjADpXRputNJDLwyjtVzTbBXsLYMP3gXnPvV2exWaGSA8ZGMiuuUuhyWtqeN6teGe7cg9TyK6n4fLJJJIeSgGcUtz4OLXhUSc5zkDINdn4V0WKwtmSPHH3iepNXKouXQzUJXuye6i3xL5gJyP8isi6s7C2YmXaHHatLxTqC6dYz3LjITAVc4yewrx+71a4vr3z5Z2Zyc5z0qacHLUucrbnuOhRxSWZkt0PmAA7QO1btvqsmkxiSVhLg4MY+8KpfDa4tF8OvfTLvURgsXA5YVl3l3FNLcXMyiLefkQnjntWElzSafQdP3k77GX8TvGaXGiyfY0miZzsYMuMceteEtNJKSSSa9g8S2MWrafKtvIryKM+WrCvNjod2GO2J9oP92uilFJWRnUg76bC+EmmbXLWOL75kGPzr6J8hBMphBGVG4g4Ga8k+HnhuaPUP7QuEKRx/c3DBYn0+lezWMckkO3Hasq7V0jajFxXMzn9R82JXm3MwXJOT0ryvxReXN9cs7O6opwADjFe1XFo4WTcuV9PauV1PwzbygvszE/B2jke9FKajuOa5lZHjE8kyn5nfd2y1bXgu3vLnVUCOUjX5nbPb3rfk+Hkk12St9EYQchjnOPpXYaPoltaWht7Rc4GWbux9TW8qi6GEYO9zAvtXW3cwwj5kGAc9akXxAbS0QXAMsrfwjuPWs7xlp9xZr9qjQqHbDNjoayfDmsSXt9Fp9zHG+4FI5COVJ/mKSScb9Db2jTtc6u08UWks670khDYG4nIrZvb61tLI3Us6FeqnAzXmht3jvGgkU7g5HtVPXJp0PkPK5jAGFbtVSpR6B7SSTN+58ekSBYw23PJz+tdv4O8XW2t2509gUlKkBjzn1rwWePa3Heuj8DySw69aeV97eBj2qZU01YwU5OWpY8Z+DNR0nUifJaa2kYmOSMZBHv6GsH+y25WUMhHTINfRk8Ju7YRysSCfXpWTqXhaKa3csuHAyGAyKzjX0tI2dBbnh9nbSWpO8Kw9xxU0EivdgJIA2fWt3W9Ke3lkRtwJ6Z6H3rl4LUpeArknNdC1MpLl0Ot8Q6BcXVrbXMC73CBSfWrXg3RtTs/OneBwpXbXc6PlNMgjmjDsEXg+pqxd3gigXzpVtlTLbVAXGPWsOd/Cbez15ji9Stb263K6yJsB+8p5qHTfDdzcWcjbt+48rjtWvdeMrGXMUt0pBbghf5mtLR9btriJhbOjgdSnYU3zxWxUYxb1ZwcvhO5Fx5flPj17V1Gk+FH8uPzWKovRMZAP9a6cSxXKb4mDNSC7kt4mDrkAdfSo9pJ6F+yUdUYmrM2jwmOCNPm5bHBqndL/aul+ag/eR849qxNY8Qz3GqOiQh0VsHdmut0K132ayIuwsfmU9jVNOKuzKEudnKWVqZJfJlj3IevbFbWq6dpU1rFFMCroMKQRuFegWWhWkkJZYlMmOa848X2MljqrRvu2nlT7VManM9Bqy0M3UdHh0/T3ezfdv5b1xWT4UumTWIyeinqK35IbmW2QxABVXBJ6Y70nh/TdOmvVljuAWU/Oq/0rS+jJnHXRHPfEq5a41eQb8hflx/Ssrwho8+qapEIlIjQhnbsAK9C8UaX4bvdULzX2yU/eRB0+tbuk2dlp2lY0wII2H3j1c1Mp2joiVT55+RyWs6xaXrC0uLfdDE20ShvmGOMgU7T9PhsGyknneYQwYjjHaudu1a4vpBt+cSEN25ruF0yS3trRCudigE1U0opJGsHzNtnn+sPJNfSOxzkn+dXYtLe60+NmbawPy5Pau3TwzbTTGYqTnnb2zXI+MYriC+CKCEUcKOOKfOnojN0+XVmDe20tqzRTjk8jHUittNBhutMi1G4uBb4GJN3IOO/1qfQ4F1FUW8h83y+VY9RV/xZaTyaXbpbwkxRsSyIOg9aHK7SGqas5dA0i40ydbeLTLiQXUPKk5UtzzWxqnh2PVr9L/cqSuB5qZxz6/WuL8IaXcy6zBOY3jihbcWZcZPpXrlzapEkbCTMp5dRycEf41nN8svdZVO0ldoz9Ds4dPfbJkIflyOwrK8Z+IH0mYW8I8x2G7cTwB/WujtVU7IpGyQckNjH0ql4k8Jy67IrWcQ24+XawBHt71nGUea8ypSa0R5VrHijUJQpLbEx0HGajstduWKlZZPz4qvq9sbK8mtbmM7onKEEYINWNJttPMT5llST0ZeDXQ0lsjOMpOW51VmtrrljuuE2zKfmx3961PDsq6Xu+xyIefUGuehk+y6ZPFCNrMMh/U1iaSZlulKswYMOR9aydNO50e1StdXZ7GymOQsOMjcRjgGnQXK7mlk5PQCud8SeJE06KOOOPzZSvQcD6msPT/FLTycptI7DoapU21cwco2s9z0Sby50dIo1EhAVD3yf5VYXT7mzUpJCqO3zFt2cisKyNxfQQXFtMq+WdxU9cegronuvMgUqwMp4wXyTWUlbQh3vbocB8WM/Z7SGM8yM0hUegGP615rpOmyXF1FDHy0jADqea9l8S6IdUaCZXXfEhXa1U/DPh4aRO95cqglBxDt5Az1NbwnGMPMU4XdzrdA0d9O8HTWDurMqkuy9M15H8Qrq4jvEjZ2CKg24PWva9HnBjaGTIjnUghuvPevH/izaG21m2iG8x+T8rkDBwelZUW3NpjekGjgLPUbu1uVk85lIPBB6V6L4X8URT7ba6UKzNkFcYJzXm8ltliGP0rU0XTbyaVBaRuz7gNyqTzXS4prUxjKUNj25mjVo+SqLnOe1bVlqkaqjxupGK8w8b6heWM1nYAskgiUykdWNX7C5k/s5ZXKKfLPI9cVzulePMdilzaHS6n44srOeaKfeD2C1nweLrGUjyyyhuoYZ4ry2/dppZXmOSx5J6ipbFlmaMrvXHcdD7VqqMbGHMz1D7Ykl1+6HydeKtWskiXTNHHszwTSeHdJaTSYJW5YrnI9M1fvR9li5A3dDnisG9bI0T0Of8W65ZyWE1pOVO5cfL2NeceH7Xyb9L5x+7iYEAc810OraPcXurN5Kkq569RWxFoS2ekXMeA0pHT1raLUVZdRWc5bbFOwEV/rDvIiDJJyfX1rM8a6A0dz5iLnA428g1nXl3Npt+rxIwfjPtit3SPFUk06peQ4Q9XxwB9KLNWaByTVpHIRaHLLFvZCfU9K2/COmAavFNgr5ZzzxXodsIL9A0aoQP7o4q7HplrARKYxk5A2jnNS6rehSppWdxWnkcIUP3eu3r+NXbK8mDruAZDwdwrN8M6paTX15GpSVojhl6nmtRgFUkowGeMisJLo0auSvYydV8KJqjSuX2xjkYPIyaraR4K03THMrobm4U5+c5A/Ct+1l+zZkMgA5yp6Vc066jleWS7G0Ywqjv70c0krGE7X2OC8TXzW82IeD2xxyK5Dxzql1NbW4fhpQWbHAOK73xFpR1DUFeP5Y854qlqfhu01KzWOZS3l52svDCtoTS1ZcoyknY8ReQFvmJBPWrUM8lqp2Oyqw5wetb/iDwo2nTFvmkhz94DBX61jTx72CIv3a6Iu+qOXla3Om8E6w9rqUCTTMIJWAOecZr1jV7URRAblJbhtvQg968Fsw7SKq8MOle06C82oeG7Z5kImiGwlupA6VjWW0jehJ3s9jiNee30rUG8pN0jjJz2rrfB+qw3unsqjbKDkrXKeMNPuRqshkj/dsoKMRwRip/h9aS2+qOGX90q84561TinTGnadlsehXeunR7Ca5ERkkUfKO1c3JrMXi6AxzxpHfIdy7f4hW54ilhWwmBjEi7cEdM149LdyaXqwe33RkNleaypwUlcmouV8x3uqWcq+HZkTlzhcdOM9K5nw/ptz/AGqvkKwMZyxXsK7/AE+T+0LGN5QNsqZYe5ra0+xisgqxrywyfekqvKmjacE2pHhes2l3bahOsqMNzE7sdea9C8MwyR+HIZbz5UQkjPpiup8Q2FpcIu+JCw68VzXj68Nt4aigiAUH5cYxxVe0c7Ix5XD3jmLzUrSTWBPGgJTow4DEd8V0um66Lp0SYc9BXlyB/PBDcV13hyF7i4TA+YdDVzjoVGTPU9OaLaw2bmHIJ9K5Lxtpiz3iyRoQG4NdBbu0aAHh8fnSNsmOJBxnIrm2dzVw5hfBnh20gtgJlzu6mpvFGlrZENaMGU+2MVftbpIYwAQABVDVb8TnarZ7YrO7crlRg09DB3fZ7dpH+8faue1Pxd9nilgsBtuPutIR936Z71172vmRnPTGMdjXEeKfC0xZp9OUvuyWXuDXRBxb94mqpbo5ifWZ4p/MjuJvPLbidxOT713/AIS169kWOVp3Mqv93PAGK81hs7mC62TW0gk91PJr0jwlpksEHmzR+W0n8J6/WtarTjqZU/eepp+NNJt/Fix3VtHHDqqrh+3nfX3964q38Gah9oQTDyIwcNk5/lXreoaTHDpSXUr+Wi5aSQfwqBXk+ueNL+SeSO3m8u3zhcDGAO9ZUXKStHZCSijrYdBtreFPl3kLjJPp3qiuiW6XQkCY5zXP6J4yuYpSt0y3CH5fn4IHtXa/bYbqwNxbnKgZ9aJRlHc6YyhNehwV1bTTyWzXIYtJAoBbuP8AGtPQPCtxPd4WM7dm4Z75r0658LNcwpFLHEUTlfUf4VK2jX9tZFLNAGUgDHBxTeJTVkcrhfqcZrWoReFNPH2tgLt/lSMHnHriuUg8Vs2ppJHJ8jYPPb2rb8d/D/UtV1IXou/NnkCqyOCACPQ1z2seAdR0u3t51jZ04Dv0XP8AhThOD63Mnz3a6I9QtbqG4topmuFw65Ynsaim1K3sYy0z715IxzXkGuRXVtqMkM8zFYsRgKfl4HaoYru8jQpHnA6nrWnsVvc0VTo0eu3viK0+yve29wCVXGwnBU+mK5G+1S38VwxwXsmyZWzHJ3WuMiMl7P5c8mCeNwrc0vwve2kwublkSBfm3buWHsKOSMdUyW5T+EvReBVMpFzqUcKIwByp3EH0rr9NvtE0C0WGO4jCI2Fy2Sx9a891/Vrm9EkVuzLt4H0rm0tLuRi7QyvtGdxzxTcXNe+w5uV+6j0L4gMZ9fiu5CTHLCpjbsevetqHS5pvCFnIqc5Y47kdjXl9rr+o20igTF1UABXwwGPrXsfgfUp9U06KW8UbjkAYwOOlRUvGKt0LpyU27Hm40+Zr8i4idYJcqW28LXQaZ4N1uDaRbJJbseJFkGCD3r1u10oXKY8xY4yfmwoOamuVS0cx2yBiBjJ6CsniXskTy66GTJqA0yzhjEQBVduOgOBzVSRotWty6nII5APf0rB8d6lLZOIzIrM8ZK+2etc34M1WWO+kiUs0Zjy2eaqNK8eYtaOx2cCw2AZrhsRryN5xivO/FXiYpqZaxfcx+6c8BfpXTeKFl1HTFEKSsd/O3P4ZrjR4Pv5IFuJkO5uNo5Kj3qocqV2yqja92Jj6xq924hYAKxXJYd62PAtxc6jfSQzoHi28tt6GtHULbTtH023j1KzluGYbtwOAPbNWvDxS9niGlw+TGrbto7fX1qm/dvYys+ZNsJtan8N3jxQxiUAFiG6CpIviB9pgeMwgSFGwTxg11WoeGYL+USTQMXVCCUXrms7Rfhak0MkrPISSeBgYBrJ1KaWppOMoyvHY8t8O6/c6RrX2hSdspIkH1717HD430+LTla7l2FhwSuRms8/CGQ3YZXYxdQCvT/Gup0v4WwrbiO5PmRn7yuAR/wDWoqV6UndmSXLuzhdR+IemRyP5cM1wecHaAKyL/wCITvabbOJo5H455AHrXo+sfBvSQrSwyzQ5/unI/WuD8S/DS5glT+y1Z4lGGDnDE+1EKtGWw1Kb1Rr/AA71yTVmKXUmZQcBj6V16Q/ZZnEgxzXC+DPDl/pMjTXURQ4ICjk13unXCXDAXAIb7uT0+tTUtfQ3hJxinIp6tZQXSEMuQ3X6Vw+peBpZbndYSqIj0Djp7cV6i1tFLFncFOcbu2fSs6/uodFglurpwUiXO1ec1MJyj8ISUZ6nn9j4Rg0lln1W4hC5BwDgmulXxPYRWZgjZU2thcdMVxC3E/ivV3a6RhHIxMYX/lmP60/UvCN3bxF4N7xgcev1rea1XO9SE7K8VoeiRyW+qWkKShJEQZ9cH2qnqL2ukWkkkKLGigscdc+nvWf4G0q5tbItc7st0XnirniXTJrqydEUjd0JGQKx05rX0NYu65upwI8SXn2h/MJljbllblee1VbnT01iU3NmxAQjejjlfoe4rcsvA99d3IZZY0GD97pXRW+gNpGn7Wb7SxPzFFwF/wDrVvKpHpuZxXM7S2OQ0vxU9pfRozZsx8h4+6PWvVY9QFxZwuuxiVGGU8EV5brvg8hXuLWQRbjkxt059KveDJLm0keK+uY1hACxq0i53e3tUzjGceaI4yle0jo/Emrx6Y0ZnbJZvlX1rN8cW8mo6FDcwqXi2g4UZ2muJ8a3N3NrzLcE7UbaqHsK9P8ABMynSViuPusvzAnOBSa9mkyZTcm49Dx6xgmuLny0ibPoBXq3hDRWt4FlmAD44FbTWdgr5hjVffbg1ZRljT5PukfTFTUqORVOFtWJdQqVIU4Y1QlYQIS56VNLfxoSGcHHbvXK+ItXSXTLhkJXcCq5GM1EYt6GyfLqytd+L4UuyigtFyDJnj/69Zs3isJqcDR82hA35689/wAK4TVblxGg6DkcVXtZZGVecqARXSoRWhzSxEm7H0TBcRSwo0ODuGce1PdEYDsa5XwfcNLodo7kh0G0k8dK27q+jiALnBPf1rlcWnY61ZpMtCGN5ATjcO9TNEolUsfrWXaXiXM+2Egn1q7JLJEmWTeh7+9LlaYmdJrFut94UuYFYjcmOK+atZtpbe+aKVMAE5z/ADr6b8NXcU8XlygEDtXD/Fjwk01qbmzh/fJllKj7y+lOhU5JOD6nG1ZuJ4YJBHIABkHrXeeAb2OZ5bSSVUWRflDd2rgPs7KD5gywJxW34YcnUrVCrLmRc464zXXJXTTCEmnc+hda1q1hSNrF9zNzuRsio7Hxjbw3MEE7bnk6VjeEtOtfEWkx3tlG8SsSGjPrWlY/D2Q6uLyTJQHoe1edyqM3zPTsa1alP2EVDfqz0aKC2uYkm2K2RnFLf6fa6hp7200a7GXBBFSWVs8UCxqBsXAGaj1/7Rb6VcT2ibpY0LKo53ECud76HDzWejOSPw/0u9ui11Gjkcc8VFN8N7G3geO2RVhJztIzk14unxB8QnVftM1/JGxY5RflVfbH+NepWHxPjh8NRX2sSrGdxUYXJkI9BXbOhWja0rmqnJu6ZEnwptluBNtA5zxW7deAYLi1VGkIYDANV/Bfj+TxpqctlpVtPE0a7mkkUBQPWu0eKfT4pLi8uvlUZdjwAKxqOpB8s3qJVezRwCfCe2a4V5GUKo/hHX61sL8PtOhh8qOMEY5GK3tG8VaZqLSC2uGaROqkYOPWtazukuSWQEc4AI61E5VE/eJ55rU8xvPh3Yw5FvZxAk5J2itDTvCktnCPL49PavSfs/mMQBgjuRxUTFULI3VfSl7aT0uOOIa2PPNW0jVZpo0gJjtmH73a2Dn2rS07TXjAjZDtxj5jk12AnjwFIBqvcXUUC78bRnkkU/ayeg/bSeljhdd8CQ6w6fa03bfukcECtTw98P8AS9MjCrboueScdT71uWnijSbm6FrHcxmckgKeMmta6uY44TIxwAM0pTqfC7mbqTvsUpdC07ygDbR4A7LWVN4dtJzm3ZVA/hxxVa88XW7ytBbyKWU84PSo7G5keQNGz7yeABximoSWrNYRqRV2x9/4J0+6tWiuIhKrckOOKzdM8CW+l7lskSJG74ya9BgErQjzOuKiNlIuWErc9eeKhVJLS5mq7T1epT0nRre2hKv87HqT3qwUtbKFyAkcY+ZiTgD3qaNgqkuQVA5rxz4o+PLKcT6JYTgSONpxkEn0qqdOVWViVzTbuzubPxjpWoai1rp91FK0ZwwHf6Vvz3QiiJbp1r5F0DV00rxDGWkZJFkxnsD6GvpE6kL7RwUbLsnGOe1b18OoNcuxrCCk7dgn8WWkd4bd5AxzyvWt6xhstTtvOiVWBHpXg194f1mbUXubSKTLMSBnqK9c+GyalbWrpqaFDxhT1qatOKjeL1HPRNLSxtyaTFGCRGPyrl/EOhLsae2UiTvtr0chWHHNQXNrGy9gfesI1HFmccQ1ueNBdWjt1jjR5H3dNv8AWr974XvNbl/fxiO0YD90ex9a9Rg02FyC2B3+XjNXDbpH90cYxWjxD6FPFJOyPO9K8H2WhwloogWbjpzV5dL3Al4sA8YPSusMe6cLKMIBkH1qxIkTLhcEdKzdRvVi+sNHGLp0UByy8dlFPuXsYYx5wVT6Gt7UFEMD7U5AyTjmvnv4latqP2x442kWP/Z71tSh7V2NIzTV2esTyaa8JjjKAnjK1No+m2KRtGJN+7ru5rx74X3F/JqYa9EpswMMWBIzXoviLxjp+husa2xmlYZCp1x61pKi1LkhqaN3V0N8XeFxqFtPbQSNHvGFYdjXmGm/CzUo9T36gziFT94HOea12+KF200gW3RAScbgeldt4S8bDVUEF1AN5HDR8j8u1W6dalG5nNKbT7GBrOjW50mW6lhjN3ECoJHPHSuGtb+W3i8478bthC/zr2bXNMivIiZY3EfUleh+tc1B4Vhkj/0TZNBnPBzg0QqJK8jo1eqZ59e+Ib0XAjjQja2Oa2hf6q2jyeVzPJgAdx713tt4TgIBMADkZORWnY+HoYZlZ0GR6ih14on3Yt6nkGk6XdwpKLsymecgMTkkCovG2mSiC3ijyQikNgZ5r6GbRYJYgdi7wODjpWLc+FbbezeUCT681Cxet2EZwa5T5gn8PXMqcIw+vrV3R/DkijZOjnLAgjivep/C8fzZUcdOKrR6J5bZjQFl6Vr9YT1EoQucHqqvouhRwRgxu5AUDqPWubiuL5540aZpQck5Oa7Px9bvLBAWGAj4b15FUPBGixz3qA5ZArHntWkJLkuazvzGNo2sfZNUVZNwGcZ7V6Qm28gHlkfOM8Hg1gax4RLXQaEbdvp3rQ0GGezjkhnH+rOFI9KmUoyV0KF76mrp0xt7pSowM4I713F4sepaSA2NyKa4tLcSAyRkKe475rc0WZ0jIdgUHFctRX1RNWP2lueaeKPCFteXEjQxGGYkgsv3WP0p3hLwTHp8r3t5IJZVA8tByFNelaxa20qF4VAkxjrgfWqdpa+Tbyja0m5cbhWqqy5bXBNPWx3/AIZ8M2Gh6XFZ2sYVF9TyTW19nWOHEZ2kdD1pQxZjioZbvIKHIzXnNyk7s8e0noVobQTOytI7bT0zVp7P5NoBI9KNMCguVxk8+9XS4EgTuefpSlJ3sOc2pWRw154G0O6v5Lm50q1aUnLNs6n1qfV/h/4d1mzhhv8AT42ii+5s+Qr9MV2EsYJ3E44waqOVVMk/L2FXGpLRpgpuWxk6Doul+FrI22h2MdvEeWI5Zj7k8mqniPTn8SWD2U/mwQEglo2wxANbbMzyAsuI+w71KPLCMIztb3p80lLm6lpqOttTnPC3hDTNGBFpB854aRyWY/ia6Ka3it1V0ABWlhljjHzMN1UPEEz/AGVzGeikmk3KUrtjXNOaVzmvFHxG0rQ5zbTTjz8fdUbiK4DxJ8Ure02SRpNIJBuG3j868v1eObU/F9zDIzDfcNubPJA5/lUOkaoNX8QHTbyCN7F2YKdmGjCjgg/h3r01hqcIcz6K7OylG3u01q9Ees2njW51XSGubGOVGOVBbsa53TPiNqUGrjT/ABAubZztLgYZQe4Pets3Frp3hieCyhwkaZUAc59a891jWtO1nT443Xbext94LjNKg6dVXjszbEUZ0ny1NJI9p03wQq31tfQ3/mWbMJAqLye459K7DxNazzaNMtvnzCpAauD8L+LrfS/D1lDJMHSCIKWHcitGP4naY0RWWXYG6F6wqQqyfexzThPRs898MaDqkevyCZZPmbv3r3HTLH7HaCWVhGQvzHiuS07xJZ6hOzWE0JbuR1q/qd9PcWYjSTcGPzYPalU5pWTLVOUko30OosdYtpZhbxTo8rdi2D9cVuhFkQE14lcaPeDxFYanbXiosOFaM53Y9sV7Ha3B+yxFzyVBNYVqaik4vc5cRR5XeJi+L7h7XTpRaL+8IwAPWvEdH+Fd1retjUb2coDKJXBHXmvfroQ3WQ2CaYhgs4iHwnvTp1JQXuhHSPmeS+MPglbXtyl5pM5jkIG8NyCfWu+8EeDTpGjxQX0vmyKOo7VvW+rWskmIZkbsea1lmQoGZ1H41E6lS1mYylOL5luYsuhpnKKAexFPj02WI5UA/jWlc3O2M+T8zevYVTS4vMrlRt7moTk0aKpUktytd3D2MMkrwysI1LEKuScdhXieveO9V1u7msoxLZQSttRoc+ahzwff3Fe/s/7o7eWqNbKBX837JAJe7hFz+dbUq0aerjdhGso6tHl3w8s9c0i7nk1jU5roSjCRnOB789Pwr0q3aSdgWyBT7uKPcrNjKmprVQE356/pU1KjqPmZU5xcbpEtzGrQ49qp28WMBTnNNvror8opbO4BYF+tZpNIhRlGFy1LZrJGwbkkYrxv4jeGdTiujcafbrNDjJXbkg17hmq1/EHtn4BIGeadKs4O6IpVpRZ8hG/8T6frCELNbxqc+X5ZCEV6RYf2V4vlhjvdOljulHDq3B9Rx2+teg+KdTs/Dnh+51O8h3LHwF253HtXHeAfibpet34hlsorWZjgEADNd7qupHmUdV1TOv21na9zlvF2j6Dot9Bb3dpcQRFdxZH4YfjV/wAEwaZb3O+wlMsO75SWBIHvXqXjzwnY+LtDkhlQLOFzDKByrf4V83S2OqeC/ESwTjCk44+6wPeqozVaHLfUuFZSeqPpKFoynrxXMeJLiLw4jajHEBblh5qqMde9YumyT6lb295p87xTKMMrMSrD0xW3qUM+p6RLa3qxsHXDY6VhyqL1Zv7NrWJPo3i2z1CIS24WRQMnHUVzfiz4nWelXv2eCDzJ8fPzgL7fWuOs/Der6HqxksXLQE4x7eldDqnw7j8QwreM5gvSPnwOG961UaUZXexk3ptqdX4U+IlhrG2PPly91NdnK4kQbDkt0NeC6V4RXw7rEbXlyAQcjnrXtGhXCzQptcOoHGKxrQitY7GaWlyzJaMDjrQliFAJXrWvsJCnAqw1vuiOBXNzWJdZo8s8W6THcRXEcq8MM4+lYPhi0ttOYNFuJJ5JNep6rpyXSEMPmxXE3fhua1ZjExAJyK6adVW5WdtOpGa13NIRJKQxIKn86z9ea2slUzui5HGSATVDVJ7y1tHEPLqPl+teaazLrN8WM1u8mTlmyeMVvSpqWtxNOLuej6LLbagJDbzK+D0FaDQTW7FskI3O0dK8e8Gald2PiOKJlYCR9pVuM5Net6vcxyW5CTCNx/OqnBxlZbFRnzEN5cuBhWKj61JpmrS2/wB7lT6964bxV4mjsXjRCGOOWHrTNK8RC6tVkkYYBAwKPZNq7Nbwfun0zC5U49TTLphHICo4PFPVFZwx4A7U6QiVwIwGxXmni3s7kKQ+WfNRjvwe9OEtxneCN3cdjVhLQ79zHA9AaJYwi/KeB+lF0yeZNkEs07pljtOei1HEHlYEjAX261NFsMxGMnNXo4VQEDof0pN8oOagrWKgdVfaepFQXkLllC/ePpVi+iwgZeo6mlUkCNm5oT6ocZWtJGaNLeV92WXHeprm3RLZopRu38ZrazVLVYTLaPtGSBnA70KbbsxKs5SVzwzxH4Jt5Nb+2QuYJQ2Wx0JB61lat4Wa2lkudJtbdbyY/O2MAj+h+leqXETIHa6jfOcDcO1ZVwk0M4dijRE/dIxxXYpuS5Xqj16NTlfMtzjtO0jUPskkU6IGZcbjyK4HxZ4OGkRfaCxLyMQAOgr6LMdr/Z/2hMfdJ21naFbm+M73kcbwZ+VWQHminP2ey0XQdaqq95z3R434J8M3Gr2Mi3PnJahfkkIxlvQevFR6n8N7gXGUvMwj+91r6Ni0mKUCONAiAdAMD6VR1Hw3AG5YhT1FN4tuXY5PaUn7sjwVdHbw5o808VyXmf5VKdq1/homs3mqCQh/s+fm3cg16n/wh1jdEI4Dx5zt6ius0XQ7TTIAkEKpj0FE8UuWxlVqxjojOj0S2ys0ivvXnA6H/GrcqyONvzDPAxxW7gY6cVBIyZyCM1xe0bMFXbepj2+neWGPmNvPTd2rA8ZeF9Q1i3CRXbqmeiHAP1rtLgA7AMFj6VZQbVAoVRx1QnWe54vp3gnVdOmVvtEqgHvyK7W1sL54NlxOSvTg4rqr8qUCnrUCDMeNvFaOrKWrNo1Xa9iOwgWODGc7eBWjGo2jv9KzLVJN7Ht0xWjCCF6cmspGNXfce+EBYgfUUhkB6YxS7CfvnIqN4UGGPA9PWoVjFW6kEu3KqhDMTmpFt2DbgQPUetLblTM2BzVgsAcE81Tdi5Sa0RQltVAJ+859e1Zd2phIB4rolA6Vj6vDuRnfhVPWqjLU0pVHezJLa/dYMsQ2BV6zmeeMO2AprFiMSBY1OQfyratNscIVenWlNIKsUle2pleNNAi8S+H7rTJjtWZcBvQ15B4b+Dc+ka2txPKDAnIweSa99BzTXUFeacK0oLlWxlCpy9DB0y5MSfZn4dOOazdf8Habrd7Fd3Ue5lxx/CcHjNa17ZEsJFHzE5qSG42rsl9Kak07xZ0t396BnWXheztU2wKFUdgKln0dVU7eRWityMYWuG8T/EzSPD+uppd0zGfjzOOEB6VUIzqO0dRxnUvuajafGo+ZRn3qQQFU2qMVwXiX4hGy1r7PFFHJCFVvmJyc8133h/UrfW9MgvbXOyQcg9VI6itZ05wipPY3cmtzzD4k6Lfyv9pt1ZgvYVd+Ds1+7tFeK+wdM16w9lDKm2Vc/WmWmm29m2YIwpJzkCk67ceUwlK70L8ifIOKEm2pgqSamAWWMr7YqosJViM55rmMY2ejIJRmU/WmzQJIvIFWJItp5qNwwU4596Zqn2OV1bShIW2AGsyHQdzfOuBiuuuIJdyuv4+4pk2AhY/KV9K1U2dSqtqyZ55qXhqGG7E8cA8xTkMBXOXmnXE178xKpnmvUpLyAvtmAyfWoLmxtrgEoo9a3jVa3Nd9z578c2C2+oKsYJBX5s0nhPRJ52UIMKzZxXr2r+D7bUZt8jYb861ND8NW2nxjcEyvQitniPdsiuVJts9MIjlQ/NkUmmr80hxjnAqrBHNt4HXsasRSvDw4/KvOaPKcdGkzQdtqE+grjtW1eSO5KKa6IzN5RG05bgA1z2q6R5kvmFsmqpJJ6hRiov3iXRNQ86ceZkN+ddUrEqDiua0WwEJDA5J71tySMV2jtRUSb0Csk5aE1x8y7T37U2aEeRhc5A4qFZT5gBPHpT5L+GPhjzWdn0MrSVrD4JdqhZD8wp08saxkyH5aqy3NvKu7cCV7DrWVqt0rMkKyfK2OnXrT5DSFLnfYNdvrWy06R5igQ8BnwBXNP5TQJPMwMOM8HgCvHPjN4kvrrxDPYSM8Vhbny4IVGA3TLN6nNTeCvEd1P4fvNKuA8k0kRNvx6dq9NYRxpqV9Ttp+6rLc930C+0q4iEduY3wc4611EMEJjG2NQPYV83fDHTNbbW0eRZo4QcndwK+lLRStugPXHNcWJioPRnFWbHMBHGdowB6VhXMct5Pzwg4ArelKhDvOBiuZ1jWLXQrczXAdtzYVUHX/AArGmm3Zbio9bLU2bSwEEa7DgitAdK5Twf440nxTJPDp8o+0QcvFuBIHr711Dbj0FKcZRdpqzM58zfvDZWG4JnrVG6U+auzpVt42IJOA3rTUicrlsbvUULQqDUdSgpaGUHOeavtKTAzD72OBTVgUncWJx2pr8joNo9e9PcuTUiBd0j73/KpsORlTj2p0LRsDhgW9u1ISvQnaAaYN3ZLDyp6ZJqdBheajiZcDH61CswZygOcHrUPUyabJ5JQnBFQbmb71Tuq4y3OKjKk4x06U1YcWhEZU5ziq8kmXyrcmm3SOwwo5JqI20kh3Mdo6YFUjVRW7ZdifaAWI644p05ikQq2Pp61Xjs2A65+tEtuVGDnn0paXJtG+5nNEqTHaAo/lWtER5YwenGazZ7PAyCcDrmktwsQyCcHrVHRNc60ZsLKB94053IQk4A7VUjmiQEqAT/OpIVaU5b7vvUNHK4W1ZXlmY53Z2/zqlcvGwA3gMSK17xQ0fHb0rJcIDiRAR61SdzopNNXGgCM9eK8b+NHw11PXNVGueHYvtEjoFnhDYYEdGGevFe0IYxkEVctpYvL2jitKdWVKXNEc20tD5ZbwZ4juLC2nv4HjvYRs8tiAzoPun69q9i+E1rPpOjG0vTidnMmzrtz2rtdQsIbqVWOAynOcVWn01YD50Jww5rWpiXUjys0UoyVnuamC6E5wan7Anrisy3u9wBY4zwRVpJSx2jnJrmaMZQZOj4JxzTycPk0IuOxpLgEJx2qTPS5BfygD5etFk3mqVYcioJ13gZNT6cNrMD1pmjSUCWSHYPasu9tjMGC8ZrfbaRgkc1E8APTg+tJSsZwqtO5wut6dshDKPn7VgS3txZWFzJI2xUUkMema9C12FmiUbT8vUgVwfizSxqGlS2omeB25BTrn6d66Kck7Jnp4epzpNnJW3iCa6kRln3EH7wPBxXTxauL2BkjYrIB+Nea6R4e1DRbiZLt/MiY/LtHH1q7pEFxb67HcM8mzoRnjFawi+aUZO6Wx6Vf2cqcakVZvc+n0jVRhRgUySBW5OKhuL+GEH94pb0zWbJqXmnbC2WPHNcShJ6ny8Kc5ao2MRp1K1UZd5Y9j2qO3VmYKef71TFfn6YFUlYpLle4yKMRjjApkwk8wKn3j05qeWNWTYMgnuKiCsjdzt/Oi5SfUjmtboRMQYy+PXmvF/G3hjxpqOqObe9JtWOVSOQrj617m10skZChs/SiyQNHuYAnNXTqyp6oTk+V3PL/AXgbV7ACTVL+aRm/h3kgV39v4egjffI7s3bPat2op32jHrUzrTm9SI1ZrRM4Dxz4OsdWmFybZZp4+FG0Vb8IeFbTSrRWktYVmwcAKPlz1rqgPmB3YANTlo2GCBT9pLl5b6GzqyUeUwzbxwSB4UVRnsMVr2s4eMfNg1BdxGVGjhGCehHamabayWqbZTvPvSeqCbU4a7lwBjKSeV9Ca434seE73xVoSwaXMIplbJBJAYeldojEv909as1MZunJSj0MHJxeh5D8Gfhnd+EL+41HUpkM0kflpEnOATySa9dYgDJpQRVTUJhHbkg/M3Ap1Kkq0uaRKTlIDcCQ4HrU4cBQCRx1rHjEkbBuob9KsD5zuPek4m0qS6FqSYMcRjPvUDJ5jYY8elPWPC8MBTRtEu05Le1C02ErLYd5kcK/NgVXlm3ybY0JNOmjWQ89FNJINpBVmbPbsKaLikLFI5bayH69qc6LBG0jOq89TT4oC6BuQ1Vr23Zk2S5ZKNATTdkcP8QPH48MfZ47eJp55SeG5AHrx1q14A8b3niOa5hnt4h5KhiVBHWq/jTwFY+Jrq2uY717W5hUqMKGVgfauj8IeF7Pw3potbMFmY7pZn+9IfU/4V0SlR9lZL3i58ltjoYpPM5YKCOwqUMmRzjNVzEVGRinou5cjrXK0c7S3LQxiggGmr8q4Jpeq1BkVrja6tGuM9z6VTlhVHVQetXJlWNGPJrLndwwcnI/pWiOqim9hohZJOSTV2PcyKSzHH3aitphKQAv51oxKNppt2HVm1oyjKpduXPTp2qu0RZcY5H61ZaPfIR3pzLsi45xRcalylG3XL7D07f4U57dkOVYgVM0ZYiSNSq+/XNSZDL1wfei5Tn1RB5RVc78n6UoAZCDn3qXbuXFRSqY03KfqKBXKctrtnDk4Rj2rVslVF5Az61Tc+bDyfwpttcY+Umh6ock5KxrOQDxUbsCMGqvn885pHk7ipsZKFh1wi7QF6k4pojaJspUchLKD3HIqRZg2KZdmkNmkZl+bj0Ipq3UsZxu3j0PWppyjIQOpqrDAS2aBxSa1LRvonQh/lPoaxb+yt7qTeGHTAXtn1rT8vDkOMiql1ZI2TExR+vHSqjZF07RehzUugzM7BhvQnPPcVRm8OCJ9wU4FdjZTlRsmHzDg5rQeGOWMn1q+do6PrM46PY4KPS9WmuPnlbYT9a7PTbD7PEEUBpMclqvqsak9Afap4dpOep6ZolUbOOdRvUS3UxKO/fNEs+eQO1WX4THU+1Qm3JGcnNZJ9WYqSbuxqb9udnNTorbgW6U9V4weagmn2OR19KV7iu5OyJJkUjI4b1FNi/cxY4z7UkTF1LMKVJFVeTR5Cs9gS4JYgKQB3NV2lAR33BvapXBkG1BhO7VALfL4AO3P501YuKj1JbIHZ8+Cx6+1WGt1OccGm7BERjpU6nIzUt9UZyld3RHEGUHeFGOmKNyseDSTv8rKvBPeq27YVV+p4oSuEY31LSAhqrytIr5BOBTnlEYx2pY5ARzj8aduo+V7kU9/HHGcff8A61nNK0j5bkipriBZLpNv3c5NI0OZWAPA9KtJI6aajFFpIQ0eVbBI+tLDbsuctnNTWrBRg1K4XdnvipbZhKbTsUpnC5Ck1NZw/Jufkmo3Rd+5j93kCn3l7HZWD3MhyijPFDvshybtZD7uMMn3toFNhiRwCpyPavmjx58YNWk114NO/c2kLFSpHLY/lXdfDX4iDU/3XzSShNxi710vCTjC9y405OLSeqPaFGBVTUZljgbBG88AVRt9TmmRmePyh2GcmkINxIC361zKFnqTCk07yGWsAkkDdT3NackJVRtJpltGkKkrgtUsDu3+tXn+VDbCpNt3WxMiYHPJqOP/AFjkdOlTnpUQXy0Izz1qLmKYjygHC1EwkJGxsUqBWYsetPztJ71WxW2whiOMueMc1BLbx+WDt+XPerUcnmKccdqdszGVbnNK4KTizPFqIG3J0qR2ZyFj4Pr6VYjYOgU/exinpGqDinfuU6n824yCARgk8sepp/ljcTmnbgOM06puzJt7kYiAHHA9Kq3Vpuwy8EVepCM0XHGbTujPjQ7e+aGUMhDd6l+6X4OB3qBH8xjxwKs3V3qQOoQYycGqUg8pt2OD1rWYLjDdKguFj24Zcr600awmVvLeWLdF+VMO8cGpFD2zbozuRu1TPIkkZfAoKu16EAlO3awphcI+VIyOtSlPky33TTVtRKCd3Pb1oC6RJDJG7c8mrLMqYYVhyxT2Mhcqxj7mnXGpxRweYzAKBnNO1wdLm1ibUypLg5I9xVV4SjfeJX9RWDb+KLGSXyvPXd0xnFb1vPHcICrZ4puDiTyuJUu4d3KttPTNQxXFxbMFk5jPG4c1ozwnbgHNU5G2kbh+dCZonzKxZ0K5t9S0+O7gffHIMj29quLKYZcYznpXmnwS1Vn0IWkxyUPFeoSbFYScY6Z96utDkm0tjmvrqWI2J5b8qkRsdSDVZJVz6VAsymZz/FnFYctzPkbLkjAEBeneq6oWkLEfL15qWJ1c4UZxUjhiNo4+lGwJ8uhGHUIRnOKjhMLPgNmuf8X3kunafI8YywHauL8HeJbu7vyJA33q3hS5otpl8vY9hRdowOlMP7vLE5Xr9KdGd0an1FVL58lVDY+lc6V3YyiuZ2LBcSIMd6kQbVAqk11DBEO5qnNqM0q7YkxnvT5Wy1RlLbYmublvMZVxkGnhsqDJxjmqdvaytliOfepWtZ92cZHsc1eiNmoLS5Zj2yEk9+lMaNFAIJPbBNQzb4VUucc4xQqMWBl3KKBcvW5Ytk+TfzuPH0pdgDMRUyOgQBetU5pChIVgzMfypLUhXkycyKuMkCsnVtft7WQQRSqZzjIwTipJbeHO5hv4/iYnNQmzt5pCxiQA+lWlFas2jTje7ItOmu7iZiqMykZJPY1NqcU720kBOEcFSDW7YxLFAFQAClvIRJEexHINRz6kOuufbQ8VvvhXb3s7tLglupxziuh8G/D+x8PuXtkPmngsxya7RC5YrkE+1SMxh4fr7VrKrJ6XN5Tb23JYbFdoAY5qyloqpjOWx1osmJXODirIO9eOKwbZxznK9rmS/nRygEbh7VdRm2gkc1Z8tfSl2j0pOQpVFLoVzcbevFNe4Uj1qd4lbtVd7Qc459qFYE4dStIju25Gx+gqxDGCRukz9KesRJ/eDhelCvEQykgYP0ptlSldWRLuSNcD8qUMzr0K/WlREAyop9SYsaFAHApNh9afmikK43YO9OAxRRQFwoopHyF+Xk0AQumAcnqaqImJfQZq45ym7vVJWLzcYq0b072Yt5yNqUJDvhA9KkliATOadbNlSKGPmtHQgmtyo3IN3GCtVB02np79a2CQBzWfeR78lSAeooTHTnfRkAO6PYDzSq/lNjPSqrzSRHJQ4z17VLvEq5IxVG/KWmm+X1BqpcWFleQOkkCDcOSBg1IjBRjOaa+VXKcmhabEpW2PMfFXgOcX5vNLlZe+3NdN4RF3bQLHeElhxmuiMjPFh8Zqu+wemT6VpztqzNYre5o+YCBTNgYnPIpkDAoNgz71YIKpuxketQZv3Wcr4Z0CPSLmQwg4Y5wBiu2BLQgY6DoRTBEcoJOgOauSIGGVOGHSic7mFSadigy7G4PvimbAr8kY+8BU08LOAy/KepqaOMOgEihiOaVx89lcRJlCgCny3SQx5PJ9KrzIof5V4HSs243yTryAB1o5bjjTjNk9/aLqETCTkN/CfSqWleG7TT5/OCqpzmtBJD5W1SAc+lWreJncFsbR61V2kEvdQtzORDtiPJ4qm4kWMFju/pWrPAsqbSOnSs+9gnCBUUFQQSfapi0KnKOxLaQAp8wDZ5Jqf7Mu7pUltHsjGetTZqHLUylN30GBAvAp4ooqTMjaJWcMQCRxzSuqlfnAwOeajuLhIFJY5PpWRdXs87ARxkJVRi2awpymLdzO8vlwnancipFh2IFUHJ/iNMs7Z5JQ59ea0/JzJk88Vo5JG85qFoozGtirZVjU8dsqEMuM9auBMtgio5RtG3jPXBpXI9q3oWYR+7HaiZC0ZA60sP8Aqxin1n1Od6MyrWyeOdnOauT2wmxv4x3Wp3OFJAzjnFJvwBlSM0+Zsrnd7obDHsQA9RUtNBpSRSJerFopAQabISBxSCw7POKCcVR+1eXJiTipZbkGAugzjsarlLdNos5FVbq3D8g4PepCyuUbOAOamBB6UtiU3F3Qy3UrEoPXFSUzG0swyfaq63L+cyvCyxgZDZotcLOWqLeKKarAruB4NNMnpSsKxJRVG6vBDjIOT2FU31Zw2DF8vr3FUoNmioykro2qRhkYzioYp1eNW9alDBhStYzaaKs54KrnrSQxgDOOallQZzTkFM05rRE25UiqaSGNzxgZq+FFRTQhjkdaLhGS2ZA8vPTj1phO7oamaMkYqNbcg/Ice1M0TRSuo8oQ3So7WMvExQgkcfWr84+QiRSD69jWLYXax30sIOV6/SqWqNoNyjoSksJiM49qsplRzz60jKZZ9ygbRzVkkKR3yKTHKWxQuolkGVyKwL2O5t5wctsJxntiupkCt0wCKp38YkgdCO1XF2NKU7aF3T40EMe3sBUt3IEj5HHQ1naC58poyclOM1duo/MQg1L3MZK07M1Z1BTJ7VApJbrU91/qH+lZm9gzAE1MVdHNCPMi+Nz8MeB+tRXGUQmIc+5qSDmPmqV3I2QM8U0tRxV5WK4aRmf5s5PX0qxaQKXOeR0Oe9VYycZ70b2CuQxBqzpkm1ZG4YoyF+UcdKSSWOEckCudjupt5HmNjFSj94mX+b61Ps+7M/q7vqzVOp2iwPK8yIifeLHGK5nUviPoFhIVadpcdWjGR+dYPjKGObSbxJASoQkAEjnOe1fPN67PMUZmKg5AJrsw+Fp1LuVzT6tBH1TpfjrTNXhY2Ds0g6owwVq+mrSbgWjYA968e+EdtCqTShP3hwCcmvabRV+zdBWVWEIStFaA4QjHYcusR7trA5xnoaRtRdziNcA9zSJGjHJUE4pVjRXUBeD1rGy7GfLT3sMii81izEnnrVxVRMDFIOEXHFHv3zQTKTZOJQowBSedg5qIAZ6VOijHSoaRm0kNV2Yk1FdRM3OeelXAB6UycZSknqKMve0IbJiF2NzjvVuoIFAJwKnpS3JnuISAOTTPMUqWBAHrWbqzsGADHFKgyVB6cVXLpc0VK6uWjc4OI0LCmNcv0ZNpqZgBgAcYqC6A2Kcc5oSQR5X0J4JN61MenNU7T/WEVcpMiasym8KPLhwMnvUnkL028YqaVQRnHSg/6snvtouPnZTGYgRTUnZX+tLekhOPSq8XOc81SRvFJq7NCS5VItx6njFMhVpV3N36VTmGeD0rWThFx6UnoZTSgtOpXa3b+FtoPWpok2LjFSUVNzNyb0ILiBZVOetZoh+dhIc571sHpUUsUbD5lBpp2LhUcdChsKAeWcj0qW3m+bDce1I8aps2jHNRXAw6kdao10loX3ORQjYFRR8gZqVOalmVrEg5pf6Ug6Up60jMaRmminCopSdpplIivXAhYeorhx5q6v8AL9011F0xIbJNYSf8fwrWGiPQw8eVM2YpNgVQPvVOCWPtVbA4PpVlBwKlkSJY0G/OBiotQSIguR8+MA065ZkT5TiqU7FnXJ7UImKu7lTSboW88yScMWzW08ivHlTmsG5Rd/3RU1mzBsZOKpq+ptUpqXvH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23041=[""].join("\n");
var outline_f22_32_23041=null;
var title_f22_32_23042="Glaucoma view PI";
var content_f22_32_23042=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    How glaucoma affects vision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Glaucoma damages how well you see at the edges. It can cause \"tunnel vision.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: the National Eye Institute. Available at:",
"     <a href=\"file://www.nei.nih.gov/health/examples/\" target=\"_blank\">",
"      file://www.nei.nih.gov/health/examples/",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23042=[""].join("\n");
var outline_f22_32_23042=null;
var title_f22_32_23043="Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity";
var content_f22_32_23043=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23043/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23043/contributors\">",
"     Michael Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23043/contributors\">",
"     Ayrn O'Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23043/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23043/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23043/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23043/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23043/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/32/23043/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digoxin-specific antibody (Fab) fragments are the definitive treatment for patients with severe digitalis poisoning.",
"   </p>",
"   <p>",
"    Prior to the advent of digoxin-specific antibodies, treatment for cardiac glycoside toxicity was largely supportive [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23043/abstract/1\">",
"     1",
"    </a>",
"    ]. In 1976, antibody fragments were first used successfully to treat patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23043/abstract/2\">",
"     2",
"    </a>",
"    ]. These antibodies are highly effective, safe, and widely used in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23043/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dosing of digoxin-specific antibody (Fab) fragments based upon different clinical scenarios is discussed here. The indications for treatment with Fab fragments, the diagnosis and general management of digitalis poisoning, and the clinical use of digitalis are all reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link&amp;anchor=H16#H16\">",
"     \"Digitalis (cardiac glycoside) poisoning\", section on 'Antidotal therapy with antibody (Fab) fragments'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link&amp;anchor=H17#H17\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Digoxin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=see_link\">",
"     \"Treatment with digoxin: initial dosing, monitoring, and dose modification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHAT ARE FAB FRAGMENTS?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digoxin-specific antibody (Fab) fragments are purified preparations consisting of the Fab portion of IgG antidigoxin antibodies derived from immunized sheep. These fragments bind free digoxin, thereby forming digoxin-immune fragment complexes. As the level of free digoxin in plasma falls, the resulting concentration gradient facilitates dissociation of digoxin from the sodium-potassium ATPase.",
"   </p>",
"   <p>",
"    Digoxin-immune fragment complexes are renally excreted. Because the size of the digoxin-immune complex molecule is large, hemodialysis is not an effective means of removal.",
"   </p>",
"   <p>",
"    Fab fragments are available as either of two commercially available immune fragments: Digibind&reg; or DigiFab&reg; [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23043/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. These two agents are considered clinically equivalent products and can be used interchangeably. Each vial of Digibind&reg; contains 38 mg of Fab fragments; each vial of DigiFab&reg; contains 40 mg of Fab fragments. A vial of either product binds approximately 0.5 mg of digoxin.",
"   </p>",
"   <p>",
"    The pharmacokinetics of Digibind&reg; and DigiFab&reg; differ only slightly [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23043/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Each has a half-life of approximately 15 to 20 hours, although Digibind&reg;'s may be slightly longer. However, the half-life of each may be up to ten times longer with renal impairment. The volumes of distribution are comparable (0.4",
"    <span class=\"nowrap\">",
"     L/kg",
"    </span>",
"    for Digibind&reg;; 0.3",
"    <span class=\"nowrap\">",
"     L/kg",
"    </span>",
"    for DigiFab&reg;).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CALCULATING THE DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of Digibind&reg; or DigiFab&reg; is determined by different methods, depending on the clinical scenario. The indications for treatment with Digibind&reg; or DigiFab&reg; are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link&amp;anchor=H16#H16\">",
"     \"Digitalis (cardiac glycoside) poisoning\", section on 'Antidotal therapy with antibody (Fab) fragments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neither the digoxin level nor amount ingested is known",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric treatment when the amount of digoxin ingested is unknown consists of 10 vials of Fab fragments for an adult or 5 vials for a child. These are starting doses; they may be repeated if clinical response is inadequate after 30 minutes, or sooner in more severe cases. The empiric dose given to children is likely to be so much larger than necessary for the great majority that body weight need not be taken into account.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Amount of digoxin ingested is known but concentration is unknown",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of Fab fragment vials to give the patient with an acute overdose, when only the amount ingested is known, is based upon the total body load:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 1 &ndash; Calculate the total body load (TBL):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TBL for digitoxin = Dose (in mg) ingested",
"     </li>",
"     <li>",
"      TBL for digoxin = Dose (in mg) ingested x 0.8",
"      <br/>",
"      <br/>",
"      (the value 0.8 reflects the bioavailability of digoxin).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 2 &ndash; Number of vials =",
"      <span class=\"nowrap\">",
"       TBL/0.5",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The number of vials should be rounded up to the nearest whole number. As an example, if the TBL is determined to be 3.125 mg, the number of vials is",
"    <span class=\"nowrap\">",
"     3.125/0.5",
"    </span>",
"    = 6.25, which is rounded up to 7 vials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Steady state digoxin concentration is known",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of Fab fragment vials needed for treatment when the concentration is known is calculated based upon the drug concentration and the patient's weight:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Number of vials = [(serum digoxin concentration in",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      (patient's weight in kg)",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      100]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The number of vials should be rounded up to the nearest whole number. As an example, if a patient has a digoxin level of 6.7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and weighs 65 kg, the number of vials would be (6.7 x",
"    <span class=\"nowrap\">",
"     65)/100",
"    </span>",
"    = 4.4, which is rounded up to 5 vials.",
"   </p>",
"   <p>",
"    This formula provides an accurate and quick estimate of the antidote needed for treatment. It is derived from a more complex pharmacokinetic calculation, which is available in the US FDA prescribing information [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23043/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Note that the formula for calculating the number of Fab fragment vials needed based upon the serum concentration of",
"    <strong>",
"     digitoxin",
"    </strong>",
"    (which remains in use outside the United States) is",
"    <strong>",
"     not",
"    </strong>",
"    the same as that used for digoxin. This formula is available elsewhere. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/15/27895?source=see_link\">",
"     \"Digoxin immune Fab: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiac glycoside poisoning other than digoxin or digitoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative serum levels obtained in poisonings from cardiac glycosides other than digoxin or digitoxin do",
"    <strong>",
"     not",
"    </strong>",
"    correlate with measurements of these drugs and cannot be used to calculate the Fab fragment dose. Therefore, empiric treatment is provided as if neither the amount ingested nor the concentration was known (10 vials for an adult, 5 vials for a child). These are starting doses; they may be repeated if clinical response is inadequate after 30 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HOW TO ADMINISTER THE DRUG",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Basic guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fab fragments should be given over 30 minutes in all patients except those in cardiac arrest or in whom arrest is imminent. In such patients, the Fab fragments can be given as a slow IV push.",
"   </p>",
"   <p>",
"    Identical doses are used for either Digibind&reg; or DigiFab&reg;. Furthermore, vials can be used interchangeably. As an example, if a patient needs 10 vials of immune fragments, it is acceptable to give 5 vials of Digibind&reg; and 5 vials of DigiFab&reg; if that is what is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic toxicity without severe signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individuals with chronic toxicity who do not manifest life-threatening arrhythmias (eg, patient is bradycardic but maintains a normal blood pressure and clear mentation), half the recommended dose can be given initially in order to avoid unmasking the condition for which the patient is taking digoxin. Giving a full dose can elicit acute decompensated heart failure or atrial fibrillation with rapid ventricular response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Digoxin-specific antibody (Fab) fragments consist of the Fab portion of IgG antidigoxin antibodies. These fragments bind free digoxin, thereby forming digoxin-immune fragment complexes. As the level of free digoxin in plasma falls, the resulting concentration gradient facilitates dissociation of digoxin from the sodium-potassium ATPase. Fab fragment complexes are renally excreted. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'What are Fab fragments?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dosing of Fab fragments is based upon the clinical scenario, including whether the amount of digoxin ingested or the serum digoxin concentration is known. Three dosing regimens and guidance for administering the drug are described in the text. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Calculating the dose'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'How to administer the drug'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23043/abstract/1\">",
"      Bayer MJ. Recognition and management of digitalis intoxication: implications for emergency medicine. Am J Emerg Med 1991; 9:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23043/abstract/2\">",
"      Smith TW, Haber E, Yeatman L, Butler VP Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976; 294:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23043/abstract/3\">",
"      Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 1990; 81:1744.",
"     </a>",
"    </li>",
"    <li>",
"     DigiFab&reg; US FDA approved product information. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on May 10, 2010).",
"    </li>",
"    <li>",
"     DigiBind&reg; US FDA approved product information. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on May 10, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 328 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23043=[""].join("\n");
var outline_f22_32_23043=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHAT ARE FAB FRAGMENTS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CALCULATING THE DOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neither the digoxin level nor amount ingested is known",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Amount of digoxin ingested is known but concentration is unknown",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Steady state digoxin concentration is known",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiac glycoside poisoning other than digoxin or digitoxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HOW TO ADMINISTER THE DRUG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Basic guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic toxicity without severe signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/15/27895?source=related_link\">",
"      Digoxin immune Fab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=related_link\">",
"      Treatment with digoxin: initial dosing, monitoring, and dose modification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_32_23044="Intrauterine sucking lesion";
var content_f22_32_23044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intrauterine sucking lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 397px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGNAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6nzRRR0rAYtGaKKYBRSUtFwGnpXAeNb0S3AgUt8vJAPWu6upPKgd8ZwM4ryLV7hb67lnZxHIdxK+3auPES6HZhIXlcqXMss6QW8MKLhsuWGCxzVG6kSK4aSOPbh8ofSkWR2uAUR84yGPpUHnB5ArFmwfukYrz5M9unGxNLKvy5G6RvvOTzn2qpHuDushL7hhXJ+771JMjN8luzB8HIYYyOvXvVGAXD3RQoNpGDuGMetZ3ZvGOhfLSyT7pJIwcfKex/wAKVollmjUSiRsHI6VTlt3t5tsm1ZCOSpzx7VMk0bKGb76ngp/F6Ut9B2tsSuQFWJ4ygU58wDkfWlUNuBjk3EjCkDhh7053LyCaZRjAUsvB6en9aejqQ7qpYJgDZ3osF2RXPlugTLlDxn0NJEI0fdASWAwwbv7/AEpJHKEsBy/Q54z70hZGP73IX1A/SjcpRJZXkbbvGGXge496ZuBkyY2YkfdNOgVfMUyBmjByBnANDkswV22kHIOf84popNLQQSyKwxGwcDoO4qS1cNIVuZmHBJwOQfpSAsZFljJLA884PFFsLWOUyvHM0jEnaW4BPf1prcmT6DQu1y6cZGCSOvv7VZi7KSPfNNdTG53kD6VJEqMeD8wHT1p2IcyaOFVbaCSnXpVuGTZlA3ynsRxUCx7VBUk56gn+VPT0985qWTe5YUAHd1x26CnqyjDdKiU5H+z6g044Chh9CKNQH8CQM2Rnt6mluGQysI+BxjmowwO7k8EYNDDAIPUkEetJAD8SYPAIqEABcNncDU7AnDP24xUMnOTnHtWiRMtUVLsBkypJI9KoqoGCO5zVu4yQ5JwQOap2+WkVc5TPHFbxR59Z2NGPKqozWfq0wQMoPNXJX2kk9QKxpo5L252xqW7V2U431Z5tapZaDNFgM16oOTzXuXhWBYLNcDGRXFeD/CUzFJpxtWvTbS2W3jVF7VpH3pe6YRXKtSbk0oGKWiulQtqyQopjSqDgmitLE8y7hSk0lLXPcsKKB0oFAC0lFFAGR4ouWtdIneMZcjCj3NeOXjiZjGFIk6lh3r074iTmLRhgkZcKcd68qutjEFlwjDOM9Pqa87EyfMetgY+7crEsm7DgsOvPWnRNvDs6nP8AezkVBC8JJOwBAMlMYJ96WFiQTHiOHOGAbcPrXI+56yLTyG5IDxKCMLvjOB9Se1QSbsGJZgykZbDZBx/OrJnja22RsEVjgqQMPz60xYWkuv3AMRXBcAggr6c9O1S07jiyuqooDSh0yfTNWYoVmhkChRInzBhxuFQtJKksj+X80ZyQw6Z479ajheWQ7lfGTtC9DUFa7k5mG1XLeZIpGMjIx6Upm+YMQEdQdpQfzqKSIK44AkJ5IPGR6U1ZAxzKSXPHIxj2oHZFjKkckM+eVPen4Yf61xgHjGKgWRV3A8nBGW/xpxYHAbDd+f6UFIsxSclt44HIJxmmMFd+MAjnDDrTfl8vBKkD/GlYhAUchhnPHP15o8iRrBkTAUDJ5NWrRlH8eZXwMKMHPtVV5cr83IPUDmpIJSjoU2LKOUYevrmtIomV7GlPE6BlSQGRBhg+MCnRNHtDNCFcfeUDP/6qgRhM7mZFyDgsTwT607ydq+Ws20duf61ra5z6vRmhbxQT26kRvEQe7f0piRhHYNnpxioISz8B1cqM7W61YMsxQttLMe2MYHr70NaCTaCOEkttzjrzTthAweM8VatyGGWVy+ckk8moQI2j2lslSTwM96nlGpu5G8LhD8vy560wEiQE96ftcxs0akqnJOelRq528GpasWncszBpNrZ+XHGKrNHuwPfBNPD71zyTims2xDkdRjPanYT0KF1Bh5VU5Xsc1SslZJGVsjae9bBEflkcFveqHlM12qKMl2xxW9K1zhxT925NbWNxqUyxxKfmP516D4a8IwWSrJOoaTrWl4X0iOzs0d0HmsM8jpXQAYr0KdNyV3seO3Z36jI41jUKgAA9KfRUckoT3NdSSSsjNytqx5IA5qLLSdOF9aEQv80n5VNTuTZy3GLGqjGKKfRQVyohSVWxzTwc1xGmeJIpgv7wEmuhtdTjkHDCuBVDplRfQ16AarpcK3epQ4PetVMycWh9HekBozinzJiOE+LEyxaZaK7FVaXnHU4FeTvcIzBjIyx7toFepfFyWH7FYrJncJGZSPpj+tePykl9ouEOCcjHNeXiH77Pdy+N6aLKlzOHwZI1HIPHFXYpIzGrPbq3zZGzI2+mR3rJg3I2VZARz8z8k1ZL3DqZ5FcYOflbJPvWN7anpOPQvTfvEedYlUZCfLhcn6dzT2lZAwWRuUAkyec54/8A1VnLcBrZWEjEI/ygrnH4+tN3hnLAsjH0pN6ijDuXp7jKeXuIAbh5CeT61XIZWORk+g7j1FRyKXcmQtuJ45+X3OKRJY0TYxxnoy9Qf8Kz1NIrsTGQBX5fkdcDKmmrLLgbl3DGSw6UxpWQ4kIfjrjk0zLOxKgEdsH+lK5aRbLjbgjBYAjipQ5z82B6ZGKgXL7QD84PzYGanYHYoLA7juGeQfoaBNEiLtBDo24cnPpTo4xyOGP8vwpmMgE5AxjDHPFTRPbKyFjI6nkBMZPHaqSuQ7rYqEbZQASMHk1Io+ZhL1P3fm/pUhmhwu9jv6kU3zYtmWXH1HStEiJNj1Zh8hAB68HqKc0zgAJkL1/H2qOJIycRgZOMZOM1ahjVrmSM7BDuKZxknj9PrWmxkld2Fgu33iQDkcE8DFXorh2XafujrzxVG4sYtxkguVfPBjJwyexOBn60W9wbUETmQqOjEAKPY0c19wlFWujZt5zFBgM425wSN3HsO1PVpZAr+WoBP3k43D6VTimTzCGyu3GR7VPG6mPAY/Kc4+tPRmOhIQ+5mc7R169qZ5DNGJCQQR2FSEMy5wGjHb+tJv2nILIp6hTSsupSkyEOQuFXrT1LPwoyO+O1PSUFWPGex29PeoTvXn17UWsF7jZFO7JYYzxW/wCB7OK81NzIMmIBua56STcPlQDj1rpvhsc6vcjGP3WT+dbUknJI4cS/3bPRwABgdBR0pGYKMk4qm8rTPsh6dzXs6I8RysST3G35UGWotoWB3y8uf0qSGFY+eretS0txKOt2FFFFMsKKKKAPDdS8JatpLb7VmZQelVrTX76wcJdRuMd8V7o6q4wyg5rK1Dw7YXyESwrk98V5zpSWx0qocRpXi+OQDdIB+NdNaa9FKBhxXO6r8Okyz2T7D6VzV1oOuaWSU3Og6Vm7o05k9z12DUkcDBq0l0jDOa8Sh8QX9mQLmJ19e9bdj4xQkBnx9aamw9nCRf8AjPcRnTNNidCQ85JZfZemfevKPMt1Vw8CAZJyo/rXdePNeS90iDYQyrJuJB9jXEB5VAM3lbWXKjbu6+tclTVtnsYKPLTRCXt9yFUkHPOF/rVu2mbzFdAVVSBudOAKpSPvA3jj03YNRC9aEssQlYjA9QKyeh6Cg2i6biQNtdVKAkBk5x70puR5fksVPPBxyfQGqTSzSDdgKh7euKeqq0f75AoY8EL0+h7Ui+VLcnmugHWN42+XjA6elRrc4c7HyeU3Ac49/wDGm2Uc0ryJCXLKM/Uf1q6iIhKbSbjOA3pxyM1I7qOgI7ug2sqlMDJwKjjlBc4jIHQjscfypMcKXO0E8kj/ANCqQHAUKhfB4GePoPWk9QWg5pHdVMI8ojp/FVva6qmGC8dV6n6j1qHaC0asGU89eKfGWjn4G/69PrR1FKXYeYGfYx5OcYB4FO2bBgI29enYn3qZXL/MAoYDDrjp7+9TorEAuUKZ5APNNIylKxUKxuh4YNyQSKRVT77iQLjG7ORmrqsAyl0VhtOMnpSXE4QjYi7eCQVGBWsUYSqMzb6JVMDxsPI3hnycKwxnFUDrM2WmjukSISbVCJnr0Bz24rX1zMmnW0RJCMwJXgLk9CT7VkKUMbw3EVuQOrBR94f3sckfShvUilK6bZbi1C5lnJvpWPAAJ/Qj0p95OZ9hjdSdu0oWwV+tVWkSW3jw80kgc5OcKUwMD357VsyC0liRTGJHwDuHBZR1GT70rtpl+0SaJLGSV9KtWUsJImaJ1LbiR1B+nNamls0twhYbicnGcc9qydMVY42MRLKHHyk9K1kJ8wPEQrcAjNVDYxm1cekzvl5SQ2eAvHXqKcsmJCsnIbnmlaUyMzLkZ7Z9PWkkC8HCsuOgPIprQUfMlBDJG6jgnGPWmuScs3fjPpTE8z7OYkOFyTTGLJ8rDtkY9KpMTIXf92B6cV0vw5nWLVbkswC+V3+ormZj+7Yrwc5FLod08MkvlZ3MNua6KHxps8/GP927Hqkupfap/LiPHtWxZxCOMccmuX8KWjMBI/JrsAMCvRjJzd+h5UYci13CiiitRhUcsgQc0k0oRT61S3NPJjtWM6nRFKPVkxkd+VziirEaBVA4orPlkx3KkF5DKoKOD+NWlcYHNfOej+NLq2KhnLD3NdvpXxBR9qzEjiqHoz1cYPNNeJHGGUGuY03xZZXCg+YuT71uQanbTDKuv50aBZ9Cve6BY3YPmQKSfauW1X4d2U+5oPkbrXdJOj9CKeHB6Vm6UWPmktzwbxf4Qu9D0ua62PcQJyVXnb7muARbydd1tKpBP3sYA+nrX1VrnkHSLsXODCYmD59CDmvl17dLRFW0nC24Hy7+o+tefiKfJI9vLKt4tNAITF88ha4k53FjwPwqeLUCkRKxND2YZyGFVZLh4ocK7SSscELwB+PfNMinYplYxvyBk9a59tj191dlxnidPMOAOuFNV5Lob9sTuEz91jnFRpG0ol2OwOMhMck56VJbeWzZkYAqu05U5zQNWLMMzNxnKnOSpwc+hqcrC8Uiwht78NxjGPUUyKIvD58AO/ncqsDnHtT45HupUaLYzsuQuOPfFS0TzXd0Wkhlk6JnzFwFHI47ipI4hDiI5Dj7ynn6VEIlCcEZ+8UJyPw71aSRdrLLG2AMIzHlD6g9x9aLdSXJk9u0iHBzGcEh1PJHTBB61GqKFcLIm44wFb+Xof0oaQbozMco5yAecYPY0edGGKTBZB/A4Hagh33Jo2jJALv5voeoI/xqcOy5KkZxjnjFUmBG0NjIAZX74+vrUqsJIg/O8nO8d/Yj1zTIkyUlZYcuCTnoDyBVWRCQQFLr7t2qSUsp8z5dw5GRgmh3aUeaqjcmAD3Iq0zKRIUa6tVSNC8kY2kdQVHP6Vl3dqWneZJvszeXtYxruXPYZPqM1p2zeS0cmGGWGM9Dz6jpU+potspuFYm3mYLgNu2nngj07VcoO10c8anJPyMK2l3JCom+0IjYEoBPHcfrWhIqi2MkLI0wOWQHnZ6HsPbFZywk3ERSSMREEcLgoPTPcfWra28cMyxwTMZpRg7Vzz2qLM0lJNqxq6S6tp7B4yF3ZU/xDHX8KmUhVxJzg8c9ahC+VBDC7bvKG0t3z35pY8EOjDnovsatR92xlzXd0aEUitgk7cgg45qSKTDKVwxPGMcH61Rj3jB+Xb/L3qwu3dgEnPYetA0TRt5gdWIDA56Us5HDHH3QuB3qurbV387s/pRuIILcgjA9qAkRTsPLJxV7wrYs7KdvLHOT6VUEJllREGdxxjFei+F9LEaBmHAAxXVSVzzcU9bHQaTbCC2UY5xV+kUYAA7Uua9GC5UcLd2FQzTBB15pJ5Qo4rIvJ+T3NZzqN6IpR6sknnMj7VJ61es4wq+9ZtjHubc3XNbEWMVCWpT1JaKiMuKK05yOVnxwsmDVmKdhjk1HLbSR8FSD0PGKiwQfQ+tRe+wma1vqU8WNshH41sWnim7gx+9b865QE4AOfwqQN0z371SJPRtP8fXUYG8kge9bdp8Rjgbs14+HIH/16kDncAOuelTYpSfc9U8VeOpb7Q5La0GWm+Rj6L3ry+4neJH2Ks0QbJDHla3dTt3t9LhEaHzAMuQetceZ7n7UGW2DM/HPTivNryvI+ly+lyx16j3vImcNFKVbsG6D8atQyx3IIV1EnZgcZ+tRndvCysikjDIUzSiGBQWG4uRwsYGM+p9qw2PTbRajWO3coyyNzlWOcZ+tTKS5ZkzIig7hnlR/T61DGxW0V2md42OHQnCnPQgVaCN5m+JHDnG5AcZHqP8ACh6oxch8c7BFBKpNGQUlXhzjsexq+kryMZHDrOi8Muc7T149OazodkqMpUSOWxgjOT6jHQ1oDckCglxGQVbcCGz6H8akTaCWQO5yoYggBTwG96voYyqSw5KAfOjc4/GqsEgaRGm8whFwCMDae31q1EEt5XaOX92BuXj7w6kH070LUznIaE2OUCs0LndFjr7ipVCmIODmFuMjqp9fpUrXHkMsceBbzHchYZK/Q9jUIZYVkygMDAE7esb5xg+1O1xOTYDbtOT5gU4dM84HoaVhukZ0O5W/hPBJz/Oozvf5URRIMlJBnDcdD9aZvDy7Y1aObHIU9T6j15piauTtKyHnLDBwGFPcFotsZZSvIBXnHoadbwvOh+0oYwTnry34VqW9pBd24RYREwzsZJGkb6tnA/KtIQ6nNUrRizLR4zCqgMVJ5U8/N6e1aMUmnwWzwXUk86v8rJEmMEerGqt9FLaLsnjhMykK+ecLjgkdOfXtiqKOkrZmhklZsYkTIXPTH58ZrSPZmE7vYe9ppskJ+y3l/bvgod2HH0yMVZ0q3sLWC4czSLdAqqO0eeT1GR0471VBeNXURIqnklV3MB/jU6LNa2nl/axBb3KklUQbmHXBz2x2q4049jKUpWtclIQD58jnB4pSBLwrAY7nqR61WgubN0RA9ykgO3LqGU+/HIq2F+f5edpwfepaNIscoyCASHXnHqKmZsJ+74Y8E+lR7yv3UA2nJ9xThghZFAIIycVDRomOik2ShZQcdeetTu0R39VJPyjtUVzyIySWZl5PpTGKsE2MCe+T0NJK43tctWE32e7hfqFYAgmvZbJFSBdvAIzXhc0vG4jaEOSTXsPhrUFu9MgO4ElB0rroOzscGLg7Jm5UM0oRaZPOqKeaybm63N14rplK+hxKPVkl3ccE5qlEDK+T0qF5fMbr3qzAyqRnFSkO9zRgTaMZ4qYy7e9VUlyvBqGeXA759KTY0Svcgt1oqmqNIN2GoqC7nIDwrp2u2CXmnlWjkH4qfQ+9c5qXw8lRyY1z+FZXhDxTc+GdRJbMlm5HmRZ6+4r3fTLy11axivLRlkhkHB9PY0qUlVjzQZtisM6MrS2Pn668GXkOdsZPHpWXPoF3E3zxHj2r6beyif7yD8qpz6DaTD5o1rS0kcjiu58yvpdwhyY2qNbeWN1bYcAg19Hy+FLJ/wDlmOfaqM3gmzkBwg/Knd21J5GtUzyCW7WSHLMGbO3FcpepMk7bVIhdsxtjgHuDXUfEyzHhnXhbABYp4hLG2PQ4I/SubmuftiSFSCVIb5SRXly1bPqsPrBTXUilnxsb5Qg+YcZBzSMpSbKMgjfJCn0/xqCAowNsX+UnKM38S+h96W0gO4xxyROq5+UHJB9DmpOm1iSK6uHtfse1ZrXcTt2Dcp4JIPXHFXN8ilp92QpB+/ll4wBUEFw6Rv5e2MyYJJXkAe/brT4JPKdEKhY2G7fu9exoM2aVrsnZDHlbmQ43joD24q6pNzDK8qPEWbeFAyCQcNt98isSQmF0YfIV5Uj+LvWkmojUIrWHabYw7mST5iXDNkk/0qbGcovoPR/K/wBajGKQkAnncB29jVp3EDsRsYMgwj+v+NV0kjLGM7GilG7dk9fx6GrMrG8t1MxXzExHHJxtcdvx96FsD3JYmSWFYw5VPvFerDHXb601pl+07wAQCUkQd1xnH/16cYZXhEqKEkWXbhWBwR/Q0/7SLoTwXOwXHymJigDLj+H6UxX1FjWKa4tbdxIjh1XIf/WIW68/xDvTL+BI9UlhjVTtnLQsg4XnpUKgG5S2uo9kbcrt7H1FXbRvs2mvJJIGuTJ5Kqx5K4zkHrVLUicrIsLHLK4njcA54KDdx7jtWvZ3UemQvdXW3y48lFbgu/YCuTnZoPJZZJ7NDncsT4cN03Z6/nUkOq3kpWGd/OZBtEjAFiOxzW8ZJbs4p0ZNeRZR1uBLcTysDLneSMflTIkwzLFIEAGUVjjd29cHmpUtiGPmSLG+Om/I3Y9KS6RPI82e5j8xMbVQ7j/+qmkJ9kO/06CTZJF5Ky5B5GM1FMr3BVZJhwOWbsKS7aKZUZJJCAcAbegqi95DEqhNzSA5Of6CtNtzNK5pWESIzuBlkGVYggt/h/8AWq5DKV4YHaTnDDO761lWUt3K4WO2bErA5I79vpWk1rOR++dI26YBxj6VLt0KSfUmVwhIHXPU/wAgKUCYuRsKhh9OKhRUVlZRvwMZPb6VI6uuBJKdjZwM5K1D1NYjo4lAIL5PY88GlAaIsyhXJHAA71H5wjYL91uvPWpEUiIZYHec/QUkapX3KdrFJczl5jiMchT3rrNA1Z7FUTJ2LwPpWKgUZ7GpoQOh6dquD5ZXMcVB1INLoegpqIukBDYqtcT9ga5+zmaIAZ+lXklMmCa7I9zxXJl5JCSPyq5b7mNUraPJX061rQIFUE9qTZUVcmX5F5PWo442nl6HFNJMrgCtnT7YRqGP3qSTkxt2RLBbKkQBHNFWaK6VTRnzM+VbtdykgY9zXQfD7xdJ4b1ERXBd9PmOHXP3T6isWQEqQAAcelZdyhXn8CO1fPUasqMuZH2FWjGtBwkfV1nPDdW8c9vIskTjcrKcgip8V4L8L/HLaNKunaixaxZsBj1QnvXu9vNHcQpLC6vG4yrKeCK92nONSPNE+WxOHlQnyyH4qnquoW+l2Ul1duEjX8yfQe9XfpXjvxg14SarFp8EgKWy7pAD/Gen5D+dRWqKnG4Yai61RQRzXxK1FPFjxG4RYY4M+WVXLjPqfT2rzi8hitpbdYJHjuIlKseqvk8cemK3J79tnzuMH+dZt28kciSzAbGGV2jODXlOXNK59RQp+yiorYoSG6uzHutRvBOCi7Qfp/hUSzXMdxHFcW0sTj5S46kGtLzRcMZYZHWQ9xghj9O1Sgie38m5KNJu4OPukd6LM0btpYqQvLs8uS1aTZwHByrDtzU0InjYiOFpI0G54nwSB6gVPaxIZ9k7tIrgLn1Hof8AGkm09EmLBmiJ+ZYyx+YeoNOwk1ew2RoiVSUPtzwT8pTPrV8SxRWq/aboJ5TbYSELMzeg9vrUU0KfZoVJmi2pt3k795z90+g/wqSIS2iBIbmWOOQkh16E/T196T8xSd1ZFxLgGELNGUmVjmLGN4GDkD+opLS/jgvFZVbyHPyqc8H1qCdHvIPtLO0rZ2yIByp9QTT41nhJWYKwdthy3KHjBx6UupKirGoreSJJEkAW4Ugsc/OQe/v70/Yt1ZvvA85TnzQMnA9apW9q5gMZcrJkgpgkD3A+lP03fHKDbube6iyOuUcEd/Tn+dFk3ZmTjZaFiY+ZDFE6hCOQ4+9v7H6VZhmhns1ivdocOCJY1w6HodwPXPFVZy4AO4DzMHAGU3Z5HtipEt1aVWusFDjJRsbh/WrTs9CJRTWpZ1CJbS6Md3PFc28nCSDBx6Z9xmqiwW1mzLO7Mhx/qxyQfU9CKnltLcruZtsL8sHJO36H0qR7a3gWOTzTPZggPs/1ijvxVaXMpOy3EgadlEdnCTD3ZgOV+vtU0dvKSHfZaqoKMcqWPuRnirFxFMxUC4SRC26IBQNueg/LtVZkhNzmCA+cowQ5yCR2rRHPoUZLG0hldGuZJmY8JF933GfTpWrFZWkTCSC1ePGAHEe857gGoIpT5nl7BHJ/cEfNTWU8lo0sJuNoIUjac49smqSRE5PoWLpp0kaBgFQqGA9R2J96jERBPBZTnGTxUckrNPKZd0qMR87EAn8fSljZnQ5O1UOML0qmSkyUHDcKA4707LSAtMwUk/eIqOFlJJfGewq1LEfKzKTu6BCMY96iyNI9jPaMtJkAB8Z3EVcL8JnoOgpN29covz/xHvQqjjGMDng1lbU6Y6kin93znk5FWoUy3zA4HJqiJC8mEXp1FXrYkMQPuk5zjrVDcdC9ECTz/wDqq9auN4qkD82BTwxV8+ldNOd9GeLiKPLLmWx1lkimMEYqWVwTtHSsayv8IF/CtK0cM4LEcmrMtkbWl2w4dq1cgCsg6jFBHgEZArIv/ESJkBxW0PdIZ1bTopwTRXm03iYmQ7WGPrRV8wtDymM8lX78fSql0gaJiO3b1+lT7vnUEgsD1qJV8xJFBBcgbfb2r5tq59q9NTDeQxzN0Ab9K9i+C3i2aWcaLevvQgmEnqD6V43qK4IPIOcHNLoWryaRqdtdw5V4nDdetdWDr+znrszDHYZV6V7ao+vtRuksrC4uZThIULk+wFfKOv6rNe6pd3Vxt33D+Z9fQflXtvjjxVZ6j8K7m9ik2PeIIAoPO9j0/Q14g6w+WPMCsR0yM10Yxtz5ex5+U0uXmnJeRUjj86PzXUCZeQueKkMym3YSyjb746+nFMRSCXzmEnkelWBHaxbjAoO5SSWGRn/CuRHrNlRobe3lDBSoxuIXndxSbo1nWREEnQqhY4qeVZWVJoEEgJ2ZQ5wcdPpTYreKRJsqsUiLvwrYIYdR+NP0Iv3HOyXGwkFGU84bGfp6VPGZLuLEsUTFFwBk5I/x+lVgIpBFsdt4wA3b2z6VO5ljjjdcQyRZSQk8nJP6c0EW7GhpdxFskFxbLIn9xRghuxP0qOC/lszLHFI5tJCQQqA7ajeVFdJo9yyKuwqwyHGOpx1+tWLRYJrU4fbPux5bfdbPqRyKNSXZasfuhgyB/q5xg8f6tvX+uKtCERoEkD5OCrbMZHqvrVKISqDbzRFokI3Ljle2Qw61cSR/KFr88ggYlAX+bn0zRuTJkqqNqMHyo/5ahTxxT28t9jKR5mQAwG0P9aggdUCncSr5Ys4BKNnkY9M00op3RuqQyY3KR0I9v8KFYm5cRo5PMUIwHWSMDJGP4hmpI1ktovNiy9umMk4/lVWMw+TC8zFSy5WZeqn37Yq/YzTRswVRKjY8xGK7T6MM9DVIiVxwn8xzcBUnjPzPGMK6+o+lMb7LAElt3Z7Zjl4z1GeopiB/tAntNrzs2GRjgE9wPenrIiN5hVljkOJIZF2gnPqeMiqVjJkuwKGiG9rZwcc5Kc5AHrVi8gnubh7mB0DcbwxCEgD+L3qviaxlbEYWFwNjFdwx/nvUw3xSy79zBsSFC2Fb04rVbGLTvcdGiMVEheZ1IdQrEKM9Mn0qVbcKJxtQx4zlsgAn0PWpY3dogyJDFGeF2DBU98+o/So5J5lJScq8PDAKu3afQCqVjOzuVpkCqpjRSwGSvPNAPQDA+n9KV2LlhF9zOeeaZG3zjaPn6ZxnH0obLSLMXzdBsOPvHnNWCzscsSSB97NR28ckxYQDcEG5ixAA+n+FRncc7GYIwzuPU/4UtCktSWVxGuVClTxk+tQBkdhGQy9xtPSmW0bc+YD9D2q8IRHwRweck1F0dEVYbHCocnp6YHWtGAAoMDb7CoIovlXIPJ6+tXoBxjoQMVNyakrkkSgZzyw6UxwfMz69RUxB+9njpkUqg9QPlBwTWidnc55pSVmQq5jORxU/9ovEOM5/lVeZSrHpULAEc11Qd9TyJpxdiO91SZieT+NYd3eSN1JxWjcplTgc9qyJYXZiAp9K1uZtXKrSsxJzRVhdPlYZ2sPwoqboVjn4jgjHJ65z29KiL7YpCm7dkYNLA2QSTyFJIqNj+7dieCwU14i3ufcSfQydRfgkjJPJz61gXEuHwDjNbGrNtcryeOtcpcT5nQBjkt3oSuzTeJ2VrqM0lhHayvutlbeqE5AbGM0+JzHIRu3p2yelZNoSE+QndjkEVp2iiRSHxhhnk9a1bb3M1FRWhYMhV8AKEA4BGRmoQo2SGUMgPGc/dNR7yudoLAnj2HvVxLgoECBWLrhg4zmp0Ym7aoalwI4hDKJVywYleh9/emZ+0QEqVWSBsllGSR7jvU1uQJ2TfJCSudqtlV47A8U2SLClyBsxt+XjP0qzFvULhVSBcokZXgyoxIk9z9KHhCQqxKDzFDAkffHt6VHOt0qx75Fa3KYjA424ONuO9SQyItsiQqyRkhlBJ+Rh1BpWDm6k1rbMzQyQTREvldkmcg+nFXLWON42aOXyJYiRNFJFywHcj1qrF5UbSRXa+cgJEiL95R/eHbFWQwMaoJHaVTuinJyWH90+v40cvczk2OdWbMckvluANhckjHGCCOtSyCWOCGO4WVc5KtuGWHqB3FQNIWZElh3AHClQQcmrDoqKIJELRMPlmP30PqSKdtSSwkrLM6vEruVIYDgHP8WKdD5mC8DM8asS0ZOSn+7/AIVBB5oWJc7W3bQc/pnuDU8cSGVni/czdflYjp1BHvTWpL0JwsfmbhtjL5wpj+UnvkdvrT5d1oY5lCmIDDmM5z3z7VPFeLBbBbi3I8yTKzZymMYIB/nmozNFaReXcwo0DnYJYzgkHsfUCq5bEK7HTqtwFkiBw2Czrx+P1p6XUksMttdSSJn5XkHIYds4qPyfLiD2GXz95HOVcY/Q1LBLHMYyw2NjkE8fSqQmkSpcqd0d3uEgON4BAA7HI/rUnnXUG5TIcGP5Xb730B64qvHKEiEVxKdrE8xE7l9AR3zS2zscbo1eIHaGk+X9TVp6Ecly1Fdl41BZDwF8vuPf605FlmEx2BjyQm3n6Z7VSQFJMIyeZzkBeoq55Z2iC4cx4ywWMEu31p37k8qWxTduAhYx47Lz+dIsuAFVS2ekaH731PYVO9ukYBCgD+7uyfqxoCnGdwCjPAHANK9i+XuPQGdNk8qqF5VUHCn6dz71dtrdiFiUhiR8zNxx7mq0QXa2EHK4q2kh8pYyT8p6etJsXL2JdiI4xynY9M05oyGYtj0xS2x8y4iBPGMHA+7U18oW53D5h2qHrsCethIegVgTgcDPapYydwDMBxnNV0DMdoDeYRnjpVsEMqHJyODmhXIZIrER8HPPSnoSV2sMEHPSkiVWb5D2zyeKFBUgAj5j19KpEMSVQVBI5pscHmNgd6c+ThWIOOn0q9osDXMuMZIreEtLHDiKd/eGporSjIHWp4fDYPJX9K7aztFSIAjmrIiUHpW6i2c3uo5OLw8oQArRXXbBRT9mPmR8mIN0bNjG0AccUsxyiYGNzE49qAxS2IOSJG6564//AF1HI+zbnovX614/LqfUupdmDrrbWlXdyuQOa4cXBbUkGAQW5FdN4gm8qKUNj5hxzXE6bL5mouw5OMAGtqUL3Zt7RKJ6BZzAovy4YHnPSraMTIWbgkZXHTFYtrIrwqWYb+46VoWs4xHsJEgyTkis2ir3NAs0uPlPmdQd2OMUi3BbZ5R8p4xjI5yPp71ArhtrEk88gj+lJIHch0YOwUqWxwR2HtQt7ktlgzLJsAVUMh+9kr+NX1MlncCRsJNBlWGfvA8fL+GaxppC7LHtxKDuwOfrike4VJDJLlkZs/N/CfWmjGWpsSSxyyCNpQpyHV2BG5fQ1PmWFHDSxv8AMAyOcLjqOe9YssnzQKZY5I2w0bZ5I7r9R/WtTKoPIkiCAqECySYEqkZAOOQc9KtIl6bFmOAPE3kfvW3DaPVccj6CmRSwK5iuLYxwsDjY5HPqPSmQSta3SyRkEqgkwRnaehBqxMLd4TJG7G3dcn5gTGc9PpntSa6i5u5csbhEiRLoySxctGQu7PPfjr6GpbS4NikgLpcWVwFWY+UWkCjnvycHriqVu5gInaVzBwpkKn5ff8DVp1eKePNxHJA4G1yxxGT0/D/GqXchpXJkVkM0CxyzQOQ6Sx/NwDkcHpUxidt8kCTGSMeZnOF29zTLPcskjGWGNy3zYJZAM+w/lUsMwClYZi8OxmdVUhQfbPIot3JuN064N6lyFi2yRLukikHyOOmfQHmkVrmNli2K0QG4LwDjuM1ZsbuK2aOeyt900mA8crDa3Xv6c0+yBYSRyTonlrv2vndjpgYFGpV1d9hYIfLJa2d5I2wzo5wU9fbFWWjKxhlii65bndu/D1oNtFhjHM7nomxCO3U5PI9sUkbD7QzGMb0XJQnIbjqKLE8yZLJLKVVYZ2aAkFT5e1x7Z7ilMLhmkvUkZGO0FpCpb8uPzpyxeU20SKYnAb73Q/SrkILSDMglPI3Hvgf3e1UrkSkrDFkkVVRIxHk4PHbsM9qn+zRtEXeY+eh3ExgnPsDULuI5VjiUlCucOeopjuyhiuRGeeDwaas9zO/VDbgRz/NEjhNuMHg/nUcalSqgjp0PIqSQg52kFevX9ajVt5wp9+D/ACqGNSsrEyDB781IhDMcnjsKgLYIz36U6L5TycHPJPNK5aL6gMrKAF7HHeppJY5EXzM7gNvA/nVaMgDLD5fenliMjC4oT0JtcuMip8qkMsgB4GCPrUkpxHGSCR0Bqtp6+cGVAdycHJ6irm0iPYTvbOVweKpamUtHqMjEhPyfKSOlKjAsQxJGMD0pp4yAQGHAFSA5MauxLKcnHb/GnYfQGIJB9Op9Kt6He/Y9TiZvuscN9KrzrvBXcAOvTGagOQoK44/StFoZSV1Y9aQgqCvQjinVi+E74XulqGOZIvkato16EdYpnlSXK2hKKWiixJ8fNId+1lG2MbTjuTVe6IS2Uq3zNkn2FV1kMkx3H5ickk45rL1a9I83YcAHaDnj6/1ryFG59M5WOa8VXxWMjPzH1rmNJnAuF3Z3E5p3iG5e8vViiO45x9ahvYG0y5ijcYcKGPPrXdSppQs92YTr+/psjuIpldC8a84yRu6/Sr9pIJIEcLnJxyRwa4q3v1XGxtwGDkdq1dM1ZIph5i+bEQcp2Oeh+tcs6LVzsVVS2Z1gucfISd6nhh0P+elTmSNtot2eNj/rFPQn29qytMnt3hLXTM6qyrEykDLe/tUxZVfbLlCuf3ievYEVlawOZqSyLNbqXQygrzt+VlxUFpJHaSKTIxgdShZsHGRypz+lVhdm43NId0qjA2dBjuRS200MqhXkT5xg8blJPXmqSM9UWPKkQx210h+zScpNtyUJ6EHsf51bhnimntYb7aUUkGVAcNjjJzjFZ0jeXDthWdwMb1DZ2EdDGepH8qmjiDu0kbiYSHD7jwx9fQfjTsO6NMztFKzeYZJ0f5XI5ePHU+1TwSR29wEmEaIwZWLAY3Y/zj3rPMqMY7e4wrr9yQryRjIHHcH86ely4QrISJFJ2OV+U+oOeneiwlPQ2/sZhMrJJFJE4wroSyc/wsO3+NLbxiCdYz8wZDhGyVGOwPc1StLhVU2xcNbNzycFT0IJHpU6v5SEqzywnsGw6N3xSsJTezLsUYFwGgYCPAYMT8qn09vrWhbTNJeKrHyJ8kSlBy4/rWXayRlB5jAcbfMTGV/3h/OrLSZihiuQyyLKdjIvylT3H+FGxm3qSQMxvHJg8picRNv+TcOo/GrjuZQsiGRJlyG2tznPf2qtJIjQhcBhI2GIXGw9N2M9fp1oWTNvIrbS4baJeAHHpU631HzX1NTzvNbYVVZAAwwMZ+hp8zoUikbIjkA2t0ZWqmJZPKW3MSvNG3YZJXsVP9Kt+aCDHIDsddy/L2PbHanuS3YsI5GbeeNW2gHn+IeoqwJhEPMidS8YIdB1weh9+Kzo/mCwzEpJGN6OWxt+vpViBpvtcTQqTLk+Yq4IIPcDvVmTehoXLbobZSweFgWQqMMD3FUppBG/yk/vONucgkUl0FkiLJkRSHI5xtf6dqqyuzq0cgAdeQc9/aiW5MWTEkn5s85+lHmbZCpBwTnOMbagMm+IMZMYOabNKC6uCR6AdDU6su5eV/nOADg544zU8IPQj5icYzVOKTMjA+gYDHapopf3jogBYn86LCUuhoBt4CgEqD+lLKvHHGefwqGPJYqCQDxUkxBJCnOOM+tDWmhpF6luyG2KSbqCQMHox96041BtkLDhsnGeQf8ACqFtb74UJYCPG8kflVm6l/fRkgFFHIz39DWkFZXMZu8rIZERhmI+YHADd6WNv3gJBz60sTeeC75BQ8A+lSFkRQF3AnqOtIGxHIY5xwTwPSonkMabQARTnOQcHaOAPaqzPyQecVSYlqdB4Lvfs2qeW5xHMMfj2r0SvHUYxyK4yGXBGO1er6VdC80+Cdf4lGfr3rsw094nBioWfMi1iilorq5Ech8O3UhhzvYbm59xnv8AlXL6/frFbs3TA4561qX9yMuQwZmzknoPpXn2v3xu7ny0PyKe1eZRhzyPcrVeVEnh0edqomkycZYe57VBrh338oznnGc5rQ0yL7NZFyrBn6GsvUg6SjzEAPUE+ldUXeehhJWhqdt4T8Az61o0lxDeQRXIcKkTN8zk9Pwq9Z+Dpbdp7LUtkV/G4V8HPXoRjqK4jQ/E13pN2kkA+VTwma6vSvF8x1wau0CmVSrfZ2yVlI7e1c9anVvq9GaUqsGvdPSNG8BeGdIsWbxPqN5JcsGCiEbFUdsAgk5q/wCJvhhBHoem3fhKed0u7gErdPkJEf4vXg9q878ReLp/Feqi6lgMMbJhYllzs9h9PWu3+FXxGttHkm0zxFO1xbbcQxuS+3PXb/WuV0pybV9fwNeeUUmUz8MfEkUNzcR3NmJYJdkSjOZAf4gcYx9a0T8MQsFtt1WNb+cb9jR7U9D82ex9q6fWviPZXNusfhOCee4jfAQHIH0BrKh8R+IhYg2+iw6jHG257eZvntyTyCPvLz9a5bz2lKzNvaSeqHL8NILfUILd9ed1KEmRUCmI+o5/Q1yGu6FcaJeyNI0pglYxrfxKPKl9FbsD7V3Vxc6p4g0e5mimttOdY9k1pDH+8/NjyMUywttS07wbJZ3aw3WnzR7lnVt8EyjlWBPRsZUg9xVe0Ub3exEeZs4c6bdtYRRS2MqPNJsikYEFhjoBzyDyDUEsd9o4kGqRzQK6sAlyhAdgOgYjg455r1jw74w0jWrK3/tP/RGsmD210iZ8hk7Ef3eMHNSeK/EHh/xTqNlZXN3BeOsu+FthVdwHbPBzWzlJaqzIVV8zi0ePwTGeK3ntpPMwp3jjeuDjkflz71fS5Vm81PlUkFlBPbv/APWr0XUtAsNauBb2pSwutpP2mBVB/wCBDv71wWqWeoaRrj2Oqsi3Ub8OmP3qnofT8DSp1VJ2ejNea+w+O7DStFcSmOfI+cdG9M/hV0zNbxGO5jZ4fMGGBwCPUGsyTR5NTuBaw4hu1O5S52YOQCTjtWraRzWMs2ma5+4j2k/aWQthh0AAzuzjitFZvlvqJyVrktgzCVjFuubWPcThfmC+vvirNvfrZX7DMc9s+WbK8g/TtWHepcvPAmhs800h+ZJP3e8fU8CrcEFzHIkxtnhD5jmSRDj6hqLxTUW9RO7XMzXstkd0qCZeUaSJ8EkE/wAJ+nWp7hjcSbHLLdFMMd3Ug8f0rlY76fT7p90UrWiH5ZnBAA9Aa1hdtdurxyxuhbCsZMYbGef1oVnsyGmmaomN0svmR5mRPn9c96IZn8orHIUYAMrIcHPufSs2znl/tF5LWCe5CLifYC2z1Jx0qWG9iil/dmMxzElDjP1Ummmu5MuxpGY3KefEB5v8aMcZ/Ad6RZVlKOrAcbWLDBX2rOs7tYriWNsIMnKn+A+n65FJM3kv5nmOwbnAHQ0t9SHpoTxuYlKgjKk/e5x70xrp9queSrYx3qKWbOGIO9emBzVMTZVSRwZMEe/rVWsLmubgmxcBhJgOOpGT+VW4ZAAxQnIwenWsVTumOCdwAGOmKvptG4BwSSM4JwPxosO5sWzl8b2O0f5zVtDvIGR/gKy4ZSkjKBgY4xViKQsGbOMgc0jSMjctJwiwDy93lHA55Iznkd6sSn5YgAwOSWBHeqelYRHfG4gZUn+dW2l3hGyWbpjqDVrWJjKa5tB46ckdccc0rIVX5jz0yKYjpyPl2rj8/WmtKdmAe569aLCbYkjAOD15xnpUbECQj7x9fWq08jApkY985pYyQAzf/rouaRRL1A7Hpkf1rtfAOoZgks5Dyp3LXD5ySSRwK1vCtwItat1OcOdp5rSEnFpmVePNGx6pRUZdV4LYor0eY8ux+dHibUREnlR43sMKPQVzNnbtLKF6sT3pkkj3U7TSk7jW7otqSBIeE6Z7muZpUo2R61OPtZcz2NmwsgqxGM+ZMBkgrlU/xrB8S2vlTBidzHqa7WI4s/L2LGg6/wB41heIrcPbMiRZlX5mPWuWnNqdzapGydzkNI0641G/SG1iaSQnhR3r0+/8M2uneH7KdlkS8kkaP5/lIkHOPyBrD+Gtx9ka5uIJ4FuERnCSe3THvXsqTaY19Zr4qt43lt4MyxCXMTyOvyuB2bHBpY6dRT5dkjHCqCg3HU4vRPBN1f6LaTQxReZc3BhkMqnbH0+YsPrWtD8Kb+8exMX2dRbuW3xNuYqOoI9PSu48PR2x0k6fBqLWdkxEs4z5mSpzgZ9e1JH4oez1yVPC9tJKxUk7oyplHGcKe46/jXne0lzaytudbWmiKdn4Jl02JZ9DvbjYrA3ETKNwz1weo5qvceC9S07xydQsYDe6BdqEmDy8xuR8xYE5x7iuw1a+1RXa/lsUt5bTa8yR9weQxX0z39a1LnVNH8R6fa3NxGBLs3mNyYwwHUj1+lYptJtPy+RTlK6see2ekTeG2meOO3vf3nygXoJZfVkb09vSmaq+q6N4otrG0ljh0fVY95hhjKxbmGeASVBOf0Nei6fp2j6uJbu4sbd58/KiINy46MCO+ADVS6028l1azXTZLKWCTIZLo/6t15VgmM5/lQnODWl7oXNF3v0PNbKHUfDPiEzLBaQ2BOS7wSKjgjqTgqD2PrWx4q1Gy0XSZdZt7u3k02QqPsDWYlt3Yn++CCp9CK7bx3pmoQabaXi+I7y2t4zi+USjY3YjBHA7/Sqc2jW9p4Te1uY4dS066KzI6YAf0ZW7HHX3FHPytOfTciNprTqc5Le2M+jWPiAWNzZHCgSW032hCrcBWU/MueMHtW3LH4Z+IUcSX0u3VLdSjCNvKdwOmc/eHvVPwtpenPo9zpEd1eXKhmKJGFWWNOoBJ7jsfaqb3DaYqTaZquuukLASQ3ECPxnBAZeR9apTjZx2G4Pm8ypBoum2l7BczLrGgvayGMi/t2mtpeeglUZ+lafjPw3caiBf6Qq3Von3Raku8RPdl64J71L8R9N1iaFr/R9TvZbQRBpbbzd5DDk/L6Y68d6uxSNdeGdI1eystTedUClrHKTBf7rLjDjOcZ7VSktGmQ3LdmL8PtLMHiIwa5EYmmTKNtwWPbI9c11Gkajd3mmy6drug3xhGTuijDhSCcHAOccelYxltLrXrKW8vtftp/NIht72yCbiT90NwPpU3ieXTdO1+S0udG1u2vsb1v4bg7lPXI2emcnqKuLfM+v9epM/eaNzQr6C7ivrk2witSDCgMJUKenKnp+IrkNf0nR7uWKHRLO5gnWTdPNsPlyg8ABSfvZxzXbaVdTah4WT7a6atHMDHKJSIZdh4DCTg/8A6qlttJtra8thY2LQmNg7TTTglymMb26twOtZc/KrrcEne5U0myPhGOCCfZ5cw23EKn5tp9fWqEvgjRZoZLXTmKzzEvBKJCUHfBHbHtXRXkcIlmN+LaYySllktpVkkGT0Yd6s6Zo/lqUs5TLGshYrt2yxE/wkelLmktEtgbXxPd/ceb3fw51oWi3MsqNdglJLaMZ3qD99T9PWtK+8Hpb+GYbuC8Z7hlICEg7+On4V3TO6W+oyJcGNhItupdsHpkj2FR6S0lrcIL6H5LaJvIDfMsxbGMetaQrWkk2RPma32PEvLvJnhj8qR5fulQDk89KLmKWC4MN2jROkn3WGCCPWvWb9rCxkh1o25iDytCzDhFAHYfnXk2o3MPinxrcWVlqUP2yfMsAeJgGjH3VY9jx6V6OHjOvGUoq9uxzzqKDSloSRTo19gSE5XnA5zVyKYeS5ChcPgbuM1Qi0DU7DWrW0voDbefII1uPvqc+hHfAp3iCw1Cx1ttJsYZr2ZJFYpGu5juGRxUSmlHmextGzlyo3ftG5QrNlz1NWtPlVmw/zfxCMZJPaqqeEdeliRwsEExOfs0zFZQPVuMD86bc+HfFGmAAaTFdSTKWW4julKIO/p81RGtBy3HLRbmu17HDA5kk3Tkhdq8bBnpipm1IkqBnIPU8Z/AV54NSuYL+4tNQhktrlCD5c3Vh61eg1HGC7HIHCiuhTutCIxO6juC24Ifm6HnpU7yqvCuWXqCOtcdbaojMqRkj5sk571t212Jc8YHYk1S7F2tuXpB5oYry4PapzjYOCABzx1NRDats5iPzP1OelIHBQc7iOB9KVilK48t9SetTQXBhlhmBwUIbp71WByewOenpSXBAhbjtxinFXFLVG5qvj6OK7K7h0B4NFfPWqanLJqE5MnRyP1orq9rbQ4fZs8gtYC7qoGcniuy062CRKZGCKvr1z9Kx9GtgW3E8ev+FdHbAleACB0J5Oa48RVvoe3TgoRJwgVhIWJlPdv4Kz9WujDbJLFIsMRlEe8jJYnqQO9abIkkQErEkc7R1I7kmqWj6f/aeruL6zmksMEWjqwCq4IyT6+9LDOKlzz2jr6nBjJSkuSG7N+HwGt+LCLwxcSKL9hC100fCIBlgV65710Hg3RNW0+fXP7an8+0ij+xFhEC10pfAKE8qMDr71t6Vop0q5F/a3hLwJhkWT5EBX5WIHfOa6HTZdSvPCdnvtoEjilWEMrEuQQTuJ7A1zVcbOUJJv70VDCQhKNv8AhyAaLbsbabY1oEAU26y7yyr0JB9+KjaeTStbhvbZLa6mnmPliNtxRmwAT3H4ULeSahpY82J7a7iWRMsDiaMN2I7jvWxsi1TTYbmOILaKf3ijA8mUdAccgHivMScfeWtjvctLMo6DOYPHN5crcSXQEmyQTvkMu35s+3Jq9quoWGkw6ebKO6vLlN3krIAttICQGTB55HAPrWfaxxXOk3Vx9nsbRITjz0JWT5m24OOuf1rU1XTEv4NKkutSgtWjthHGswI3EE44H860T0V1dmUkr9kT2un2kusLdaVJeRwahaGa2jhILwzLwUIPHB45qp4ia9sEsdV+1pM1xtRHChCsinDxnH0NU9Pv7uzi1O1jlTz4IGb7VE2Q4/2T2zVfw/dSjRjol5GJEeRLuKRyR5Tg8k5655p6dHZ9EKz66o6nVdWE9rcQzabciR2EdxFNFmPkZ6nvg8VPptiLXw9H/Ytw2nRDauIwJIuvO6Nv5iqUXiKxs/EVvp809xc2l3H5d1cydIm6R478etV9Kh1iG41KCO7lhlgnaNYo0D7488uCeAMciqd4+9LZ9vyZOj0Rb0aI2HiZ7q4v7OedB+78m3EZYE9GH+FcD4v1nxF4V8a6i+nBPsJdZ4YxEMMrcsM98Guyv9NZrnTbi3vhNDfttjlI5yo5B+lKW1O9lMWo6YIpICYTOCHViOACe3HrUQmqa1WvmD1ldO6C/wBR06+hsrrUvP0u/dN8TQndG/TP0+lHhm7kuW1mKfWri4CoHt5oH2CAAdCAecVJoPiC0vbhra6iRvJOEDKAPl44NWoH0NtTnubOBbU3C7Jgh2huc8j196FCUbOL3HzKzTRylrq2m3usLpWoeItUmun2vb3UxzbJID9xs/3h3rqfFMIaaCfV7O5kt7SPck1sxZ5V6GMsOo96z9V+H9hcWbyQXbNKH85VkUbW545HPtW7ZazBa6kti8MtpA0YOJDxnHJB67TWklzStF2f5kcytzJXIvCrWt/oA+w6I66dA5jCTXByMcn73Qf41b0aNIdXtrhdNuI7YxFtry+aBkcEY9PSrd/MLO8WJQ9uJ8sTuBSbgcD17VB4Q1S1MN5ZQutrcq5KKT0OecfX+tZ+zbl5g5rlbWqIrrQxcX0UlvFtbl5DypAz1/DIpWj1C3uXurqCeUE5EsTcMBwA2Dmtu6n+zKzGWRdg8z5ssx452jqc+nSsW7j0m5nZrqWSwnkhBj3KUDBhw4IOD6fpWU6b1aZUJ62ZpedNLoqXkMVkfNJBjMO4qR6nPWqWkXd3DAzKVuY1uGieINjbwCrpnkHk0afA+l2ypd3CmWU4igXo3+0T2zVbUkd2iSfTntt7A7w5wpJ659aTlJWlazEoRd43uiDxfdtc+DL6ytLS5aZ5GdHMQbGRyNp9Rn+deNfDfR59e8Vy3CRPpuq2Vq6Nb3G5WlA4EiEjsDz1r324gguI2SxcN5WE837QTICOc7f1FJZa1a6hdfZktZ5L6BSS21EZweuD3FevhsZWo0pUUkr9ev8AXc8+tRp1Jqpf5GHb6bc6nNp8mqZMdjGCIQy7mZRgnA5x710YaztbuJSlhaX0igg4YkgjnDfjWVczWk9/ZzXckFm6uwiijy8znuMj29ane0h1Ly47BmbyJhI883GwD+HPf6CuNqVm2r/10NnJNrWxcXyLCU2iNc3dxuadVU8Lx8wBPUe1JY20MVndyXUbJbOwnSKQ/M3HYehNN+1mXV4bW1LNLbhizlSuS38XPQdPwqlqaGCO4mG+ZTbmJ5VB2yNkHA9AMdaqMby5f617smU/du2cP8UNFspdP1C40pZbjWIbZJl+bJ8o9EA+pxmvCLTxLdzAIsSoc4LlyxB746V65qPir+ztRu7u43Ot2m2FYJfkjjUgAqw+82Tk9q8mt9OH26UomxGkLDnIyTnFe7PAyw1H2nR/mYYLGxqVXTa1SO58MyzsittbGe44z6131gqRwlpgXkA4BNcbofmwwptIZf7ueldJFcrImdu0keveuaC01OurLmehu+cWQHCgeg9ai8zKnAKt7VnJNgAZbnnrVmORMFgeP1NVqTF2LCseeeT1qDWLsW9jNI5A2oT+lK8ojXOc/WuP8b6myafJH0MnygURVmW3dHnUswaV2ZNxZic0Umwtzx+NFZOSbuCg0jKs4BGAoPI9K0zkLyCGx8oA4Wq8A2KCgyQRyadcykqQNy59O1c0ndndOWljU0KGOa5kZ5AkaKdzt0Ldv1q94f0O6SxtXu9jC5uG8x4+wU/dIqfwHNaywXWnXkZED4kLkjDMM8HPbmupgW40iG5sblWfT1RFZkTLxTHdhlH8Qx1+tZ1KkopwXX8bGCpxlJTfQp+GdPFrrk99cXP2W3V2C7HJ3LxhfYGussfEMz6pdi8mWSwuLTY8XCJBtJ27CO4GPxrM03wPFf8Ag3TbrfP5qyPLczBgokixwCuc9R+FbAt0lttSaYolpaqAoiRWLjgAk1lUk46Pz+4qPLK7JrLX4rHUtCWOwii05lZZZG5kkjYYbP1yDVnTNFi0nVoYftaw3N68iQBZcNL/AHd69Cp9D3rMaytbsxwTPcXN/FhY3jI2xjGRkHtxzWFrNnfakmlTxXLG+S6Z5pF+8y4/drj+HGOnes4uLtz6ehUoyu+U3tLlGk6teaZqULGyuIdk6qMmJwchgPY/pVq+vIo5YtT1o288U1pL5fk5QuQMK+G+6T2HtVmz1dzqIa80tJNbaH97LcRlY8DuQe5x0rM0zU4vGXh6eynFuNZt5XWHyo9okiJzgA9COvNDT5d07fl/XzIveV3pc17ObTrLQdM1uBLOGW4sw0MD/LulXhuOhOMH9am1zztX0RJL65icgR+TF5OXaVxkKrAjAAHemLa22mpY6TqOr2UdnMR5tmGBaJiNoYHHHOM4pI7PULHxZNpMYt57N7LbcQXR2qWU5V1bqpwTg1TSvtZP8zO+nd/oJq+iWV/MLm/u7eweS0ihEbqcnYDlmx0zu/Ssu6uLm00bU7WK9S3jitwUeJjmYZA3Etj1OR9Ke97e7ZNTtbG4WJbQrGtwAWIBPG4cEe/vV1r3T9RlTXx/pVjMpmNrKAWhkIHyle6gjjtSSe8d72KUtkzI0S/nit/7EPlpDBdLcrcyNtVByDs7k4zW83iX7H4oe306yeewjtlkuSeWvBIT82PXjipru9k1uwcXckFxbRW8Vw1k0CEDLEMQcZG32/Ws+10yyn332pXd1Hd3Cfu4bSPc4jVew+gzwOKOZrTd/wBdydHrLRE1vYWUrajo1nCmoxSSpf2budvllv4WPY9QfpWbremx3Wk3h8P3ObjTpv8ASrXfl4QPvlG/jQDn1FW9Fu7d5rV9Kv5pfDwjk3GazMbMR6vn5sE84xWT4H0zWLLT7W5s9NuWZLiRTNtx+7bI7nlc0nCCeu/5f5jUpWunp+Z0uoreWWlWC2uryPYzRBt4j3bG98ZOPermp2jXH9kavbQQanHZrmZYiGMkbDnjPI7/AIVS0a8eHw/qtlZ3MlndW8ZDTyAbxyOAPbvWX4U0vUv7MivNDhllu7e5wZIjwwJ+YY6Fe9La3M3r/XzH0e1kbN3oUUerq1jG+po4eWHfPhbdAM4PYCoraWx1V47yG0l0y8khZ7e4aXckhH8Ei/lzU0sRvNG1XSJFuLCVo8KG/dtO5O4jPZfaovDWkeR4ajGtQyXaxlp4reM7X2jjLN2FTyqMlpd7/wBMpzvHf+vyOg0S7u7/AEiT54o9eFvvdVOTEoOMA9iR39Kx/DmoX9zNLpcyxyRRBpVuJV3CBc84PofSn6Paz3t9HqmlQ2MESoUa3tyRKh/2yT82abd6dNbx3MV/dRpLdnaltayAzMOwOOBVu701t1/zMU0r33NfV7y3RvsV/C1tYSAD7ZcDcWY9Dj+EUr+SlnbJd6xbFYht3pmQv6Bf/r1gRG81DSrOG7sbm4nDGEQYy0ZB6sT/AA981a8N6SY4rywknXzIZtzXkbbo4OOVyf4h0qvdktNfT8jL3lu7W/q5Ym06+vdSins7GW1t0TPnu4V5eeAR2FZ82iyf8JFbG1kM10A0t2Y2GyAHoC3rnPFPsmiv/EdyNOt5540hMKfa3ZvtDHgsR/D14NWGNxb3SW1pKktvZH9/FAMLI+OFHdiO9VJJK3NbX7jNSe9uhHdXNvPr9npmkoGnt3a5eRRyznrz2H+FaN/p2xrNraKW4aJxI8wyVZ+yKBxwe9VtGBt9YEE1nDavMhmvJopQZAhzhTjpk9qqaHaanDo1w1vdyi4a4k8yF2+VY8ZDf0pJR1voJt6WL1xd3/8Aakq3CwuJRmYxN95+gXd3xXG6/c3+naKwt737LNfySJFGzlsbQcjB6ZrroLqc2tpc3H9n2nmLnzVU4DDrheue9cV4xt/7Yv8ASdL0mN2hWOa5jnY7pZpQwXBX+Fctkev4V35er11KTsldv5HNi21SaS1dl955NcPeTeF4bh7PyxZObVZ40whBfdnPTcTnP0FWNHtibWSOV97ZDh+5zzmu8t/Ceqt4Tu9EvopPskMgcAPwNvLMRnB+cnn0rmrC18tU3ZDqAnzdMdK93MMX7aioLpLp/X9M48sounUcpdUjTsJmigCThAdoAYD8q0Ek4A3c9RWb5TI4KAYYcD1qzEHx8zA4rykz2bamokoAGQPY+lStcjZuyCc9qz4MADIJ2nJNSvOFYg7c4zn/AAp77FJpFmW4LI3mEbQOled+Jbz7bqJCZKR8DnvXRa9qJhtHY8E8CuJ3fPuznd+tTUlyI0gnJgX28bQcUU4KP7uaK5uY6OQoKhyGZggHfr+lWNIsJLq6aTBMEOHlJ6EelVXQKoJO0nuO1dF4KCRX8kE1y0bTxnaB/EewPv6Vk9EOW5YudLkaRTeqgjnj3wiLjapbvjvirA8RwaZbeXNNdzebIE8txwyjjYD2IB4Nbd3ZRzC3g11msjb2pFtMrgq4Y/Jn3ySKx9R0aGzSKw1GcpfQlnRgM72PqPwrBSX2tmPltqjf0m4uJLq3bR766is7aEvgdFAPO4nofr61uPBfaXrcgiWK80+6ty0iSEhXjbByMfXrXG6NZanFbS20wzbXIbgI25wB8vbuf5V1Ok6vqttBb6Y9uyalBA0VuzJkrHjk7uhHAxRVknqpbd+xME0ttzQj8jR5re61RJZIb+IRlS2XjR8rg8csCBVOO8TQtSk/se5E0ecGdAN0frlTznmjw7qia5oel6fquY9UtX3ecpB+Tdk59eea1X1nSrzxFe6PPaypZzqu2+fDMkx4DY/uHoc1Hs2pXjby13Bz6SJry1E+o24/fxvParOt0W8xZQfvZyeCB6Vn2un29sWuvD0lwl6VKtI0W6PBOM57c07QZNQ0q1GiXyi6liuXig3Eq8OTwQ/Xbz6dKfZTyaJ4ibRNcLQpewyDeshYxuGyG4/CpSXN7m/9fiS7qOpV8a6emt3nh82cZmezi/e28eQxbkMcgc5HNdBod2JbyKS6iN9fQQvFHbSHDiEDIDnqcYOM1De6ncabcQWKT7ItrzSTW7j98cHDBhzmrl7JLb39tJY755pLeJ1ubhsmUMDuO4enNXzNayenYhrTlRl+G/Eo1w3r3cUEGiXZEYigG0QHJQOnv6+tMjsFutK0x7y1t5tK04zedMQYvMTp8jDBzxnB4p0Gg6VZafb2lreyySRTNtSOzaWNiQW2kjpyCc1keJE1nUNN0y0imE1206SzRRg4MX9xQPcjNDkm/e0/yFFW+E3NQsH07xp4euNInH2CSzkVHcZjkRiPldf4uvPp+NVtNgmu9Wn1CKIw2qA24McwnjiYEhkAHKjHTP0p8sN9YmCDWLe7stOWfzbVCoO4lcMA3VevSqum+KceJ7ttGs4rCw05fJeCNcpP3bd/eJGeaq11ZOy/z/QlXXmyn4U1q01WwutIv2/s+4sZ5Y7ebc32dlLkkMf4fr71s+JidTt9RS8mZo1VUiS3uAfJAxyCp6EU/R9Fs4tY1ufSXOm2tw3mRzTLldsi/Om3uAT1qt4em8PR3Nxp4ngkaCIRPqVpHtilXp86dtp4zRK8ruK/4IoO2kmbFxp6XGlG50G0iuLR445P3PzStIo+fcM5zU0TPqoutMeC9sbdIF+zIimA7sZY7e/t+Nch4Y0Kbwda61YXVxJdSQjfFKjkMQ3MbR4PIPT8K2tGFpY60sOo3t/p+ryWoaVZJPOjdG6Fu4IORio91Tfs/wDgmivbUk0CLR9W0YjSrtba5ZcSR3MzAeaowHDHkZq3plzfWV5p9pdX1jdvHAyEQMzGRc9Cx4LDngelY/hzw+dH1DUtIngtr+G9j3QvGd6kEg7uORj3rS0qV7PxOdI0/VLOeJVPmI8HyxSDnAPcYpX1vFNdwa0s3fQx7KCWPxz9ollkW2ldgxGQuOwNdJrGhWWlaRPf3k32SR2JhcHdMxzxtH5VU/4SCPzreW6gtVkWUCGO1jJjkbpk57896f430e6vteUG6b5kRGlflVB7L6cU6cVJvnenSxlUly2SXqal1NqdzZaVbpfXV5JPCGuIYVAcDuGYdj+dVracNpOp213bxaZbRMYkVZQ20ngu2Op/rVzWNYXQtJgKpIbaVxGZUwJbls4wCKnt49OtovKXT5IWg5/4mDhYkbrlmH3jzWyUm0znlKNmjL06UadoGswaO0z3cNm8/wBokXmZ/wCFfYZx+FHhTVdav/DWnSTz77qZmjlt1iWNwy9cN2XHetKzt7UW5jn1L+07y4LSTx24ysuTkAHso/lVS+afSvDN1Fphjn1Cd2SSWLlYtxy0anvxxmrSdlDZX1Zm2neRbtL2KLT7e4Ol2do9zIwSRpTIWdTz/vHjOKmDzXGkmHTCymSXEzyDbJNjlsA9BVezK6H4Xt5JOGiX95ISP9H3dgP7xqG0i0u702NoNRvpIY3DGNUw4Po7dhUJbTS/r+vUalbRs0rKFbe0USS2091b7iACCIlJz07tXLPZwRap/alhfz3VwcW8gx5LRqzZZh2JrZWwb7XNcLcRWUUi4EAIA6fmarJbtHe2zWP+lvKwjlSIDYFAPzkmijVVLWK/r9R1YOo7NhHY3sUSLdxsLSJ28rdJhgh+vXNefeMrN7fVkljiVbeZNwCLheuK9Cv4RHewQ2jrPOwPmOxLBj2C+tYfjuN4LXzLhogVYKAmBtPTGK3ozk5cr3CKUdUcJBEYsHIyBjJGTT0YlsEfjUUkoLjaxUdMYp8eMbt2Se/Su6zNb6E8ZyGQckdQDTZWUZ3EYFMjdVJAGAOfTNZ2pXe1JDt2qBn61VkhLUxNeuRcXWzf8i/zrORBgEnpximrJ5jF3HLHk5qRGG44Hy1xVZc0j0qUUkLx3NFK2c/KvFFZ8xvZGr4U03S9SCfa5/3ysWZSdoVBycmrfiOXTobxoYINktu4AIXl8gfxeoqhY6LZJJFHPOkBTuzcuTxiu21e30u10C202cGW8t4zelg4PmOOAvqcD8KzqQs00jljK5hzahba5Y3Fvdp5V5CohaM5Bdc5GD6irsj/ANm6gL3UVe7hihbyZgPnUEbQGJ64xWVJGY9Zs4yr6bdy4ldmGd27oT6cUmlz3Jk1PSL64S5s7i7KxtJnep/vj69x0NZxtLVfcXLRHW3Nzb32jzXdhctcRSxKVCSgTJtxujZeoBx1rZWVP7PsryyslSBrUvC8bbR5mcPE2fwqloWkW9pZTaLZXUcl6YNwJT743ZaMHr0xVfwbo88Eeox289xbxzNK0NsVPlsyjJUbvf0rOduZxt5olPS9yzrNrc3ltbXF/GRMsgWKO2jVNp4LKSOTwaSOznU3gbULFLibCNC8mZGxztHGM8Cs7SdcvIdVvdIvbU31jKFnjYHa1u/TjPX6V1WnEWOqPp0scFvLNJJLBJsAYyMgC7j3xUtX1TvcG3FbHM3esXdlpDSabau19dyqJbidssQGG7Hp0xXQtNba74ms9bt0lS6RQk7M4CIRj51PXOQOgqs0UVtAJLtbX7ctwA8NweYgTjOz+LnJq7e6SlvqKXoe3W3ad7eQW8ZRGZVDZKg4BPTjvRzNw12JlZO63F0j+wv7fn0q3mimvsMyX6xCNFmbOUPqpJ/A1Ho013o+heXd4mEF0YY4Zn2SRPuKkI/PHse1Z9j4UvEW41C0jjgFy/yCedY2Cbs5G4+w4qe+8QXen6HqF7ZQKb5pCpuLqMN854JUdKuMlb3dPUzers3cZPe3fg7VtPuLmCVrWW53Swq2/aGyAwP8QwetauoTf2baTXOjXCytK6Rq0jhXjTuNvXOD264rG0vVXv8Aw+LHUke6u7dFuLM+WXfeG+56FT19sVoTSW+n6jDf69FbK144jFuADIgxy4I6UrNWS17P/Mfm9Bmk3Fnq2ra0kMt0dQj2yRwyOWBj2YIUE43ZG73zik0+DRoLe7a+jmu5Lq3LSwQsE2IAc5Pr/wDqrMn0qTTvFuq3aPLbXEeBBJEmd5ABRhjrnJPHarOq2F+sV3q8YtgNQi+0Rm2UgBtvzjBHB3A/nSk4N80txK9rdC7pl5DbahbatFDqEekmLZFa3rrIh4wGXHPtzWL4b8Cappn9pSvfWKRznfAblwgwwJKn27ZpvgjXo9T8FLB4jWa0Ng5h+0shdDluMjr1I7VrXd0UHiKe4eG8AtBCRtZRHjG4BW5yQc59KuV+ZqT08v6YcvL8O43StUls7uS28u1jlihZxPHItxvwPlRCPftWf4ObVNSn1Z9TimvbpsKZZFC7Tz8uemMVrpa2eveFre78MW9osywKFhhKxsJAMZ21aiuPtFvcaZeQ3tpLDZlwrDbvm75wfmA5/Opak7w2/UbkkubqR6dDcaNqFpbqlqkMrF5zHcCR2A524/hWpvC2m2keoXd9LGFtySUhViTIzE4XPcDNZPgPUdMuI5LadDHNaBgbgRFgUz1f8fyxVy205oJ7WXQru/v7bzfNlbyh5KnsfU1Lurc239bg9b23ZrR3Q8RXy20s8di9qd0VmU2B06ZFReJbWFY7qbVb+WWUqUgtrRtzDjGS3asyxtrSHx3cXuolpopt+Fduh/hUenermrm68Nm2NnexwyXT4W08kswjJ4JPYn0NVC0m2v8Agf18zOelg1bSpNQ03SoTujgtLUzySvnKNwRk+vBqz4y1IQ+Dzql/Es+oz2ywWsci5XOPmmZemQCcZrQ1afUJkMMVzFdWsUayM8v7qGM9R5h6kgg8VnSzxa1Z6Ymo20l5f3CkhI/lDknAwP7vHfiuunKzSk72Rwzd4trS7NuOJLvTtOciSUfZhFbRRfu/OAwdz+ijpWculSwadDDqN7Hp1uJnmka2cbyCc7FHvWXcak2raJcIkflSWs7WmyF+irwFz0K1W8H/AGm0VrDU0iMt2Gns5W+Z9owNoz6H+dU4KMU5S1I5nKbSWhfsNO1fU7nXLOWwaPw7fQbIg7bnxjksT0YnB46VY07S5dCW0t9L8y4lIWG4tRJuG0D/AFhbuaZ4mt7uwgia3vHmvo2D3Bkc4C/881Xoa044XjLX09wYLJkHlW0Y2mZsclj1CispNza79v6/U0jZK5X1q2gSwKJH5l0p3tOq7thA+6v9TUkELpYG7v53FpLGB9lUFBITxubuAP1qLTI2jtjJFqluo3n57bLHB7bT0NNezvJbuaSa7WKzkUDbNJ87c9xUKya3/wAyndphprraaft0/VjNIRsJji8sg54HPTrXMePIZ00KaR0jby2RnZWz1OOv410VrYs1/NFZYfTzzcSkfKDnnFc78Q1lTw3LJFE32OSUMD3AB4J9c1tQtzJLQTueexT8h3bkcVK10OQBz6dKyUlB54H4043G7II9uT1rv5jdRNN5cjLMGzzgVz3iC+CLHbK3zvy3sPepry+W2t2kdgCK5qF3u7hp5OZHPAPpRJ8qubUoXkX48sgJ6dhU8aknLfKoGabAi7tpPHfjpVyOMk7sggHFee5HoxjcZ5sY4ZTn1opxjUklsg+xoqLmtkXb63S6vDHJjO3Ix1HvU/hM6bofimC81y+xFAAUE4Lhvak1CUxXkDDgEbSQe+P/AK1ZmsaYNSuIyznaFxj3rs06njrR3O5uPEela/quuxWjp507iWCSToQB93PbP+FM0/Tbia3s5Z2CNNbvcMqKq+WwbCYY9cgH864Lw7d6Z4Y1HUv7S3eVcW2yMqpYhs+tdroHjbT/ABFrNzYLFcS2E1rHFG0MXzW5Q/J8vfJzXPPCuL56a0NVVuuVl6HQZoNLstShvEtpMM6RykiSUE8npxUd/qup3KW+qRSvBLp13GIkVs5UnByP5mt24vxFi4m+eyjtRFJLsILRg84UjrkcipbiBNMSLy7hDFc3OTdBQweFzkMvbjPINcqlJfD3NXbqLfX9o1xdyQWMb6z9n+2SSKxEQUDcNo6ZODVLWXj8WeHBq2gzLDfttnls5WCywNkFmTP3l4zj1NaUdtJBqk9nIyebJaHfNHCEUxHIzx14/WsS107TVW1uNInur6W1JYwtakFlHdW/Lg0Jr4Ura79mQvU6o2GoaxakatNJJGbMzWqbFWSR1APXGSMZ4rN8H3Fws+t2F9bXUujM6TxyoMvEAv38dxxWVqGo3ia/omqNM0dwquw+bdgf3SPbGK2rGSS/vb/UdOe2sku4+d9xwXYc8fwj2p3Sb633M9ZKz0RXs9dtILmW8v5BeWkV6j+dJGQIkzx8rDgYxzXQanYCP7V/ajrLp7MbmJYWCicFsgBvx5ArMkFlrOmT+Gb64W4a4tilvf4yBKBzHu/iWorTdBollokWpyW3nDygrIJYhtXg9Mp0IolG8ff3/Py9Rc1np/XmWr3T01G0ll0e3tdPKrCWlguXZgWYgBlORjpkj1rEtfDd1qOuXN+0kRt/LCKZX2R7lzkbj271NDHeaD45Fh5RlhurFkubd2wHUEcqf5GkuLmHbFLaNcTaY1vm3E8eMqpO7jue2ahrZxdk+hUZW0L1jqd5p1tfW8BWS8gtmZLxZBIuAOPLNU/CGsTr4ZNj4kaW7S6lZUlj/wBartkHGeCD3reufL1OSz1NbhLjR7hY8tCoxDhcFHxyo7Z6VQtbmC8jtbeHSNLFvLfCGEzFlIY5w+5TkHOOat86bgw91q+5INO0nSvDF5bajfTR2wYzuqR75xzlcnpnI4FN0/UdO8c6JctFm21C4iCy+f8AKtyAMBs9A+BzVW0sZfslxpNlHKskl4zSxu5fBjJ/jPOM880Jo81jp1pZfbNIaYyFzCZ8eYw7AgYzz2qE425VH56javrJhoeiXC+DktLPTGu78T+ZlCFMZUkFWbsDwa1/DtrpE9xfW1mwsNeMm64s7qUsQwGCEY8Y5zgVVle61fwbewXLC2kkKxReRIwQDPOCMZPHWo/CXh6VNJ1JFs/tQnt1i82YhVDgj5txP8qacUknd37f1+gpNu7eg3w5pN5oniK+QQRpdz27xlIn3ABj9446Gm3E0dt4t03TNC1uaGWAKl8sZDIjnnoOMAdq0vDtrfW2spYXQtIbFkd2e3uA7MQp4YjtnFUfCOg21hdDULrZ+8fy441wpkdudzH0FTFtbavp0t3G2uu35lu61/8A4ncaXzRXk8chW32wheem5vX8am13R57nV7iSeeRFaSIRyn7zuMdT2A9BVq9WbUd9tNqdpZGCXL2pXZjBwDk8kd6TVDYrqcovb6W8k+UR2doCVRiMbmfGcGqipu99u+34mLnFWsX/ABJPNBYQvGiXEHP+jMOJD3L+p9/eqcevW1xpX2uGGPTbYxlJZoyZJNoP3FHbNV7bw9eTaObbUnjtbfex3SybNyk/XOOnFRWYsNOv57oqI9MQhYYicmZxj59vYE10xnZJxWpxyTbfMy9pUlnYztplvo7Qyz7ZSJ5M7j2JXsT6VDBdyz20mrraFpot0dvcTJhge6xJ+maXVLf7XqEN1cX0Sqs/mN5OWkYHoB9RxUt1qa6nHOtq/k3ETeV5WR+5I6ggev50mtWlsvIS2uTWZudR+zPLZR+aEwXucqIvdvU/zqidRk1C/wBS0edpJA6ZgmjiP7tgPlx6D29KfZXt8bp7TWi6o/FvMH3IzDsfwpdX1K/03Rbe4mmIM1wEhhQBR5Z6t/QVF5XsnqzTRLbQytL0++0ee2/tKX95LlTEg/8AHvrxUuqwxxXWmRW7tJdSzO8juMkgjCxj8a0pBdGzuLq2eOOSdPLtTuCvv75Y9h7VFMlzpumun29be4YABRg4OOWJ6/lRTg7WTuyZzXVFi7guYBBbG+jWeDc0sRcbY89FA7kdTXC/EnWn/sJEuZD50o8hFTAVkU+nYCrPifVodP0I38jpJdxJyWPBYHvXiepeJ5rmSVp5VaORvM2HkKT2A7CvRo0rLn+4mn779DRWTfgcKB36Uy81GK0iJbCheuTXI3/iXGVjO5uwXoKZYW8+q/vb4sCp+SMDAP1rZx5FzTO2HvOyLrXM+q3QdkItlPyjpu9zWvaRBFDDAcHoB+tLBb+VFkqM9AV7VoW8IYKe9cVWq5M9ClT5dBbYKCNyk4PNTqgJPb2p6gq3XJ+lKzAOpALEfrXPfqdKQiqMfKARRU21n+YA4PTiii7LsHiA7rDco5Qhic56GlsJkuIomVgMHIb60t7GJLdwx5YHBA657Vy2lXhtLlrecnYvBGe3tXfDex4i10Zb8WWRkAKxlkXOdox+ddJ8LLSwiQlVkhuCA63OTtXB4H61XMhnt5FYqdoy2O+e9M8ALO2siyXaYoXL7exwcjrU1FaEkxJe8j1Nry31vwtf2MCFJ7adhAjH5mRvvLz6nkVPpvh1EuLbTdRe3he4g/0cJJ9yVTkBhnHPSsNdMlQLe29y17diZ5JAqMQR13b+hx3FUNWfUJtaSdGIuhEzsnJIIwVIxXlvkb107/5nSk0uWJuaZrF5povodR8qUWk5jsydyzxKx+ZC3IK55w3FPAn0e5kTXZ5Le0vSRbzhgfKkJypyMZU9Ku6TrjWukNIDA2ozxNPcSbNxOOoI9q53Stba4tZtK1yNbzSb3Lw45e2fqrJ6DParV5P3n/wfn3/pmbs7qKOnuIrrQo7WeNYSbqQq91GokK8cEHoPpVS9iS21TTry98+5mntzM821FV8ZyFwAMjgY60Gwgt9Hj1HxBPCI5RGgtIXKSgj+MEHBb2INN3XOk6hGLeeDUfC2onYUkBHkT+hHVGI5yOOKqMLrRW7X/X9DNyd9dSCw0GeLRpEub7TrLbIZoUu5cNHEeTkqDtJqCfUZrHw9INHsYIJXl+yPOX3uFbO4qSe4zg0sNxqMmoXF1YoYrZt0KuWWVQy5HzDHGc8HuK2La7staWTXDHFcTLEXls5Bnyp1GDwOqnGQOxzQo9Ya2/DzFKbXxaFCy1H+0JtPimaK3k01Gtp72WTH7kjK/Ug1ZttS0nVLg6at40ep6QDaj7THsS4jPzK2D9085B9DWYL9vFkNrBJHp6LNFLLtSyBkZ0G4KhB6mqEOgx31zNrF9dRWxugqKHBZpdvHIHQY4z7U5W2mrt9v6+8IvqtEiXwz4em0uFrJZr60sxdgyXFvMFKxsx3Lu6Y596r+O9PvPD1s4tZ3kksrrzEkJ+8QcgkfQjn60/VJ5dXnmtI9QiubMRmNYYWI8hlHTp16GodH8YPqnhiys/FOmwXsysYDcSSeWysCQAzemOaLS+Lmu13Gpc2ltDftfF9rqGkw6lqEdxYXVyDA0sEJmjnZl6YHIY881VbxFZeH9A8M6jcI0traXowqqDJtcYJb3qC01Cy0awSddRDmwnFxDa2y+YkfI4ZjjsSK1fEGjW3ifwqJ/DvkXFpLIZ9quN0OcnafYMTg/hQ00udw0vr/AMMNuN+VM3b60Nxbi40e8ivbYSefsWQRkoTnBU9Djj3pCDrOna8l/EJVTD26o4IijHONoOM56/jXKQG3n8I2FubaKe7jmUZ3bSAOqnHXmuw0exsL3z30SZIpmBgms3YI8TgcqfUfWoS35Ff8bBPRe89St4c1LR7uVJYofsV/5RjkjWMlWyPvAfSs2+n0a3sdthe3V/JDNvV2XakTZ57ZJqePTNQ0nX9JluUSOVnIWCFwz9Oc47Yqzqsl/oNvIy31nI4YsIGj3lUJ/iPaotF6RVn8xym1q3oZfii2utQ1wXVuga4MSuQvzGVuM9PQCuj0y7S+jnvUnaGCGMec0BAaSQAADdjjtwKSDWtS1K3tVs5kRbiMhkgg/ec8cHt2P41iNq1vaalb6GBCqtGZFgQ/MecEn1NbU4SqTs9UtzkqzjGG1mZHhzVY7nxdq2hyGSZrhfMjDsZSmf4gzdADzXU6lbWFvaixS6MZ2BJ9QlY75G9E/uge1YdtdxSa9qVn4f0xbaW1hH2zUZhkRJjhQe+fStTTFbxTZRzfYd7xERsD8i8fxFulb1nFSvP7r6/8P+RzwUmtOm5t2RsAYL61dbm5RTELyTiOE4GWA/vY4zWLY2ul6VMLq0jupEuyXMsp2q/PJA6nnuatLpQtbswWzr9gKk3s27Kq2f4PoKm1vy9TdZ4Z7aGGOLZCJCQFAPTjrxWCSk9Fovz/AFNneK31ZNJcWVzem4kgM509TKsQU+XET79yfTvVO3+0+IEa51PToGRQXdrwFUjUcjAH8qlv9Stn0u4tLCaVLhMTK0QAEj+pz2A6Vj2uqXd79itr67ZlncwlmbjcFJ6961hSTXa+/UwlVadiMaqmqp5V7GiPuH2Ro1woHoBngetWNK02TUraY3JaKWJ3Qyy8KF9c98DkYqPw/p1tBNI+oTC3treBkQhS0pyfmIHb6mt3+zkMLAQLHZgLKzySbnCgfKBz1OelCk3olZfn/WwlDm95ninx01SKDw3YWSndNI+4yZ2syqWwSPfNeHRx3F2R5YIU9zXqnxd02K58VIMtIkUSKrO2c8EnA+prmrK0jjyoTGO9ej7aNKCitzqw+Hvq9jM0nR443WST539xgCuntYAuMDB9e1LFEqupGDgZPvVuNAXG4bV69K4KlRzd2erSgoKyQ6IAkKTgA5zVuNRjg/SmiNgh+QDuG71IvABx7c1izrjEcoyecDNTCE/MwwcHHWkUMFBJGPanlQz5Q8EYpM1ihu1yAPMAxxiilJ5/eA7vaikVykasVRkk4I+9/Q1x/iiDy7gTLncwyfSu1v4xkOow3p1BrmtaRZbOQcbgMj6+1ehGXU8BPUpaFqrzSBZGyyDGM9RVrw5rM2i+LobmKKJ8yFT53QIwIPPpXFiRobkHOOxxW8Cl8zJDLE2+MLtJCg46rlj3rpcb2YT0Z9R2psNM0LRyXEEEsTwTmN14Mo4289sdaw9VtrvRYbZrOdWWZvLkuEAYzLj5RnqDgdPWvD9H1iLRr5Li7iknCvsNsy52qV5PJ4GRXqPgS+0/xNbatqUGbV9PWO4gRpjhWU89++K4q2Ct71L+vkTGrZWmdTc6XHOsctlB5Md7bqj3sbFgxP31PoccYrHisbaWBIdJhnjmtd6gyyrnaoyTtxzWVpHjm1ne6h027e1uLuRW8hsSQ7icEj6+ldEbux0DQ0V7+2/tpLsz/Zj8peMghuv8qwnhJqW3/AH7dJWMvUdPn1SDSkjka6nmcSrFs+6Pp6CmajbXdnLFb6wZLS284ShdykShRhckH3ropb+wTSrifSx5bXEfyWjsVlQjkbCByvtXONNE8+iXuq2kF3ZuvlTIy/N0yHB9R1BqOSfNaej7f8ElVFH4S9feJLq18SaZBpUEdvALU7EeMbZRkYD+vtVeJ7fUdWaHw9YfZjckvIyEtHBcB/n57KRzj6itDWtNtLG6XV5QbuxWMLahCcMG67vQ47VSksmur9n017SyiW2WeO0soiGmG4q24569+ParUm1Zxtb70Zuy21DWE0y+kvLHS72PTNY026UxXKZW3aQYOVOfkznBB45qrd319qohgklhimMrvJuHyiVPvKdvTPr0qjp2iiP+1Lia9isYL+V9m+IyNnjJC56HHQmoJdQewgvl0u3MUd1FIn29odu5wMEYOcHvVpxatHRPuK9nrqzdEg8+y0i/li0m+TzJIElVRDdBxz846MD0PNVk1i30tF0qO1sY7243G4mkRXRnH3evXPrXKade6ne+FYLZVnuYh8sjPEZVgIHDj0OfSlmfT4NNa61BItQv4VVJIkPloV7sSeQw7Gq9lBu61f8AWpLqyS1dkbZshp9jdx6rbW9xHrFixkSyi8pLeQ5HHXLAgE+1ZXg7Rr600KW4luYIhF/q98hxOnORgdD9adJ4lu9Bt4ZNP1GLU9GuMFrO7i/ewse4/vD3FZMNzqV7fOEtJUs5GJitwdofPULk9h2qnSlHTm0fyYo1tLpHZeEPEaQRzrottBayRkqjj5yjHuM55q14NW5vH1lXie/uXkxJKwKurcHcTx19a5qK70BUs7L7WdI1C3SSOVWtywuQWyGJHRh0+lTDxodLlttLlmWUPKJJmjB/eKBgHP0qfYTekdOo3iI2cnqehvpmsaNC91a29pFIqFZZXuF3gDrgE5J+laE5ivoYJREgdYBEwdgSR1z78151qmrabo+tR3dzZy3nh+7ByTKTJFuGDtPseh6etdLYat4dk0yGWz1e7vFiyqsYQruPRmzgntkVLw01H3dfuJeIUmmzf0i9gs7Q6PY3Mcd+8ReaVeCQT932H+NcOz+FNH8Ty3up20t/qMOCrpMyGPJICqB1rR1GWPV720k0u+07Rra1lM0zTIxkmBHILgfpU0lv4Ug1WLWw7apf4CoyJthBBPUHk8mtqcVCHLytr7lfzfXzOacnKXMmrnSHUotetYk0u3SS3Mqj7EjeWpJON8h6tj0qDWtWm0vXlsb66E9ptAwkeyNW/iCgdfrWDpd3ZeHbnEDyNf3smAxGApPUKK2LqO3vJ0ii0y4urkNztYvk9eR/CMVzTlyrntbsvI3Wul/Vm8qrDEby43OjsRbRFMKF/wCejD25AqlYwaUlsFhna+MLmVYkBAznPzE9s1n32qXdhqWJri3uC4AaBeAijjaB/Fgdfei0itZrpZNNdreGQE3BU/dH91R61caPWX9fIidZbRLEOorqt3FFBEILlDLNLcBA3PQKR029h+dLpulWszJc7CUaF4PJLYEchIIZT9aNJsp2jLQypFZEFdztgu3oF6scVJbXM6W0TWaRQMwOcqzsqA9cHoT0rKbV7bDgtLsdNp8MEsSedJcW11IyXUshBZNnWPjt0wapt58FqiSvmIx/LjnYoPAI7GtCC/09b28ea1uWRpB/o+3yxuK9yeSPpWNe6ugkvwI3e7vGZXXGEiQD7oPqcYrWlH3r/r94209DwrV7yXUtRnneLZI7ncAxIXnHB7VFDEoGMck5NWJSi387RxeRE7lljJ6Cn4YsNgCj27U6sryZ7FCNkhETzWPOB6VZSBckuSFHTBp0ShTk8knkntU6p+62jOQeSTWD1OtRI0DqVB+Zf51ZSPfjPBXsaiQFTlfvZzn0/OpCdrnnO6ka27ipEu4kMemPSlQqmQxzz8pFPYgyYC4zgc0fMqleoB5NLU0F8sSks2PzooD7Rgtj8KKdmOzCSQEEEgY71iatCPLZtu5T6dR9K0p3/hJA561lXkoVNrNn0Of0rs3PDsefaom2ZtvIzxViCIx20bMAR3UjODVi5tvPv2bb8qDccfyrY0+BZ41Y4YqeR7V1c9oobiUUsDJCG24DfrVYxXdiGEUkiRvw6qSAw967qzsAUDIsZQDJUnqPUe9Tw6KNSnk80quBkcdaIzktVuc0pW3WhxGmuY5lmhkeOROQVOCD2rZ1fUb/AFu5jm1C4keRBtLDuPpU2seG5tOdWXIPUkUyxliACXCKkmfvZ4NVGo5KyOepZ+8joPhbqQsfFlvNfajMIArKv2hsKeMAcngV0/jbxfp9tren21ndQ3emHMskKkIkEnqrfT8K4S8tIGVSoGTzzzVS+sVeJGi5LdeCMexqmoPWcbsw53ffQ9R8ISweOJb22DXFlbeUI1UTA/OcnfxwRVK/1az/ALZsI4WZDYlonuISTnHoPTPXtzXkMkM9nMrQSPFIo6oxHPocVoafeG4k2XTbHzy46H/Gp9lSb5luae81psepQxJ4q8SNYWtyfORPNhlK8NLzuUj3GOabol/Gltqdhf28dzZxO2+GUkFZBwenP41gabcz2F3BLYO9nMFKCZRkAGq99pUqXU/y+aTyX3E5J5zmm8NTbu/uMZVZR0Rfi1KfULTbYDGnwI0bW8LHcuejn1H0rKhh0q80z7NBPJa30cRWXYu9ZVz1Poe1Msbu40U3Jstm+dDGWZeAMdQPWuXlhlhn3RsV3jaSOMitPq0beRl7RtnSoNOtkjttPtguFwssmTiT8elQ63b6hc6Y8cvm3UpbcrJgGIjpwOmPUVz0d5eW3lrE26GF92H5z/8AWpZdWu5brzt6xvtK4GcGpWHUXeLsVdyOgVNTn0iKLUL4vJs+VQgL4HYsec0+xFtFbBraF1uBHlZ5BukBx3zxgHtWDo+qSrOZLlpZFTDErwV+brWnb69HLqbl3NvakFwMbgzfTt+FJ0JSd73/AK7Eyco6I6bRfFsuqW7WV/ommTck744yi8dWIBwO3SmRywaPqzTTWxlkmQeTawR7YfbisW7/AHttNcWn7q2jByYV28dwcdarnxF5unxx3PmLfw4MMgGO/Y/hn8aj2Kmr6X6hGUnqjrPGE2oa21vbzT3JiXaY4IV/cqMc7sdx6mui8KXsNtaxWMk8TasEIa4deI+wAzwT71zml+PNQuY449RlmJORLtIAYY9hmo9V1XTreS0ufD0Uou1G+YTD5C3t601hpyspO6X3ITnyvQ0NN8WrZ63ew+INOtp3hIZFnDeY565DD8DXoen+MYrmzFwwWLT5lGUtiE5PHzP1P0rwy+ubq9uFu7rAmUcuCPvZzxj+VLFf3aWE2nxTlbGZxK8QQBSw71v9WpPVpX7k+0nsmer3FtFdTpeWjBBFJ5UYByGYnp71dtIZobiP5ltruS4U7P4Vxx+veuD8AaxZaJLcS33mMVBkiUHcN+OOOmas+F/E8UepzTarPc7N4kWNfmDn0JPSsZ4V6uL06FRsej2ovbKH7ZLbbpIbwEr12hgVCrn15qS21O7+xXjwzzRJGMq0aBXwD/F3rnvAvim68V+JPseuXsMFoGWaPICsfLOVQeprph4h0q41nUtNhtVe5dZHaTfhVc9AP7x5/OuaeGqxlZapdTpU48upBNqyW5e6gtzK+cRs3IjLfePufrVW5MF5cNAY9luCCrKMEepPrmtvTZNNFzNp0sckd/BCJpcrmLywh3H2Oetc7qur22paFqEuizQpJDaZdiw6jofrxWaoVGr2NKcldHm/jDQJtGumctG9rctmKRW3cVixNkMGyKo2dzdTxK11OzsORu7fQdquFmywdRljurCpFRdkz3aN7algAbFC9f72KlAJUopOO59KhLlFRScAc4HWrFupzxhs9TWZ0+Qjkc5G736ZPtRb53big5HI6U4KzLuAXbnGPepoSCMnDcd6S8i0RRod+MFVPPvQpzgHI9CR3qRichWOAD3pmBtGB8wPPNO+pSGymRnJRPl9qKdtzzvA/GijUoypZuDkAisjUpv3fy/gM0XMzpxKMN3FZEsxeRixORyPrXbBXPFWrLNqnzDkbiOfrWvpMIhuE3gbewI6is6yClM4B24HXk8+lb9nEDgN/DgjH86qSZo46G/Zw+UPMjz5RPJxyPp7VrwW6JKJ42Cs2CSvAI7j3FZumSPCqo4+Q9G6Y+ta9pmOTYOB129m+lax30Oaoi0lpb3cJSWPknjv+Vcx4h8NR+ZI6KAmSAMdK6pgqr+6Q4P8J47evrUqASrt+9gc7uuPf1q3FS9TgmnF3PKTHPaSbJkMsQOME4IFalu1tcRHY8hZeBtIGB7iut1DR7eXLbTGc8Ef1rkdY0lrdy0RKsDwy9KtRdveMJS7mfd27NI8qqS2ckHowrMlhgeQSRglyeUzj8BVh9SeLK3K4GcblqnI4kBdGyjHBx0NKcLK5tRbT1Ov0IMqjyGEsJGQJBgg9CK6V7ZrqJWhgkDxjBwhOP6GuL0G7RUDwStCxYCTcNwIJ6/ga7e1vVdAs0Uzyp91VYiNz7qODTpt2Kq0tbo5/V9NME0iSOgwM7l+bb7HHeuVv48HcGG0YIKjPI9q9LMzSOyXCi2t2bzAkUWOenHp+NZGt6LH800SHknjA5HY1q59tTnlSSep55tWYOuPxHWq1xD1HQqBnj9RXQy6a8TE/KU7DHSqM0JVy2zkjBAFCdzN6PQy5ECgheQ3XFQn5FBDLuA4NXZEClgOp/Sqk+QCQVzimkwRp2ev3sOi3On27KlvMQ0hVAXIHPymsq2UzTJmB9rHILfy5qi8uQpweuQKt2criRXIO4NuGR1PvUzfQ6oU0k2blrJuDnHB/h9DWnGP3fbkevSsu0JaQyEEAj5gB39qvBn6S/cHOBV03bQ5Jx1IpVWOXciY5xz60+LLKuSAysSex/8A1U8FSCQOB3x0qXGD90EN+dNu4ooWHhm3559O1TKjAFhjA45qWMBY9rY3nnGMnNT/AGcJbs5O9sAhQOKHoachTVsTq6bgyn5SPz4rS0+WeC+S6gdvPA4zzz3qXT9PMke5l4Bxk/0q4tuLck4JABOSannbZoopaD7fxXcaFp2t3cpWbz4GWR5WJ69h9a8e8N3DyNLmQqJvvgHg/Wug+IV1u02K0TrLJng4yB61i6LAkMKAhix7Ac49qivPlhaO7O/DQXNzWOmsyxhwq5D9Djp7Vdjw6AAHzF5J9qpW4Ks6rJmLBOcdW7Vbg3qy8jGeSK8aVj1qZYhAkOZMFj+ntVuAbShBxEGz6c+lUVc+Y+8D1UjoKnjZlZWYHb6DgGpOhbEz/KWVTkbz19KkQr5KED5ucAdqjmb94rIfvDPPP4U5XZvmDAE8MD2pW1GiTDThiuS3B578U3acr5hHzDqOwpCp2ER85ORt5pUDSKFyoUevAqS0xTEuepHrxRUTghiGMmRxkDrRVXEc/fyxbCXGVOa5m5wGLx8KTnAqvd6pdTsE8srk4q68RaHPOMdq9Pl5dTxKUtSbTnBbkcfyrsNLJeMKGVTjKuR09veuJ0/G4YGBj611ulybVTaFzgcsM5rOW52tXR0tsy7CcPu9D6etadsRtVXxJHjg+n1FZVq67iYclyu1kY9/p6Vf09wGBGCOflJq0c81dGnHhHXyz8vdWOatBo5I8gH0Jz3qlFtX7iFf9k+lWoyjIH2qwIJH0781pE4qsbBKSFw3cYrKv41mDqQVB9utac5ygHcDGDwazZsYyFABGMCtos4pQPL/ABPGLeRxnK+3NchpU8qzThJCsbHOO1dt8Qj5VoWXAOcD6n0riNNjOO4PXNF7JnXQgmjq9BvZIJSM+YMfj9K9E0eb7RCsUr+TIOQ3VTXk9urI/mfgRnFdZo2oldg3tgcc9qxTszpqQutD0IhDbnzGYcDlTwfrTFuo0iROGbHynsaqwXQliGPm46KetWphG0O3YCvB29x9DWy0OKcL7mRfWqOrurbWzkAj2rmbhZFfDg55ziuwlhxHuHTk7Kw9Qj3Z+UA9wetWcs4nMXihlZjn1z6VyevXUsY2JhR049K7O/GxSqg815/rTFr4xZyAcn61ttqiaSu7MSyuLggBsMuepFdBYASYCqzcZIPFZlhAFAGM/Wtu1Tb0BLDkgVzTbb1O6VoxNWyPCrggD16fWrbSR7gu4HBz9CKoRytkKTtGMHIq2BAsY8sbUzgkjk/jVrY4pK7LSyKEJZwB7c4pPMaeUCOI445xwPc0yPy2IXy8DpuNX4SisoAwDwRVNvoOELFu3RQBuYuTztHHNaRXdCiGLHH3h6dqpx7QoLEY7kDNXYpFHIJwe5NQ9TSxch228Y+Ysn90niqWr3yQ27biABk4ps9yqZOc8cYrhPF+ugQmMZDk4GOv500tNS4xu7mDqsz6jrA+YMsXCjsK1bHAWM4IOT+FZGlQhcSMuWPzEnqa6KAIsa7uQw3cdRntXDXnzM9SirF+Dgqi4YY5GOuasJhXUM20BemOp96rwYXAUZC8gjuKe+3eow2QxCknOa4mdcSxuG07efWnnKgbXJUjp0qHYSd6DgZ4NPBUwKoQdSDmosbqXct7mK7u6naR2qSHO8EEH+8D2p0GwRPHJjpjJ9PeokfDnP8AdHt9KLdylIljGGZowSwxk9hT1LuBkrk8n0WoVDEsingr/wDX/OnL/q2GMSEce/4UWK6jxGSAUk2j0Y0VGQrsx3beehGaKkd0eR6O73d5vdvkQd6623iWSPB6Dg8YrlPD332BxjNdZDKYSjjndxivXrr3rHz9J6XKV1am1m3p80eepGAK2dJn2FJFPzDgHqBU0sSzRDdnBJ4z7Vk27eTdOigY4YVyt9GelSfMrHa2smQGY7XBHTox/wAK0om/e5kVQe2BgGsLSnaRcDgA455/z1roI5P3MQdQwxgHoevc960jK5M9EW45S4cCRdsfIO7GR/WrkN0ipgEjjj3PpWTLAquVBIXcBj6mmG5JkMYRR0IPoK1iziqJGs9wHbB5ZT25qnPISjuMbh0plzI4C7SBzt6dqbcqFTA7cHPetIvU45pHmnj53vdRgtlOQPnYdvSqdrpO5BzhxVm53S+ILiZm5aUxhSMgAVsRxhGynykDqKxqzdztpL3TEOnTAfd5H93tVq1t5QT+8G70bvWusgkfDL14OKdDGPOZMnBrPmbdjZ7FvTJZIFUTRsi9mByP/rV0NvdLMAWZgOMcdfxrKso8xEoxU7SeOnTOKsIFKZCgEZrqhexyTV2W7h/N3Yzj3NZ0ylhyCW9Ks914HNV5WwQTk5HrWqZzzjoc7qKNtfg8A9q8suJt2oySZONxAPtXqXiJ2jtpWByTGT9K8iJ5J71stjmirOx0tlICB3HfHFaVtOVXOW+h6muf01y0fpj9a00mZUPfr1rOSszob5kbMLlyd6sB1B3AVo2xWTBf1yC7f0rnoJjgAAYxn6VqQNlwcDPQ0MzcTcWQtjAxxjIPGfarcY2fxhmAyfaslT+7B6ZNTQSuCApxyfxFRvoNWRtQyHHAwp565H1qaa72f3QByMdCaxJJJVdcSHacHbjA5qhqd3IuQnAyB61cbE3LWuaykcbBDtGOv4V57NL9uvBIzbl5/A0a7eSyTCPOAas6bEmxBg4wfzzSqvlWh0UfedjYsoNqcZ3D0PatG2K7l3MGA7dM1UtogHVcnG7b+mauwxffQnO32rzZnpRLW9o1K4O0NgcYOPSpcbZgVBBGRjrUHljcVbJ5HOanRmZQSeDkEAelYtG8S4kpLxiPgL82euPUUcHlsenTFV0AUfQEfWrDriIbiTz64/z1rNo1TJ4CNw3Y+b5fqKeQNhdyQxyOnO6q4UKF7qCTj6VYvEAeJiAd6b8ehpdLsvdixgjcCSMcg+9LjKksM5BXg8jmhUIdFLHO0MCOnftUYkJkK4AO0HNC0KTJxNEo2uPmHq+KKFjMyhmbnoSRnNFFkFz/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intrauterine sucking lesions can be seen in the dorsum of the fingers, hand or radial aspect of the wrist of newborn infants. The lesions may appear as ruptured (pictured above) or intact vesicles. They can be multiple, unilateral or bilateral. Rarely, they may have a hemorrhagic component.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerardo A Cabrera-Meza, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23044=[""].join("\n");
var outline_f22_32_23044=null;
var title_f22_32_23045="Acetaminophen, isometheptene, and dichloralphenazone: Drug information";
var content_f22_32_23045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen, isometheptene, and dichloralphenazone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/29/17876?source=see_link\">",
"    see \"Acetaminophen, isometheptene, and dichloralphenazone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous;",
"     </li>",
"     <li>",
"      Sedative;",
"     </li>",
"     <li>",
"      Sympathomimetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine headache:",
"     </b>",
"     Oral: 2 capsules to start, followed by 1 capsule every hour until relief is obtained (maximum: 5 capsules/12 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tension headache:",
"     </b>",
"     Oral: 1-2 capsules every 4 hours (maximum: 8 capsules/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F129584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Limited, low-dose therapy usually well tolerated in hepatic disease/cirrhosis; however, cases of hepatotoxicity at daily acetaminophen dosages &lt;4 g/day have been reported. Avoid chronic use in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, oral: Acetaminophen 325 mg, isometheptene mucate 65 mg, and dichloralphenazone 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F129595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of migraine and tension headache",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Midrin&reg; may be confused with midodrine, Mydfrin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatological: Rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F129575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen, isometheptene, dichloralphenazone, or any component of the formulation; glaucoma; severe renal disease; hypertension; organic heart disease; hepatic disease; MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12925526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: May cause severe hepatotoxicity on acute overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity/ anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported with acetaminophen use; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use caution in patients with cardiovascular disease, including hypertension and peripheral vascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency; rare reports of hemolysis have occurred with acetaminophen use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment or active liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced hepatotoxicity. Avoid ethanol or limit to &lt;3 drinks/day.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F129578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Acetaminophen and dichloralphenazone are excreted in breast milk; excretion of isometheptene is not known.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F129577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Epidrin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     325-65-100 mg (100): $97.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12925532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of pain",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12925530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Although not fully elucidated, believed to inhibit the synthesis of prostaglandins in the central nervous system and work peripherally to block pain impulse generation; produces antipyresis from inhibition of hypothalamic health-regulating center",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dichloralphenazone: Prodrug, converted to chloral hydrate (sedative) and antipyrine (analgesic/antipyretic) that reduces patient&rsquo;s emotional response to painful stimuli",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isometheptene: A sympathomimetic that reduces stimuli leading to vascular headaches via constriction of dilated cranial and cerebral arterioles",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barker JD Jr, de Carle DJ, and Anuras S, &ldquo;Chronic Excessive Acetaminophen Use in Liver Damage,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1977, 87(3):299-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/900673/pubmed\" id=\"900673\" target=\"_blank\">",
"        900673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, Campbell RA, Cooper SA, et al, &ldquo;Suppression of Postoperative Pain by Preoperative Administration of Ibuprofen in Comparison to Placebo, Acetaminophen, and Acetaminophen Plus Codeine,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1983, 23(1):37-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/6341415/pubmed\" id=\"6341415\" target=\"_blank\">",
"        6341415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Licht H, Seeff LB, and Zimmerman HJ, &ldquo;Apparent Potentiation of Acetaminophen Hepatotoxicity by Alcohol,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1980, 92(4):511.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/32/23045/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9439 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-110.137.129.113-29A72C8F4F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23045=[""].join("\n");
var outline_f22_32_23045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129593\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129582\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129583\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129584\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129572\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129562\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129595\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129573\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129598\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129591\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129575\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925526\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129589\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129568\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129580\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129578\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129577\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925532\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925530\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9439\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9439|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/29/17876?source=related_link\">",
"      Acetaminophen, isometheptene, and dichloralphenazone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_32_23046="Bald-faced hornets";
var content_f22_32_23046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bald-faced hornets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23046=[""].join("\n");
var outline_f22_32_23046=null;
var title_f22_32_23047="SAPHO syndrome";
var content_f22_32_23047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    SAPHO Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 37-year-old woman with a history of palmoplantar pustulosis presented with severe chest pain. The patient was first diagnosed with palmoplantar pustulosis at the age of 36 and soon afterwards suffered from upper chest pain. Although the pain and skin lesion had been relieved for three years after excision of the left first sternocostal articulation, she experienced subsequent relapse of sternal pain and palmoplantar pustulosis. Medication for rheumatoid arthritis, such as prednisolone, bucillamine, and methotrexate, or antibiotic therapy failed to ameliorate the symptoms. At the age of 45, she underwent palatine tonsillectomy with resolution of symptoms. At present, the patient has neither palmoplantar skin lesions nor sternal pain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shimizu Tominaga, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23047=[""].join("\n");
var outline_f22_32_23047=null;
var title_f22_32_23048="Congenital cervical anomalies and benign cervical lesions";
var content_f22_32_23048=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital cervical anomalies and benign cervical lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23048/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23048/contributors\">",
"     Donald Peter Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23048/contributors\">",
"     Marc R Laufer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23048/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23048/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23048/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23048/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/32/23048/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign abnormalities of the cervix (Latin for neck) are commonly seen in gynecological practice. The relative ease of cervical examination allows observation of physiologic changes that occur in response to normal cyclic variations in ovarian hormone secretion, as well as a variety of structural abnormalities and pathologic conditions (premalignant, malignant, infection-related, benign neoplasms). Diagnosis and management require a combination of visual, tactile, and laboratory assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY, NORMAL ANATOMY, AND HISTOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Embryology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusion of the paired m&uuml;llerian ducts at about day 54 postfertilization results in formation of the uterovaginal canal, which is the precursor of the uterine corpus, cervix, and upper vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/1\">",
"     1",
"    </a>",
"    ]. The caudal end of the uterovaginal canal migrates down to meet the urogenital sinus at a point termed the m&uuml;llerian tubercle, which eventually becomes the vaginal orifice and hymen. At about day 66, stratification of cells in this area give rise to the sinovaginal bulbs, which proliferate to form a solid vaginal plate by day 77. The central cells of the vaginal plate then break down to form the vaginal lumen. Endocervical glands and the vaginal fornices appear between 91 days (13th week) and 15 weeks, thereby providing the first clear signs of the cervix.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal cervix is fusiform in shape, with the narrowest portions at the internal and external oses. After menarche, the cervix accounts for one-half to one-third of the length of the uterus, and measures 3 to 5 cm in length and 2 to 3 cm in diameter (in prepubertal girls, the cervix is twice the length of the fundus; this ratio reverses with age). The portio vaginalis is the visible portion of the cervix that protrudes into the vagina. The portio vaginalis is surrounded by a reflection of the vaginal wall on each side termed the anterior, posterior, and lateral fornix. The supravaginal cervix is the intraabdominal portion of the cervix that lies above the point of attachment of the vaginal vaults; the peritoneum posterior to the supravaginal cervix forms the lining of the posterior cul-de-sac (pouch of Douglas).",
"   </p>",
"   <p>",
"    The cervical canal, which averages 3 cm long and a few millimeters wide, connects the uterine cavity with the vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/2\">",
"     2",
"    </a>",
"    ]. The external cervical os (where the canal opens to the vagina) is small, round, and centrally placed in nulliparous women, but is more likely to be a patulous, transverse slit in women who have labored into the third stage (",
"    <a class=\"graphic graphic_figure graphicRef72718 \" href=\"UTD.htm?1/49/1823\">",
"     figure 1",
"    </a>",
"    ). The internal cervical os (where the canal opens to the uterine cavity) is normally no more than 3 mm in diameter in nonpregnant women, even if parous [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/2\">",
"     2",
"    </a>",
"    ]. The vagina is at a 90 degree angle to a normal anteverted uterus, thus the external cervical os faces toward the posterior wall of the vagina and the cervix lies between the bladder and rectum.",
"   </p>",
"   <p>",
"    The cervix is supported by the uterosacral ligaments, which surround the cervix and vagina and extend laterally and posteriorly toward the second to fourth dorsal vertebrae, and the cardinal ligaments, which are fibromuscular bands that fan out laterally from the lower uterine segment and cervix to the lateral pelvic walls. The blood supply comes from a descending branch of the uterine artery and lymphatic drainage is to the parametrial nodes, then to the obturator, internal iliac, and external iliac nodes with secondary drainage to the presacral, common iliac, and paraaortic lymph nodes. The nerve supply is autonomic (sympathetic and parasympathetic). The nerves enter the upper cervix on either side and form two lateral semicircular plexuses, called Frankenh&auml;user plexus, a terminal part of the presacral plexus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the body of the uterus, which is principally a muscular organ, the cervical stroma is predominantly collagen, with some elastic tissue and smooth muscle cells (15 percent).",
"   </p>",
"   <p>",
"    The portio vaginalis of the normal cervix is completely covered with smooth, pink, stratified, nonkeratinized squamous epithelium, similar to the lining of the vagina. The squamocolumnar junction is the point at which the squamous epithelium covering the portio joins the columnar epithelium of the cervical canal. The junction can be identified as the line of demarcation between the pale pink squamous epithelium that covers the portio and the bright red columnar epithelium that lines the canal (",
"    <a class=\"graphic graphic_picture graphicRef64778 \" href=\"UTD.htm?22/51/23344\">",
"     picture 1",
"    </a>",
"    ). The division may be at the external os or inside the endocervical canal. The columnar epithelium often extends well beyond the external os (ectropion, see below), particularly in newborn infants and during puberty and adolescence. In postmenopausal women, the squamocolumnar junction may be high in the canal where it cannot be seen. The union of squamous and columnar epithelium may be abrupt, but more often there is a transformation zone of cuboidal subcolumnar epithelium or reserve cells that have the potential of developing into either columnar or squamous cells. Cervical intraepithelial neoplasia usually originates in the active, constantly changing epithelium that comprises the transformation zone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cervical and vaginal epithelium, including the mucus producing columnar epithelium, are responsive to changes in estrogen and progesterone concentrations. Estrogen stimulates production of profuse, watery, alkaline mucus, whereas progesterone causes a thick, scant, acidic mucus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONGENITAL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;If one or both m&uuml;llerian ducts fail to fuse, or if development of one or both ducts does not occur, or is incomplete, duplication or agenesis of the cervix can occur. Coexistent anomalies of the vagina, uterus, and urinary tract are common since anomalies of the mesometanephric duct frequently occur in association with those of the m&uuml;llerian ducts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=see_link\">",
"     \"Diagnosis and management of congenital anomalies of the vagina\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of congenital anomalies of the uterus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Duplication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplication of the cervix (cervix duplex) may result in two distinct cervices or two fused cervices (",
"    <a class=\"graphic graphic_figure graphicRef77029 graphicRef75163 \" href=\"UTD.htm?8/60/9155\">",
"     figure 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76867 \" href=\"UTD.htm?17/54/18275\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62754 \" href=\"UTD.htm?6/30/6624\">",
"     picture 3",
"    </a>",
"    ). It may be difficult to differentiate and determine if there are two separate cervices or if there is a single cervix with a septum. Nonobstructive duplication of the cervix is usually asymptomatic and does not require intervention. Obstructive lesions require surgical intervention (described below) if hematometra or pyometra occurs. In cases of cervical duplication with a longitudinal vaginal septum or an obstructed hemivagina, great care should be taken when removing the septum so as not to compromise the blood supply to the individual cervices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Agenesis/hypoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical agenesis and hypoplasia are rare. With complete agenesis, both the cervix and the upper vagina must be absent, as the proximal portion of the vagina does not form in the absence of a cervix during embryonic development (",
"    <a class=\"graphic graphic_figure graphicRef66336 graphicRef78045 \" href=\"UTD.htm?8/32/8706\">",
"     figure 3A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69790 \" href=\"UTD.htm?13/43/14015\">",
"     figure 4",
"    </a>",
"    ). When the cervix is present, but hypoplastic, the vagina can be normal (",
"    <a class=\"graphic graphic_figure graphicRef80051 graphicRef67197 \" href=\"UTD.htm?5/0/5127\">",
"     figure 5A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cervical hypoplasia is typically recognized at menarche. Adolescents may present with primary amenorrhea, cyclic or chronic abdominopelvic pain, or a pelvic mass (from hematometra). Radiologic imaging with ultrasound and magnetic resonance are helpful in defining the anatomy.",
"   </p>",
"   <p>",
"    Historically, the preferred treatment was hysterectomy, given this condition was not considered compatible with future fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, less aggressive surgical procedures have been developed. One procedure uses molds and both skin and \"mucosal\" grafts to create an upper vagina and cervical endocervical tract to allow menstruation and potentially enable spontaneous conception and successful pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. The disadvantages of this approach are the risks of recurrent obstruction and ascending infection, which can lead to sepsis and death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A treatment algorithm, proposed by one group, is shown in the table (",
"    <a class=\"graphic graphic_algorithm graphicRef74618 \" href=\"UTD.htm?12/57/13215\">",
"     algorithm 1",
"    </a>",
"    ). Since patients vary widely in their degree of cervical hypoplasia, clinicians should select a surgical procedure carefully and be certain of the diagnosis (eg, differentiate between a high transverse vaginal septum and cervical agenesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/13\">",
"     13",
"    </a>",
"    ]. A safe, successful surgical procedure is more likely when there is normal cervical tissue that just lacks a patent cervical canal than when there is significant cervical agenesis.",
"   </p>",
"   <p>",
"    Advances in reproductive endocrinology and fertility therapy have enabled women to avoid the need for surgical intervention. Long-term use of medications that suppress menstruation (eg, combination",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    therapy, continuous progestin only, or a GnRH agonist with add-back therapy) can prevent development of hematometra, dysmenorrhea, and chronic pelvic pain. When pregnancy is desired, these medications can be stopped and conception may be attempted using assisted reproductive techniques. Successful pregnancies with planned cesarean delivery have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/14\">",
"     14",
"    </a>",
"    ]. This approach is also applicable for some women with variations of cervical agenesis in which there is a single midline uterus or hemiuterus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diethylstilbestrol induced changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In utero exposure to diethylstilbestrol (DES) is associated with cervical hypoplasia, collars, hoods, and polyps. Gross cervical abnormalities can be seen in about 20 percent of exposed women. Cancer is rare (1 case per 1000 to 2000 exposed daughters). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3322?source=see_link\">",
"     \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cervical adenosis also occurs because remnants of the m&uuml;llerian anlage persist beneath the vaginal plate of squamous epithelium, an area where glandular elements are not normally found. Most of the glands are lined by mucin-secreting columnar cells. They may be buried beneath the epithelium, but often glands and their secretions are visible away from the transformation zone on the cervix. Cervical adenosis is typically accompanied by vaginal adenosis.",
"   </p>",
"   <p>",
"    DES-related structural cervical abnormalities do not require treatment. There may be an increased risk of cervical insufficiency during pregnancy; such women are closely monitored and may be candidates for placement of a cerclage. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=see_link\">",
"     \"Cervical insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ECTROPION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectropion occurs when eversion of the endocervix exposes columnar epithelium to the vaginal milieu (",
"    <a class=\"graphic graphic_picture graphicRef64778 \" href=\"UTD.htm?22/51/23344\">",
"     picture 1",
"    </a>",
"    ). The everted epithelium has a reddish appearance similar to granulation tissue, and may be covered by a yellow turbid discharge. Ectropion is common in adolescents. After adolescence, it may be observed in women who are pregnant or taking estrogen-progestin contraceptives or who had a cervical laceration during labor and delivery. In parous women, the external os is wide and patulous as a result of changes from prior labor and delivery (",
"    <a class=\"graphic graphic_figure graphicRef72718 \" href=\"UTD.htm?1/49/1823\">",
"     figure 1",
"    </a>",
"    ). In some of these women, opening a vaginal speculum to inspect the cervix causes the anterior and posterior lips to separate, exposing the endocervical canal. As the speculum is withdrawn, the anterior and posterior lips fall together, and often the ectropion disappears.",
"   </p>",
"   <p>",
"    Ectropion has also been called erosion, which is a poor term because it implies that the superficial squamous cells have eroded away to expose underlying tissue. Although this can occur, most \"erosions\" represent areas on the portio of the cervix where squamous cells have been replaced by overgrowth of columnar epithelium.",
"   </p>",
"   <p>",
"    Ectropion should not be treated except in the rare occurrence of excessive mucous discharge or spotting that is very bothersome to the woman. In such cases, malignancy should be excluded before undertaking any treatment. An ablative procedure using cryocautery or electrocautery is effective, but is invasive and will result in copious vaginal discharge until healing is completed, which may take weeks. Ablative treatment can also result in cervical stenosis, which can adversely affect future fertility and, if pregnancy is achieved, labor and delivery. As an alternative, we suggest a two-week trial of an acidifying agent, such as boric acid suppositories 600 mg vaginally at bedtime, which may be effective. Use of deoxyribonucleic acid 5 mg vaginal suppositories has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44343?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Ablative therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CERVICITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervicitis is classified as either acute or chronic. The most common symptom, and often the only one, is purulent vaginal discharge. The appearance of the acutely inflamed cervix varies greatly, depending upon the degree of involvement and the infecting organism. Mucopurulent cervical discharge, cervical friability, and cervical edema are characteristics of both gonococcal and chlamydial cervicitis; the latter is more common. Punctate hemorrhages on the vagina and cervix suggest trichomonas infection. Vesicular or ulcerative lesions suggest infection with herpes simplex virus (HSV). The clinical manifestations, diagnosis, and treatment of cervicitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=see_link\">",
"     \"Acute cervicitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CYSTIC LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cysts are usually asymptomatic, but may cause dyspareunia or a pressure sensation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nabothian cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nabothian cysts (also called mucinous retention cysts, epithelial inclusion cysts) are discrete cystic structures that form when a cleft of columnar epithelium becomes covered with squamous cells and the columnar cells continue to secrete mucoid material. The cysts vary from microscopic to several centimeters in size; the larger ones project above the surface of the portio. They may appear translucent or opaque (",
"    <a class=\"graphic graphic_picture graphicRef73788 graphicRef53598 \" href=\"UTD.htm?30/1/30742\">",
"     picture 4A-B",
"    </a>",
"    ). Nabothian cysts may occur following minor trauma or childbirth.",
"   </p>",
"   <p>",
"    The only indication for treatment is relief from pain or a bothersome feeling of fullness in the vagina. Ablation of the cyst using electrocautery is the usual approach; however, if the diagnosis is uncertain, excision to evaluate histopathology is advised. The main disadvantage to surgical treatment is the possibility of causing scar tissue, which itself can lead to dyspareunia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mesonephric cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic remnants of the mesometanephric (Wolffian) duct may be found deep within the cervical stroma when tissue removed at conization is examined pathologically. Occasionally, one or more of these remnants form a cyst, which may be confused with Nabothian cysts. Mesonephric cysts seldom reach a size greater than 2.5 cm, and are usually located at the three and nine o'clock points, near the base of the cervix.",
"   </p>",
"   <p>",
"    Intervention should be avoided in asymptomatic women. Treatment similar to that recommended above for Nabothian cysts is indicated if the patient has bothersome symptoms. A large cyst can be marsupialized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NONCYSTIC LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical neoplasms can be asymptomatic, but often present with spotting, especially postcoitally, or discharge. Most are benign, but if a cervical mass lesion is observed, exophytic squamous cell carcinoma should be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical polyps commonly occur during the reproductive years, especially after age 40 years. The etiology is unknown. Chronic inflammation of the cervical canal may play a role, as may hormonal factors, since endometrial hyperplasia and polyps coexist more frequently than one would expect by chance alone. Differential diagnosis includes leiomyoma and endometrial polyps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Single or multiple cervical polyps usually arise from the endocervical canal, but can also originate from the portio (",
"    <a class=\"graphic graphic_picture graphicRef53131 \" href=\"UTD.htm?29/39/30320\">",
"     picture 5",
"    </a>",
"    ). The tear-shaped or lobular structures appear red, purple, or flesh-colored, depending upon the vascularity and congestion present, and usually look succulent and glistening. The size is typically less than 3 cm in diameter; however, polyps large enough to fill the vagina or presenting at the introitus have been described. The pedicle is usually long and thin, but may be short and broad-based. Histologically, cervical polyps are characterized by vascular connective tissue stroma covered by epithelium, which may be columnar, squamous, or squamocolumnar.",
"   </p>",
"   <p>",
"    Polyps should be removed when symptomatic (eg, bleeding, excessive discharge), large (&ge;3 cm), or appearing atypical. Polypectomy can usually be accomplished by grasping the base of the polyp with forceps and twisting it off. If visible, the base can be cauterized to prevent bleeding and reduce the chance of recurrence. If the base is wide, such as is the case with a sessile polyp, the main portion of the polyp should be removed with a biopsy forceps and the base destroyed with cautery or laser to reduce the likelihood of recurrence.",
"   </p>",
"   <p>",
"    Malignancy is rarely found in a cervical polyp [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]; however, polyps which are removed should be submitted to the laboratory for histological study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Warts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar, perineal, and anogenital warts are frequently associated with vaginal and cervical lesions. Single or multiple condylomata acuminata due to HPV infection may be visible grossly, and are asymptomatic. These warts are often flat, in contrast to condyloma in other areas of the anogenital region. They become white, and thus more visible to the naked eye when swabbed with a solution of 3 to 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    .",
"    <span class=\"nowrap\">",
"     Cytology/colposcopy",
"    </span>",
"    may reveal squamous intraepithelial neoplasia. These abnormalities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Endometriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical endometriosis, which is rare, appears as red or",
"    <span class=\"nowrap\">",
"     brownish/blackish",
"    </span>",
"    areas (\"powder burns\") that do not blanch on compression, or as firm nodules on the portio vaginalis. Affected patients may be asymptomatic or may have discharge, dysmenorrhea, or dyspareunia. Clinical manifestations other than discharge are most likely due to implants at other sites in the pelvis, such as the ovary or uterosacral Iigaments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologically these lesions are the same as endometriosis at other sites. Excision or biopsy and pathologic evaluation are the keys to definitive diagnosis. Superficial endometriosis has been confused with endocervical glandular dysplasia and adenocarcinoma, which can only be excluded by biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/18\">",
"     18",
"    </a>",
"    ]. Differential diagnosis also includes cervical gestational trophoblastic disease and normal hyperemia related to early pregnancy, both of which can be excluded by negative results on human chorionic gonadotropin testing.",
"   </p>",
"   <p>",
"    Asymptomatic lesions do not require treatment. If the implants are tender and are causing dyspareunia, electrocautery ablation is therapeutic. Indications for systemic therapy of endometriosis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link\">",
"     \"Overview of the treatment of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical adenosis is a lesion consisting of columnar epithelium surrounded by fibromuscular stroma. Although it usually occurs deep in the cervix, it may arise superficially. Adenosis can be associated with intrauterine diethylstilbestrol (DES) exposure (see below) or be a variant of normal.",
"   </p>",
"   <p>",
"    Superficial adenosis appears as cherry red dots. Colposcopically these red dots appear similar to gland openings observed near the transformation zone. The lesions are usually asymptomatic, but can be associated with an increase in clear or white discharge and, rarely, dyspareunia. Electrocautery ablation is only indicated if symptoms are bothersome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Papillomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillomas of the cervix are rare. They arise from the ectocervix near the squamocolumnar columnar junction (transformation zone) and are usually less than 1 cm in diameter. Microscopically, a central core of connecting tissue supports a covering of squamous cells.",
"   </p>",
"   <p>",
"    If the papilloma has a long stalk, it can be twisted until it detaches from the cervix. Papillomas can also be excised using biopsy forceps, laser, or loop electrosurgical excision procedure (LEEP); the choice depends on their size and location on the cervix. The base of the papilloma should be cauterized to prevent bleeding and recurrence.",
"   </p>",
"   <p>",
"    Papillomas are rarely malignant, nevertheless any tissue that is removed should be submitted for histopathological analysis. Differential diagnosis includes epithelial tags resulting from obstetrical injury, condylomata acuminata, or exophytic squamous cell carcinomas (see individual topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomas are the most common tumors of the uterus, but it is rare to find them isolated to the cervix. Leiomyomas of the cervix can be subserosal, intramural, or submucous and can distort the cervical canal or upper vagina. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pedunculated leiomyomas are often removed because of their propensity to twist and infarct or bleed. Myomectomy is indicated if there are bothersome symptoms (bladder or bowel dysfunction due to mass displacement, bleeding, dyspareunia), or if the leiomyoma prevents adequate evaluation of the cervix. The removal of large, intramural cervical myomas can be complicated because of proximity to the bladder, bowel, or ureter. Hysterectomy can be considered if childbearing is no longer a concern and the cervical mass is large and symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital ulcers related to sexually transmitted diseases typically occur on external genitalia, but the cervix may be involved. The chancre of syphilis develops at the site of inoculation, which can be the cervix. This ulcer is painless, in contrast to the other two major causes of genital ulcers: herpes simplex virus and Hemophilus ducreyi (chancroid). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=see_link\">",
"     \"Chancroid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CERVICAL STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical stenosis is usually caused by contraction of scar tissue, agglutination of raw surfaces within the endocervical canal, or obliteration of the endocervical canal by tumor (eg, endometrial or cervical cancer), although some cases are congenital. Cervical surgery and radium application are common causes of scarring; secondary dysmenorrhea or amenorrhea after cervical procedures strongly suggests cervical stenosis has developed. The hypoestrogenic state of menopause induces endocervical changes favorable for agglutination.",
"   </p>",
"   <p>",
"    A cervical canal that does not permit the insertion of an instrument, such as a Hegar dilator (2.5 mm in diameter), is considered consistent with cervical canal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/19\">",
"     19",
"    </a>",
"    ]. The diameters of the cervical canal in nulliparous and multiparous women are approximately 5 mm and 8 mm, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential consequences of cervical stenosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impeded menstrual flow &mdash; Menses may be scant, painful, or prolonged. In severe stenosis, hematometra can develop. A menstrual blood flow modeling system using a rigid tube suggested that a cervical os greater than 5 mm would allow almost all menstrual blood to flow out through the cervix; however, a diameter less than 2 mm would result in significant retrograde flow out of the fallopian tubes [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impeded access to the endocervical canal and endometrial cavity for diagnostic and therapeutic procedures.",
"     </li>",
"     <li>",
"      Cervical dystocia during labor.",
"     </li>",
"     <li>",
"      Postmenopausal cervical stenosis may completely close the endocervix so that secretions and cellular debris from the atrophic endometrial cavity cannot escape and accumulate in the body of the uterus (hematometra, hydrometra). Infection of the accumulated debris leads to pyometra.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of cervical stenosis consists of dilatation of the cervix to allow access to and drainage from the uterine cavity. This can sometimes be performed as an office procedure. A paracervical block is given and an examination to determine the axis of the uterus is performed. The cervix is then grasped with a tenaculum and dilated with the smallest cervical dilator available; however, in many cases, even the smallest such dilator is still too large. For a very stenotic os, a small silver wire probe or lacrimal duct probe is usually the best instrument with which to begin. Brute force should be avoided because there is a high risk of creating a false passage or perforating the cervix or uterus. If office dilatation is unsuccessful, the procedure can be attempted in the operating room under general or regional anesthesia and with use of a hysteroscope. Ultrasound guidance is also very helpful to guide the probe or dilator into the uterine cavity and avoid cervical or uterine perforation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=see_link\">",
"     \"Uterine perforation during gynecologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a hematometra is present, entry into the uterus will be signaled by passage of thick, brown blood and mucus. An endocervical curettage should be done to exclude a cervical or endometrial tumor as soon as the curette can be introduced. Pyometra should be cultured and broad spectrum antibiotics administered. After the contents of the uterus are drained, the cervical canal is dilated to the largest diameter possible using standard dilators, unless future childbearing is planned.",
"   </p>",
"   <p>",
"    The cervix can be \"kept open\" in a number of ways. One method is to place a Mallencrodt catheter (16 to 22 french) or a pediatric Foley catheter after the cervix has been mechanically dilated. The catheter should be sewn in place with a permanent suture through the catheter and through the cervical tissue to decrease the risk that it will be expelled. The catheter is left in situ until the tract has healed (average of 10 to 14 days); the patient receives prophylactic antibiotics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg orally twice per day) until it is removed to decrease the risk of an ascending infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, a 3 or 4 mm dilator can be passed through the endocervical canal once per week until the point of stricture remains open without force. This usually requires three or four weekly dilatations carried out in the office following administration of a paracervical block. A nonsteroidal antiinflammatory agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    600 to 800 mg orally) should be taken one hour prior to the procedure to diminish patient discomfort. An alternative procedure using a carbon dioxide laser to vaporize scar tissue and enlarge the cervical os was successful in small series of patients with iatrogenic cervical stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Hysteroscopic resection using a wire loop followed by placement of 12-French pediatric catheter for two weeks has also been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23048/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If symptomatic cervical stenosis in a premenopausal woman who wants to maintain childbearing capacity cannot be resolved using these techniques, hormonally suppressive therapy can be given (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Agenesis/hypoplasia'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In rare instances where patency cannot be maintained and future fertility is not a desire, hysterectomy is indicated, particularly if there is recurrent infection or pain. Endometrial sampling is essential to exclude uterine cancer before hysterectomy is undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PREMALIGNANT AND MALIGNANT LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premalignant cervical lesions and cervical carcinoma are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonobstructive duplication of the cervix is usually asymptomatic and does not require intervention. Obstructive lesions require surgical intervention if hematometra or pyometra occurs. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Duplication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ectropion occurs when eversion of the endocervix exposes columnar epithelium to the vaginal milieu (",
"      <a class=\"graphic graphic_picture graphicRef64778 \" href=\"UTD.htm?22/51/23344\">",
"       picture 1",
"      </a>",
"      ). Treatment is unnecessary except in the rare occurrence of excessive mucous discharge or spotting that is very bothersome to the woman. We suggest a trial of an acidifying agent, such as boric acid suppositories 600 mg vaginally at bedtime (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An ablative procedure using cryocautery or electrocautery is effective, but is invasive and will result in copious vaginal discharge until healing is completed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Ectropion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nabothian and mesonephric cysts occur on the portio vaginalis, and have a similar appearance. If these lesions are associated with bothersome symptoms (discharge, pressure, dyspareunia), we suggest ablation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cystic lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical polyps are common and usually originate from the endocervical canal. We suggest removal of symptomatic (spotting) or large polyps (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This can usually be accomplished by grasping them at the base with forceps and twisting. If the base is wide, the main portion of the polyp is removed with a biopsy forceps and the base destroyed with electrocautery or laser. Differential diagnosis includes leiomyoma and endometrial polyps. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Polyps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a cervical mass lesion is observed, exophytic squamous cell carcinoma should be excluded. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Noncystic lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical stenosis is caused by scar tissue, agglutination of raw surfaces within the endocervical canal, or obliteration of the endocervical canal by tumor; some cases are congenital. Dilation of the stenotic cervix can be performed starting with a wire, lacrimal duct probe, or standard mechanical dilators, as appropriate. We suggest placing a Mallencrodt catheter (16 to 22 french) to keep the cervix open after it has been mechanically dilated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The catheter is left in situ until the tract has healed (average of 10 days); the patient receives prophylactic antibiotics (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg orally twice per day) until it is removed to decrease the risk of an ascending infection. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Cervical stenosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     www.pathologyresources.com. (Accessed on May 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/2\">",
"      Hricak H, Chang YC, Cann CE, Parer JT. Cervical incompetence: preliminary evaluation with MR imaging. Radiology 1990; 174:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/3\">",
"      Niver DH, Barrette G, Jewelewicz R. Congenital atresia of the uterine cervix and vagina: three cases. Fertil Steril 1980; 33:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/4\">",
"      Dillon WP, Mudaliar NA, Wingate MB. Congenital atresia of the cervix. Obstet Gynecol 1979; 54:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/5\">",
"      Rock JA, Schlaff WD, Zacur HA, Jones HW Jr. The clinical management of congenital absence of the uterine cervix. Int J Gynaecol Obstet 1984; 22:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/6\">",
"      Fujimoto VY, Miller JH, Klein NA, Soules MR. Congenital cervical atresia: report of seven cases and review of the literature. Am J Obstet Gynecol 1997; 177:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/7\">",
"      Deffarges JV, Haddad B, Musset R, Paniel BJ. Utero-vaginal anastomosis in women with uterine cervix atresia: long-term follow-up and reproductive performance. A study of 18 cases. Hum Reprod 2001; 16:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/8\">",
"      Bugmann P, Amaudruz M, Hanquinet S, et al. Uterocervicoplasty with a bladder mucosa layer for the treatment of complete cervical agenesis. Fertil Steril 2002; 77:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/9\">",
"      Creighton SM, Davies MC, Cutner A. Laparoscopic management of cervical agenesis. Fertil Steril 2006; 85:1510.e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/10\">",
"      Singh J, Devi YL. Pregnancy following surgical correction of nonfused m&uuml;llerian bulbs and absent vagina. Obstet Gynecol 1983; 61:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/11\">",
"      Geary WL, Weed JC. Congenital atresia of the uterine cervix. Obstet Gynecol 1973; 42:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/12\">",
"      Casey AC, Laufer MR. Cervical agenesis: septic death after surgery. Obstet Gynecol 1997; 90:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/13\">",
"      Rock, JA, Carpenter SE, Wheeless CR, Jones, HW. The clinical management of maldevelopment of the uterine cervix. J Pelvic Surg 1995; 1:129.",
"     </a>",
"    </li>",
"    <li>",
"     Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric &amp; Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Wolters Kluwer Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.188.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/15\">",
"      Belfiore P, Costa E, De Cantis S, et al. Effectiveness and persistence of a topical treatment for cervical ectropion with deoxyribonucleic acid. Minerva Ginecol 2005; 57:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/16\">",
"      Kerner H, Lichtig C. M&uuml;llerian adenosarcoma presenting as cervical polyps: a report of seven cases and review of the literature. Obstet Gynecol 1993; 81:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/17\">",
"      Van Renterghem N, De Paepe P, Van den Broecke R, et al. Primary lymphoma of the cervix uteri: a diagnostic challenge. Report of two cases and review of the literature. Eur J Gynaecol Oncol 2005; 26:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/18\">",
"      Baker PM, Clement PB, Bell DA, Young RH. Superficial endometriosis of the uterine cervix: a report of 20 cases of a process that may be confused with endocervical glandular dysplasia or adenocarcinoma in situ. Int J Gynecol Pathol 1999; 18:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/19\">",
"      Baldauf JJ, Dreyfus M, Ritter J, et al. Risk of cervical stenosis after large loop excision or laser conization. Obstet Gynecol 1996; 88:933.",
"     </a>",
"    </li>",
"    <li>",
"     Krantz, KE. The anatomy of the human cervix, gross and histologic. In: The biology of the cervix, Moghissi K (Ed), University of Chicago Press, Chicago 1973. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/21\">",
"      Barbieri RL, Callery M, Perez SE. Directionality of menstrual flow: cervical os diameter as a determinant of retrograde menstruation. Fertil Steril 1992; 57:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/22\">",
"      Yanushpolsky EH, Ginsburg ES, Fox JH, Stewart EA. Transcervical placement of a Malecot catheter after hysteroscopic evaluation provides for easier entry into the endometrial cavity for women with histories of difficult intrauterine inseminations and/or embryo transfers: a prospective case series. Fertil Steril 2000; 73:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/23\">",
"      Baggish MS, Baltoyannis P. Carbon dioxide laser treatment of cervical stenosis. Fertil Steril 1987; 48:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/24\">",
"      Luesley DM, Williams DR, Gee H, et al. Management of postconization cervical stenosis by laser vaporization. Obstet Gynecol 1986; 67:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/25\">",
"      Noyes N. Hysteroscopic cervical canal shaving: a new therapy for cervical stenosis before embryo transfer in patients undergoing in vitro fertilization. Fertil Steril 1999; 71:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23048/abstract/26\">",
"      Noyes N, Licciardi F, Grifo J, et al. In vitro fertilization outcome relative to embryo transfer difficulty: a novel approach to the forbidding cervix. Fertil Steril 1999; 72:261.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5428 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23048=[""].join("\n");
var outline_f22_32_23048=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMBRYOLOGY, NORMAL ANATOMY, AND HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Embryology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONGENITAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Duplication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Agenesis/hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diethylstilbestrol induced changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ECTROPION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CERVICITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CYSTIC LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nabothian cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mesonephric cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NONCYSTIC LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Polyps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Warts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Endometriosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Papillomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CERVICAL STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PREMALIGNANT AND MALIGNANT LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5428\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5428|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?12/57/13215\" title=\"algorithm 1\">",
"      Amenorrhea pain workup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5428|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/49/1823\" title=\"figure 1\">",
"      Parous and nonparous cervix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/61/17375\" title=\"figure 2A\">",
"      Uterus didelphys normal vagina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/33/29215\" title=\"figure 2B\">",
"      Septate uterus and vag septum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/55/28543\" title=\"figure 3A\">",
"      Cervical agenesis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/49/34590\" title=\"figure 3B\">",
"      Cervical agenesis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/43/14015\" title=\"figure 4\">",
"      Cervico-uterine hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/10/26799\" title=\"figure 5A\">",
"      Cervical hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/19/11572\" title=\"figure 5B\">",
"      Cervical dysgenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5428|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/51/23344\" title=\"picture 1\">",
"      Squamocolumnar junction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/54/18275\" title=\"picture 2\">",
"      Double cervix in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/30/6624\" title=\"picture 3\">",
"      Uterus bicollis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/24/12674\" title=\"picture 4A\">",
"      Nabothian cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/36/23104\" title=\"picture 4B\">",
"      Nabothian cyst2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/39/30320\" title=\"picture 5\">",
"      Endocervical polyp",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4457?source=related_link\">",
"      Cervical insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44343?source=related_link\">",
"      Cervical intraepithelial neoplasia: Ablative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26633?source=related_link\">",
"      Clinical manifestations and diagnosis of congenital anomalies of the uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12473?source=related_link\">",
"      Diagnosis and management of congenital anomalies of the vagina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3322?source=related_link\">",
"      Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4408?source=related_link\">",
"      Uterine perforation during gynecologic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_32_23049="Treatment regimens for Helicobacter pylori";
var content_f22_32_23049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment regimens for Helicobacter pylori",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23049/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23049/contributors\">",
"     Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23049/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23049/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23049/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/32/23049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple regimens have been evaluated for",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    therapy in randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Despite the number of studies, the optimal therapeutic regimen has not yet been defined. The treatment regimen that is selected must be effective, but considerations such as cost, side effects, and ease of administration should also be taken into account. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link&amp;anchor=H2#H2\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\", section on 'When to test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss treatment regimens for",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    . The indications and diagnostic tests for",
"    <em>",
"     Helicobacter",
"    </em>",
"    infection, as well as the bacteriology and epidemiology, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43271?source=see_link\">",
"     \"Bacteriology and epidemiology of Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3006516328\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various drug regimens have been proposed for the initial treatment of",
"    <em>",
"     H. pylori",
"    </em>",
"    infection (",
"    <a class=\"graphic graphic_table graphicRef65237 \" href=\"UTD.htm?18/49/19228\">",
"     table 1",
"    </a>",
"    ). These include triple, quadruple, or sequential therapy regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Triple therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regimen most commonly recommended for first line treatment of",
"    <em>",
"     H. pylori",
"    </em>",
"    is triple therapy with a proton pump inhibitor (PPI) (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    30 mg twice daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    20 mg twice daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    40 mg twice daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    20 mg twice daily, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    40 mg once daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (1 g twice daily), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (500 mg twice daily) for 7 to 14 days. Increasing the doses of PPIs has small effects on eradication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/6\">",
"     6",
"    </a>",
"    ]. A longer duration of treatment (14 versus 7 days) may be more effective in curing infection but this remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. A meta-analysis suggested that extension of PPI-based triple therapy from 7 to 14 days was associated with a 5 percent increase in eradication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/9\">",
"     9",
"    </a>",
"    ]. Most studies included were based upon amoxicillin-based triple therapy. We suggest treatment for ten days to two weeks. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33209?source=see_link\">",
"     lansoprazole-amoxicillin-clarithromycin",
"    </a>",
"    is available in a daily dose convenience packaging, Prevpac&reg; (TAP Pharmaceuticals, Inc).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    (500 mg twice daily) can be substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , but only in penicillin-allergic individuals since metronidazole resistance is common and can reduce the efficacy of treatment (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Antibiotic resistance'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6063086\">",
"    <span class=\"h2\">",
"     Quadruple therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quadruple therapy consists of a PPI, combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    (525 mg four times daily) and two antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    250 mg four times daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    500 mg four times daily) given for 10 to 14 days. Quadruple therapy is appropriate as initial therapy in areas in which the prevalence of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or metronidazole is &gt;20 percent, or in patients with recent or repeated exposure to clarithromycin or metronidazole [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/10\">",
"     10",
"    </a>",
"    ]. A meta-analysis of 93 studies showed that in populations with either clarithromycin or metronidazole resistance, quadruple therapy resulted in a higher rate of eradication than triple therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/11\">",
"     11",
"    </a>",
"    ]. Fourteen-day therapy with clarithromycin in place of metronidazole does appear to be effective in patients who are resistant to metronidazole [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A combination capsule containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    subcitrate 140 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    125 mg, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    125 mg (Pylera&trade;, Axcan ScandiPharm) has been approved by the United States Food and Drug Administration (FDA). A regimen using the combination capsule (three capsules four times daily plus PPI twice daily) is simpler than standard quadruple therapy (four to eight pills four times daily and a PPI twice daily). This could improve compliance.",
"   </p>",
"   <p>",
"    Studies of the combination capsule suggest good eradication rates, including in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one trial, 137 patients were treated with three combination capsules dosed four times daily for 10 days along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    20 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <em>",
"     H. pylori",
"    </em>",
"    infection was cured in 88 percent compared with 83 percent of 137 patients receiving 10 days of omeprazole 20 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    1 g, and clarithromycin 500 mg twice daily (not significantly different). One week of quadruple treatment may be sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/15\">",
"     15",
"    </a>",
"    ]. A one-day course of quadruple therapy has also been evaluated but long-term efficacy has not been established and thus it cannot yet be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85526733\">",
"    <span class=\"h3\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an open label prospective trial,",
"    <em>",
"     H. pylori",
"    </em>",
"    treatment-na&iuml;ve patients randomized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (LOAD) for 7 or 10 days had significantly higher eradication rates compared to triple therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (LAC) (LOAD-7 88.9 percent, LOAD-10 90 percent, combined LOAD 89.4 percent, LAC 73.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/17\">",
"     17",
"    </a>",
"    ]. However, large randomized controlled trials are needed to confirm these results and determine whether this more expensive regimen would be cost-effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sequential therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sequential triple therapy may improve eradication rates, especially with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistant strains. This 10-day regimen involves giving a PPI (twice daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (1 g twice daily) for five days, followed by a PPI (twice daily) plus clarithromycin (500 mg twice daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    (500 mg twice daily) for five days. In one trial, eradication was significantly greater with the sequential regimen than with triple therapy treatment (89 versus 77 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/18\">",
"     18",
"    </a>",
"    ]. These differences were even more pronounced in a subset of patients with clarithromycin resistant",
"    <em>",
"     H. pylori",
"    </em>",
"    strains (89 versus 29 percent).",
"   </p>",
"   <p>",
"    Another study conducted in an area where",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistance prevalence is over 15 percent compared sequential therapy regimens containing clarithromycin or one of two doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients were assigned to one of three regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      sequential therapy &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       Omeprazole",
"      </a>",
"      (20 mg twice daily) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (1 g twice daily) for five days, followed by omeprazole (20 mg twice daily), clarithromycin (500 mg twice daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      (500 mg twice daily) for five or more days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      -250 sequential therapy &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       Omeprazole",
"      </a>",
"      (20 mg twice daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (1 g twice daily) for five days, followed by omeprazole (20 mg twice daily), levofloxacin (250 mg twice daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      (500 mg twice daily) for five or more days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      -500 sequential therapy &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       Omeprazole",
"      </a>",
"      (20 mg twice daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (1 g twice daily) for five days, followed by omeprazole (20 mg twice daily), levofloxacin (500 mg twice daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      (500 mg twice daily) for five or more days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eradication rates in the intention-to-treat analyses were 81 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    sequential therapy, 96 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    -250 sequential therapy, and 97 percent with levofloxacin-500 sequential therapy. No differences in the prevalence of antimicrobial resistance or incidence of adverse events were observed between groups. Levofloxacin-250 therapy was cost-saving compared with clarithromycin sequential therapy, leading the authors to conclude that levofloxacin-containing sequential therapy is more effective, equally safe, and cost-saving compared with clarithromycin-containing sequential therapy in an area where clarithromycin resistance is over 15 percent.",
"   </p>",
"   <p>",
"    However, data concerning the efficacy of sequential therapy are conflicting. Two pooled analyses confirmed the efficacy of sequential therapy, especially in those infected with macrolide resistant organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In another randomized trial, the eradication rate among Korean patients receiving sequential therapy was higher (86 percent) than in those receiving 14-day PPI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    treatment (75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/22\">",
"     22",
"    </a>",
"    ]. A meta-analysis of 10 randomized controlled trials in over 3000 adults reported an odds ratio for eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    with sequential therapy compared to PPI-based triple therapy of 2.99 (95% CI 1.95-4.38) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/23\">",
"     23",
"    </a>",
"    ]. However, all but one of the studies cited were of poor quality and these studies were conducted largely in Italy, therefore it is unclear if the results are generalizable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/24\">",
"     24",
"    </a>",
"    ]. In contrast, one randomized trial of 232",
"    <em>",
"     H. pylori",
"    </em>",
"    infected patients showed that sequential or concomitant treatment was equally effective for eradication (93 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/25\">",
"     25",
"    </a>",
"    ]. In a randomized trial in Latin America of 1463",
"    <em>",
"     H. pylori",
"    </em>",
"    infected patients, 14-day triple therapy had higher eradication rates than 5-day concomitant and 10-day sequential therapy with a four drug regimen (82, 74, and 77 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, studies in children suggest a limited benefit of sequential therapy, if any, compared with PPI-based triple therapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/23,27,28\">",
"     23,27,28",
"    </a>",
"    ]. The meta-analysis described above included three randomized controlled trials conducted in children and adolescents that reported an odds ratio for eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    with sequential therapy compared to PPI-based triple therapy of 1.98 (95% CI 0.96-4.07) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/23\">",
"     23",
"    </a>",
"    ]. A randomized controlled trial involving 107 Polish children demonstrated eradication rates of 87 percent in those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    -containing sequential therapy and 69 percent in the group treated with seven days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (relative risk 1.26, 95% CI 1.0-1.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two guidelines for evaluation and management of",
"    <em>",
"     H. pylori",
"    </em>",
"    have been proposed: the American College of Gastroenterology guidelines (",
"    <a class=\"graphic graphic_table graphicRef65237 \" href=\"UTD.htm?18/49/19228\">",
"     table 1",
"    </a>",
"    ) and the Maastricht guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The guidelines differ slightly in their recommendations for treatment. The Maastricht guidelines recommend triple therapy for 14 days as initial treatment; however, they also suggest that a seven-day treatment may be acceptable where local studies show it is effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2834839008\">",
"    <span class=\"h1\">",
"     ERADICATION CONFIRMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eradication may be confirmed by a urea breath test, fecal antigen test, or upper endoscopy performed four weeks or more after completion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/29\">",
"     29",
"    </a>",
"    ]. Eradication should be confirmed in the following situations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have persistent symptoms after",
"      <em>",
"       H. pylori",
"      </em>",
"      treatment for dyspepsia",
"     </li>",
"     <li>",
"      Patients who had an",
"      <em>",
"       H. pylori",
"      </em>",
"      associated ulcer",
"     </li>",
"     <li>",
"      Patients who had gastric mucosa associated lymphoid tissue (MALT) lymphoma",
"     </li>",
"     <li>",
"      Patients who had resection for early gastric cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If initial",
"    <em>",
"     H. pylori",
"    </em>",
"    treatment was for persistent symptoms of dyspepsia, the appropriateness of additional courses of eradication treatment is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/10\">",
"     10",
"    </a>",
"    ]. The possibility that symptoms may be due to a different cause should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF TREATMENT FAILURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial attempt at eradicating",
"    <em>",
"     H. pylori",
"    </em>",
"    fails in approximately 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/31\">",
"     31",
"    </a>",
"    ]. A number of studies have evaluated retreatment strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A systematic review estimated that eradication rates after retreatment were 70 and 76 percent for triple therapy and quadruple therapy, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/32\">",
"     32",
"    </a>",
"    ]. Eradication rates from studies in which two new antimicrobial agents had been added during retreatment were significantly higher than studies in which only one new antimicrobial had been added. Further studies are needed to define optimal retreatment regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients failing an initial course of therapy, we recommend an alternate regimen (triple or quadruple therapy) using a different combination of antibiotics for 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      should not be used unless resistance testing confirms the",
"      <em>",
"       H. pylori",
"      </em>",
"      strain is susceptible to the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2854455578\">",
"       'Testing for resistance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Antibiotics previously taken should generally be avoided.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      may be more effective in this setting than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      . A controlled trial involving 100 patients who had failed initial treatment compared eradication rates with regimens containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"       bismuth",
"      </a>",
"      salts plus either metronidazole or tetracycline [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/36\">",
"       36",
"      </a>",
"      ]. Eradication rates were significantly higher in the group receiving tetracycline than metronidazole (78 versus 58 percent).",
"     </li>",
"     <li>",
"      A simpler treatment regimen could improve compliance and, as a result, efficacy. In one study, a twice daily quadruple treatment regimen that used a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      (20 mg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      (500 mg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"       bismuth",
"      </a>",
"      subcitrate caplets (240 mg), each given twice daily with the midday and evening meals for 14 days resulted in a 95 percent eradication rate in 118 patients (38 percent of whom had failed a prior one-week regimen) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/37\">",
"       37",
"      </a>",
"      ]. Such a high success rate with this twice daily quadruple treatment regimen requires confirmation before it can be recommended instead of traditional four times daily quadruple therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6063086\">",
"       'Quadruple therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other combinations using different medications have been proposed. These include therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/38-42\">",
"       38-42",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/43,44\">",
"       43,44",
"      </a>",
"      ] with a PPI and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      , as well as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      and rifabutin with a PPI [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/45\">",
"       45",
"      </a>",
"      ]. As an example, a 10-day course of rifabutin, amoxicillin, and a PPI was studied in 100 patients who had failed three prior attempts at treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/44\">",
"       44",
"      </a>",
"      ]. The treatment successfully eradicated",
"      <em>",
"       H. pylori",
"      </em>",
"      in 50 of the patients. In general, these combinations are reserved for patients who have failed at least two of the standard regimens for",
"      <em>",
"       H. pylori",
"      </em>",
"      . (See",
"      <a class=\"local\" href=\"#H3006516328\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those failing two attempts at treatment, it is important to reinforce compliance with medications. Culture with antibiotic sensitivity testing can be done to guide subsequent treatments, but we generally forego culture in favor of further treatment trials. We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (250 mg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (1 g), and a PPI each given twice daily for two weeks. Alternative dosing regimens have also been suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     H. pylori",
"    </em>",
"    are naturally resistant to several commonly used antibiotics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    , and sulfonamides [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals may also have a primary resistance to antibiotics that are commonly used in a number of eradication regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. At least two large and geographically broad studies concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistance was significantly more common in women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/51\">",
"     51",
"    </a>",
"    ] and clarithromycin resistance was significantly associated with geographic region (highest in the mid-Atlantic and northeastern regions of the United States where the rates of resistance were around 13 percent), older age, and the presence of inactive ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A specific mutation leading to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistance appears to be associated with the likelihood of eradication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/53\">",
"     53",
"    </a>",
"    ]. Of three point mutations associated with clarithromycin resistance (A2143G, A2142G, and A2142C), the A2143G mutation appears to be associated with the lowest eradication rates with clarithromycin containing regimens. Testing for these specific mutations is currently not widely available. In the setting of proven or suspected clarithromycin resistance, sequential treatment is suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Sequential therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Attempts at eradication that fail can elicit secondary antibiotic resistance. One should assume that macrolide resistance has developed when treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    fails to eliminate infection and choose a second treatment regimen with this in mind. Prior use of macrolide antibiotics or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    also appears to increase the risk of",
"    <em>",
"     H. pylori",
"    </em>",
"    resistance to clarithromycin and metronidazole, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2854455571\">",
"    <span class=\"h2\">",
"     Clinical outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical outcome of treatment in individual patients with antibiotic resistance is unpredictable but the cure rate is generally reduced. A meta-analysis of data from 93 studies with 10,178 participants showed that for triple therapies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistance had a greater effect on treatment efficacy than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/11\">",
"     11",
"    </a>",
"    ]. Metronidazole resistance reduced efficacy by 26 percent in triple therapies containing metronidazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    and only by 14 percent when a PPI was added to the regimen. Quadruple therapies containing both clarithromycin and metronidazole were the most effective; &gt;80 percent of",
"    <em>",
"     H. pylori",
"    </em>",
"    infections were consistently eradicated with these regimens. The authors concluded that resistance to either clarithromycin or metronidazole, but not both simultaneously, may be overcome by using quadruple therapies, especially those containing both clarithromycin and metronidazole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2854455578\">",
"    <span class=\"h2\">",
"     Testing for resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine culture and testing for antibiotic susceptibility and resistance for",
"    <em>",
"     H. pylori",
"    </em>",
"    is not currently recommended. However, patients with refractory disease may require culture and sensitivity testing since the incidence of resistance is dramatically high in this subgroup. Biopsies for culture and testing for antibiotic resistance should be obtained before the forceps are contaminated with formalin. The tissue should be placed into a container and moistened with a single drop of saline; if too much saline is added to the biopsy, the",
"    <em>",
"     H. pylori",
"    </em>",
"    are likely to be diluted. This sort of preparation will allow for culture and sensitivity testing on-site or transport for processing at a central facility. A culture can be obtained on the biopsy used for a CLO test if the specimen is removed from the gel within one hour and sent immediately to the laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects are reported in up to 50 percent of patients taking one of the triple therapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/4,56\">",
"     4,56",
"    </a>",
"    ]. The adverse effects are usually mild; fewer than 10 percent of patients stop treatment due to side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common side effect is a metallic taste due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      can cause a peripheral neuropathy, seizures, and a disulfiram-like reaction when taken with alcohol. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31817?source=see_link\">",
"       \"Metronidazole: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      can cause taste alteration, nausea, vomiting, abdominal pain, and rarely QT prolongation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H19#H19\">",
"       \"Azithromycin, clarithromycin, and telithromycin\", section on 'Adverse reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      can induce a photosensitivity reaction in some cases. It should also not be administered to pregnant women or young children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36662?source=see_link&amp;anchor=H14#H14\">",
"       \"Tetracyclines\", section on 'Adverse reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      can cause diarrhea or an allergic reaction with skin rash.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    , H2 receptor antagonists, and proton pump inhibitors are rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link&amp;anchor=H59974871#H59974871\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17104517\">",
"    <span class=\"h1\">",
"     PROBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics, which are live nonpathogenic bacteria that benefit a host through altering gut microflora composition, may reduce side effects of standard",
"    <em>",
"     H. pylori",
"    </em>",
"    treatments, especially diarrhea. As a result, they may be useful adjuncts to improve tolerability and compliance with more traditional antibiotic regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Because some probiotics have antimicrobial effects, they have been proposed as treatment for",
"    <em>",
"     H. pylori",
"    </em>",
"    infection but they should not be considered a substitute for standard antibiotic treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/39/25203?source=see_link\">",
"     Saccharomyces boulardii",
"    </a>",
"    is one probiotic that has been studied in the treatment of",
"    <em>",
"     H. pylori",
"    </em>",
"    . In a meta-analysis of five randomized controlled trials with 1307 patients, Saccharomyces boulardii given along with triple therapy increased eradication rates (RR 1.13) and decreased the risk of therapy-related adverse effects (RR 0.46) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18361521\">",
"    <span class=\"h1\">",
"     TREATMENT DURING PREGNANCY AND LACTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When peptic ulcer disease is diagnosed in a woman who is pregnant, the focus of treatment is typically acid suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/61\">",
"     61",
"    </a>",
"    ]. All of the PPIs are considered low risk in pregnancy, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    is contraindicated in pregnancy. Although confirmation is required, a large Swedish study associated gastric acid suppressors (H2 receptor antagonists, PPIs, prostaglandins, combinations for",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication, and drugs for peptic ulcer and GERD) with a significant, but low, absolute risk of allergic disease and asthma in children exposed in utero [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/62\">",
"     62",
"    </a>",
"    ]. The odds ratios for allergy and asthma were 1.43 and 1.51, respectively.",
"   </p>",
"   <p>",
"    If",
"    <em>",
"     H. pylori",
"    </em>",
"    is present, treatment is typically deferred until after delivery. However, with the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , the other medications used for",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication are low risk in pregnancy, especially after 14 weeks. This includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and probably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . Moreover, there is some evidence that H. pylori can cause severe",
"    <span class=\"nowrap\">",
"     nausea/vomiting",
"    </span>",
"    in pregnancy, including hyperemesis gravidarum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23049/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Thus, if indicated,",
"    <em>",
"     H. pylori",
"    </em>",
"    treatment should be considered in pregnancy. In addition, some of the medications typically used for the treatment of",
"    <em>",
"     H. pylori",
"    </em>",
"    are considered possibly unsafe for nursing infants (eg, bismuth, metronidazole). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H18#H18\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H1702588#H1702588\">",
"     \"Initial prenatal assessment and patient education\", section on 'Antibiotic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H12#H12\">",
"     \"Principles of medication use during lactation\", section on 'Antimicrobials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=see_link\">",
"       \"Patient information: Gastritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     H. pylori",
"    </em>",
"    treatment is recommended in a number of clinical settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link&amp;anchor=H2#H2\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\", section on 'When to test'",
"    </a>",
"    .) Multiple treatment regimens exist to treat",
"    <em>",
"     H. pylori",
"    </em>",
"    infection (",
"    <a class=\"graphic graphic_table graphicRef65237 \" href=\"UTD.htm?18/49/19228\">",
"     table 1",
"    </a>",
"    ); however, the optimal therapeutic regimen has not yet been defined.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For initial therapy, we suggest triple therapy with a proton pump inhibitor (PPI),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (1 g twice daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (500 mg twice daily) for 10 days to two weeks (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Triple therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest substitution of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg twice daily) only in penicillin-allergic individuals since metronidazole resistance is common and can reduce the efficacy of treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Triple therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although quadruple therapy can be used as initial therapy, we suggest it mainly for retreatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Quadruple therapy consists of a proton pump inhibitor twice daily combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"       bismuth",
"      </a>",
"      (525 mg four times daily) and two antibiotics (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      250 mg four times daily and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      500 mg four times daily) or with a commercially available combination capsule containing bismuth subcitrate, metronidazole, and tetracycline four times daily for 10 to 14 days. One week of bismuth-based quadruple treatment may suffice for initial therapy as long as it is given with a PPI. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management of treatment failures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients failing one course of",
"      <em>",
"       H. pylori",
"      </em>",
"      treatment, we suggest either an alternate regimen using a different combination of medications as triple therapy or, preferably, quadruple therapy. (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Repeat treatment is influenced by initial treatment. In general,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      and antibiotics used previously should be avoided if possible. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management of treatment failures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients failing two attempts at treatment, compliance with medications should be reinforced. Culture with antibiotic sensitivity testing can be done to guide subsequent treatments. For rescue therapy, we often use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (250 mg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (1 g), and a PPI each given twice daily for two weeks. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management of treatment failures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/1\">",
"      Qasim A, Sebastian S, Thornton O, et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/2\">",
"      Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/3\">",
"      Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter 2005; 10:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/4\">",
"      Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004; 20:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/5\">",
"      Graham DY, Hammoud F, El-Zimaity HM, et al. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 17:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/6\">",
"      Vakil N. Helicobacter pylori: factors affecting eradication and recurrence. Am J Gastroenterol 2005; 100:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/7\">",
"      Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002; 31:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/8\">",
"      Vakil N, Connor J. Helicobacter pylori eradication: equivalence trials and the optimal duration of therapy. Am J Gastroenterol 2005; 100:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/9\">",
"      Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/10\">",
"      McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/11\">",
"      Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/12\">",
"      Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/13\">",
"      Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/14\">",
"      Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/15\">",
"      Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002; 123:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/16\">",
"      Lara LF, Cisneros G, Gurney M, et al. One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med 2003; 163:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/17\">",
"      Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/18\">",
"      Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/19\">",
"      Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010; 59:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/20\">",
"      Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/21\">",
"      Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/22\">",
"      Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/23\">",
"      Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104:3069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/24\">",
"      Moayyedi P, Malfertheiner P. Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol 2009; 104:3081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/25\">",
"      Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010; 8:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/26\">",
"      Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/27\">",
"      Albrecht P, Kotowska M, Szajewska H. Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial. J Pediatr 2011; 159:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/28\">",
"      Bontems P, Kalach N, Oderda G, et al. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2011; 53:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/29\">",
"      Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/30\">",
"      Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/31\">",
"      Vakil N. Primary and secondary treatment for Helicobacter pylori in the United States. Rev Gastroenterol Disord 2005; 5:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/32\">",
"      Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001; 36:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/33\">",
"      Kearney DJ. Retreatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 2001; 96:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/34\">",
"      Malfertheiner P, Leodolter A, Peitz U. Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/35\">",
"      Lamouliatte H, M&eacute;graud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003; 18:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/36\">",
"      Chi CH, Lin CY, Sheu BS, et al. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther 2003; 18:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/37\">",
"      Dore MP, Marras L, Maragkoudakis E, et al. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter 2003; 8:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/38\">",
"      Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004; 2:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/39\">",
"      Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 101:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/40\">",
"      Gisbert JP, Castro-Fern&aacute;ndez M, Bermejo F, et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006; 101:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/41\">",
"      Gisbert JP, Bermejo F, Castro-Fern&aacute;ndez M, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008; 103:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/42\">",
"      Jodlowski TZ, Lam S, Ashby CR Jr. Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother 2008; 42:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/43\">",
"      Perri F, Festa V, Clemente R, et al. Randomized study of two \"rescue\" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/44\">",
"      Gisbert JP, Castro-Fernandez M, Perez-Aisa A, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012; 35:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/45\">",
"      Miehlke S, Schneider-Brachert W, Kirsch C, et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2008; 13:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/46\">",
"      van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/47\">",
"      Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/48\">",
"      Noach LA, Langenberg WL, Bertola MA, et al. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 1994; 26:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/49\">",
"      Lind T, M&eacute;graud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/50\">",
"      Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998; 93:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/51\">",
"      Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/52\">",
"      Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002; 136:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/53\">",
"      De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/54\">",
"      McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/55\">",
"      Windsor HM, Ho GY, Marshall BJ. Successful recovery of H. pylori from rapid urease tests (CLO tests). Am J Gastroenterol 1999; 94:3181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/56\">",
"      de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995; 30:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/57\">",
"      Cindoruk M, Erkan G, Karakan T, et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/58\">",
"      Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010; 15:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/59\">",
"      Franceschi F, Cazzato A, Nista EC, et al. Role of probiotics in patients with Helicobacter pylori infection. Helicobacter 2007; 12 Suppl 2:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/60\">",
"      Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/61\">",
"      Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/62\">",
"      Dehlink E, Yen E, Leichtner AM, et al. First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study. Clin Exp Allergy 2009; 39:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/63\">",
"      Golberg D, Szilagyi A, Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet Gynecol 2007; 110:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23049/abstract/64\">",
"      Mansour GM, Nashaat EH. Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum. Arch Gynecol Obstet 2011; 284:843.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23049=[""].join("\n");
var outline_f22_32_23049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3006516328\">",
"      INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Triple therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6063086\">",
"      Quadruple therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85526733\">",
"      - Other regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sequential therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2834839008\">",
"      ERADICATION CONFIRMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT OF TREATMENT FAILURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANTIBIOTIC RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2854455571\">",
"      Clinical outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2854455578\">",
"      Testing for resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17104517\">",
"      PROBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18361521\">",
"      TREATMENT DURING PREGNANCY AND LACTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/7\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/7|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/49/19228\" title=\"table 1\">",
"      ACG first-line H pylori regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43271?source=related_link\">",
"      Bacteriology and epidemiology of Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31817?source=related_link\">",
"      Metronidazole: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=related_link\">",
"      Patient information: Gastritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36662?source=related_link\">",
"      Tetracyclines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_32_23050="Meningococcal vaccines";
var content_f22_32_23050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Meningococcal vaccines",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23050/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23050/contributors\">",
"     Michael Apicella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23050/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23050/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23050/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/32/23050/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/32/23050/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/32/23050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal disease, especially meningococcal meningitis, is one of the most devastating infections for an individual or community; reports of documented or suspected cases can engender considerable panic, even among well-informed hospital personnel. Part of the explanation for this phenomenon is the fact that meningitis due to Neisseria meningitidis tends to strike young, previously well individuals and can progress over a matter of hours to death.",
"   </p>",
"   <p>",
"    Mortality can be very high if the infection is not treated appropriately, and long-term sequelae can be severe even in successfully managed cases. The mortality and morbidity from meningococcal disease has changed very little since the 1950s, due principally to the inability to effectively manage the endotoxin-induced vascular collapse frequently caused by this organism.",
"   </p>",
"   <p>",
"    Issues related to meningococcal vaccination and the vaccine formulations will be reviewed here. The microbiology, pathobiology, epidemiology, clinical features, diagnosis, treatment, and prevention of meningococcal infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=see_link\">",
"     \"Microbiology and pathobiology of Neisseria meningitidis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=see_link\">",
"     \"Diagnosis of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link\">",
"     \"Treatment and prevention of meningococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of meningococcal infection is reviewed in detail separately. The following discussion will provide a summary that provides the rationale for meningococcal vaccination in selected individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    N. meningitidis can cause both endemic and epidemic infection. Meningococcal infections are endemic in the United States, and the annual incidence of invasive meningococcal disease varies from 0.5 to 1.5 cases per 100,000 population in multiyear cycles; the most recent peak in incidence occurred during the mid 1990s (",
"    <a class=\"graphic graphic_figure graphicRef77474 \" href=\"UTD.htm?25/51/26429\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2009, the rate of invasive meningococcal disease was 0.33 per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/2\">",
"     2",
"    </a>",
"    ]. Disease rates are almost 10 times higher in children below two years of age than in the overall population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of Neisseria meningitidis infection\", section on 'United States'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The case-fatality rate has been estimated to be between 10 and 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/3\">",
"     3",
"    </a>",
"    ]. However, surveillance of invasive meningococcal infection in Maryland from 1990 through 1999 found that the case-fatality rate was considerably higher in patients aged 15 through 24 years, who accounted for 24 percent of the cases; the odds ratio of death in this age group was 6.1 compared with those under the age of 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outbreaks of meningococcal infection on college campuses have attracted considerable attention. A retrospective cohort study did not reveal an increase in the incidence of meningococcal infection in college students compared with age matched controls (1.74 versus 1.44 per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/5\">",
"     5",
"    </a>",
"    ]. However, among affected college students, the rates of illness were higher for those residing on campus. Another case-control study performed in college students determined that the incidence of infection was lower than the general population of 18 to 23 year old nonstudents (0.7 versus 1.4 per 100,000); however, the incidence was highest in freshmen living in dormitories (5.1 per 100,000), and the risk for disease by multivariate analysis was 3.6 for this group compared with other college students [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/6\">",
"     6",
"    </a>",
"    ]. A study from the United Kingdom also found that having a high proportion of first year students in a residence hall increased the risk for meningococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large scale epidemics occur with considerable frequency in the so-called \"meningitis belt,&rdquo; which crosses the waist of sub-Saharan Africa (",
"    <a class=\"graphic graphic_figure graphicRef63287 \" href=\"UTD.htm?16/45/17110\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The case rate during these epidemics can be as high as 1 in 1000 total population and 1 in 100 for children below two years of age.",
"   </p>",
"   <p>",
"    Travelers may be at risk for acquiring meningococcal infection, especially when traveling to regions at risk for epidemics or hyperendemic for the disease and for those with extensive contact with local residents. The Hajj pilgrimage to Mecca has been associated with outbreaks of meningococcal infection; pilgrims are required by the government of Saudi Arabia to be vaccinated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the fall of 2012, an outbreak of invasive serogroup C meningococcal disease was detected in men who have sex with men (MSM) in New York City [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Between 2010 and 2012, 18 cases were detected, 12 of which occurred in 2012. Ten of the 18 cases were in HIV-infected men. As of late December 2012, five patients have died. For 2012, the incidence rate of invasive meningococcal disease among MSM aged 18 to 64 years in New York City was 12.6 per 100,000 persons, compared with 0.16 per 100,000 persons among non-MSM males of the same age.",
"   </p>",
"   <p>",
"    The distribution of serotypes of N. meningitidis causing infection can differ depending upon the region of the world. In a large United States survey, serogroups C, B, and Y accounted for 35, 32, and 26 percent of isolates, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/3\">",
"     3",
"    </a>",
"    ]. The majority of invasive infections in England and Wales are caused by serogroups B and C [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Epidemics in Africa and elsewhere in the world are most frequently due to serogroup A and occasionally serogroup C. W-135 is an uncommon serogroup but was responsible for a large number of cases among pilgrims returning from the Hajj in Saudi Arabia in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology of Neisseria meningitidis infection\", section on 'Genetics of outbreak strains'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AVAILABLE VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several different meningococcal vaccines available in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"       meningococcal polysaccharide vaccine",
"      </a>",
"      (Menomune, MPSV4) has been available in the United States for several decades.",
"     </li>",
"     <li>",
"      A quadrivalent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"       meningococcal polysaccharide vaccine",
"      </a>",
"      conjugated to diphtheria toxoid (Menactra) became available in 2005 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another quadrivalent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"       meningococcal polysaccharide vaccine",
"      </a>",
"      conjugated to a mutant diphtheria toxin, CRM197 (Menveo), was approved in 2010 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A combination conjugate vaccine against meningococcus serogroups C and Y and Haemophilus influenzae type b (MenHibrix, HibMenCY) was approved in 2012 for infants and children aged 6 weeks to 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Meningococcal serogroup C conjugate vaccines are used routinely in the United Kingdom and other countries. In January 2013, the European Commission approved a meningococcal serogroup B vaccine (Bexsero) for use in individuals over two months of age in the European Union [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONJUGATE VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The meningococcal conjugate vaccines elicit a T cell-dependent memory response that increases the effectiveness, resulting in an improved primary response to vaccination and a strong anamnestic response at reexposure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Quadrivalent conjugate vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menactra and Menveo (variably abbreviated as MCV4 and MenACWY) are quadrivalent vaccines that contain capsular polysaccharide antigens from serogroups A, C, Y, and W135 conjugated to diphtheria toxoid or CRM197, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Immunogenicity",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14308778\">",
"    <span class=\"h4\">",
"     Menactra",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials comparing the immunogenicity and safety of Menactra with the older quadrivalent polysaccharide vaccine (Menomune, MPSV4) demonstrated no difference in immunogenicity in adolescents 11 to 18 years of age (881 participants) and in adults 18 to 55 years of age (2554 participants) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Among subjects 11 to 18 years of age, a greater than fourfold increase in serum bactericidal antibody (SBA) for all serogroups, which was considered a successful post-vaccination response, was achieved in more than 80 percent with both vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/21\">",
"     21",
"    </a>",
"    ]. Similar findings were noted in adults for serogroups A, C, and W135, but both vaccines produced a slightly lower proportion of responses (74 to 79 percent) for serotype Y [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/22\">",
"     22",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The persistence of SBA three years after immunization with either Menactra or MPSV4 was assessed in 100 adolescents to determine the duration of protection of vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/23\">",
"     23",
"    </a>",
"    ]. Menactra elicited greater persistence of protective antibody titers against serogroup W135 (44 versus 21 percent with MPSV4). Persistent protective antibody titers against serogroups C and Y were similar in the two vaccine groups.",
"   </p>",
"   <p>",
"    Data reviewed by the United States Advisory Panel on Immunization Practices (ACIP) suggest that adolescents who received Menactra might not be protected for more than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/24\">",
"     24",
"    </a>",
"    ]. Importantly, individuals who are immunized at age 11 or 12 years might have decreased protective immunity by ages 16 through 21 years, when their risk for disease is greatest. These findings have led to a modification of the ACIP recommendations regarding revaccination in adolescents (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'In children and adolescents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <br/>",
"    The immunogenicity of Menactra in younger children was illustrated in a randomized, modified, double-blind, controlled trial in 1398 healthy children (2 to 10 years of age) in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/25\">",
"     25",
"    </a>",
"    ]. Menactra was compared with MPSV4 for safety and immunogenicity. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both vaccines were well tolerated, with no vaccine-related serious adverse events and similar rates of mostly mild local and systemic reactions.",
"     </li>",
"     <li>",
"      The antibody geometric mean titers for all four serogroups were significantly higher in the Menactra vaccinees (1700 versus 893 for serogroup A, 354 versus 231 for serogroup C, 637 versus 408 for serogroup Y, and 750 versus 426 for serogroup W135).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a follow-up study, children who were two to three years of age at the time of initial Menactra vaccination had persistence of SBA 23 to 36 months later [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, when challenged with reduced dose MPSV4, SBA geometric mean titers, geometric mean concentrations of immunoglobulin G (IgG), and geometric mean avidity indices were significantly higher at 8 or 28 days after vaccination compared with individuals who received reduced dose MPSV4 in the absence of previous priming with Menactra.",
"    <br/>",
"    <br/>",
"    Menactra has been tested in infants but was only modestly immunogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, other vaccines (eg, Menveo) have been developed and evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14308785\">",
"    <span class=\"h4\">",
"     Menveo",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second quadrivalent meningococcal glycoconjugate vaccine (Menveo) has been found to be immunogenic and safe in various age groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menveo was evaluated in open-label, randomized trials in infants and was found to be immunogenic [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. It was also found to be both immunogenic and safe when given concomitantly with routine vaccinations at two, four, and six months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/29\">",
"       29",
"      </a>",
"      ]. Immune responses to the routine vaccines one month after the primary series were noninferior for all but pertactin (a correlate of immunity to pertussis) and pneumococcal serotype 6B. One month after the fourth dose, noninferiority was achieved for all seven pneumococcal serotypes included in the pneumococcal vaccine.",
"     </li>",
"     <li>",
"      In a randomized trial, Menveo was shown to be noninferior to Menactra in immunogenicity in individuals aged 2 to 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Menveo was also demonstrated to be noninferior to Menactra in immunogenicity studies that included individuals aged 11 to 55 years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/17,31\">",
"       17,31",
"      </a>",
"      ]. In a single-blind randomized trial in individuals aged 11 to 17, Menveo was shown to be immunogenic and safe compared with the quadrivalent polysaccharide vaccine, MPSV4 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menactra was licensed for use in adolescents in the United States in January 2005. Between 1998 and 2007, the annual incidence of meningococcal disease decreased 64 percent, from 0.92 to 0.33 cases per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/33\">",
"     33",
"    </a>",
"    ]. Between 2005 and 2008, 14 breakthrough cases, including three deaths, occurred in the United States in individuals who had been vaccinated between 12 and 20 years of age; based upon these data, the effectiveness of Menactra has been estimated to be 80 to 85 percent in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Except for local reactions, the percentage of subjects aged 11 to 18 years reporting adverse events was similar in Menactra and MPSV4 recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/21\">",
"     21",
"    </a>",
"    ]. Local reactions were more common with Menactra than MPSV4 (72 versus 35 percent) and most commonly occurred in the first three days after vaccination.",
"   </p>",
"   <p>",
"    Menactra was less reactogenic in the 18 to 55 year age group than in the 11 to 18 year age group [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/21\">",
"     21",
"    </a>",
"    ]. However, moderate and severe local reactions remained more frequent in the Menactra group than in the MPSV4 group. The incidence of severe systemic reactions was similar in both groups (3.8 versus 2.6 percent in the MPSV4 group).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Possible association with Guillain-Barr&eacute; syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In September 2005, the Food and Drug Administration (FDA) and CDC issued an advisory regarding the occurrence of Guillain-Barr&eacute; syndrome (GBS) in five recipients of Menactra [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Through September 2006, a total of 15 cases of GBS were reported in persons aged 11 to 19 years with onset within six weeks after vaccination with Menactra; all patients recovered or were recovering [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2007, the United States Advisory Committee on Immunization Practices (ACIP) made a history of GBS a precaution to receiving Menactra [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/38\">",
"     38",
"    </a>",
"    ]. However, in 2010, the ACIP removed precautionary language from its recommendations, since more recent studies have",
"    <strong>",
"     not",
"    </strong>",
"    shown an increased risk of GBS in individuals who received Menactra [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suspected cases of GBS after Menactra should be reported to VAERS (",
"    <a class=\"external\" href=\"file://www.vaers.hhs.gov/\">",
"     www.vaers.hhs.gov",
"    </a>",
"    or 1-800-822-7967; fax 1-877-721-0366). Guillain-Barr&eacute; syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=see_link\">",
"     \"Overview of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=see_link\">",
"     \"Treatment of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dose and route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menactra is available in single dose vials and administered to children and adults as a single intramuscular (IM) 0.5 mL dose. Menactra remains immunogenic when administered concomitantly with the diphtheria-tetanus vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/21\">",
"     21",
"    </a>",
"    ]. Although the Menactra vaccine should be administered IM, inadvertent subcutaneous (SC) administration has occurred. An examination of serologic titers of 38 SC vaccinees found that despite SC administration error, a protective immunologic response was achieved in all vaccinees and revaccination was not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Menveo is available as a single 0.5 mL dose after reconstitution of the liquid vaccine component with the lyophilized conjugate component; it is administered IM [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serogroup C conjugate vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serogroup C conjugate vaccine has been extensively evaluated in the United Kingdom, where the majority of invasive cases of meningococcal disease are caused by serotypes B or C. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'United Kingdom and the European Union'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H454501268\">",
"     'Group B meningococcus vaccines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial assessed the safety and immunogenicity of a serogroup C polysaccharide conjugated to CRM, a nontoxic mutant of diphtheria toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/40\">",
"     40",
"    </a>",
"    ]. The vaccine was administered concurrently with routine vaccinations at ages two, three, and four months in 182 healthy infants. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both geometric mean concentrations of IgG and serum bactericidal activity were higher in infants receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37316?source=see_link\">",
"       meningococcal serogroup C conjugate vaccine",
"      </a>",
"      than in controls who received the usual vaccinations.",
"     </li>",
"     <li>",
"      By 12 months of age, geometric mean concentrations of IgG and serum bactericidal activity had decreased but were still significantly higher than in controls.",
"     </li>",
"     <li>",
"      One-half of the babies were subsequently immunized at 12 months of age with another dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37316?source=see_link\">",
"       meningococcal serogroup C conjugate vaccine",
"      </a>",
"      or a dose of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"       meningococcal polysaccharide vaccine",
"      </a>",
"      . Both groups developed a rise in antibody titers, demonstrating immunologic memory.",
"     </li>",
"     <li>",
"      Side effects did not differ among infants who received routine immunization only and those vaccinated with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37316?source=see_link\">",
"       meningococcal serogroup C conjugate vaccine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent open label phase 4 trial evaluated the persistence of serum bactericidal antibody (SBA) titers after initial immunization among children who received the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37316?source=see_link\">",
"     meningococcal serogroup C conjugate vaccine",
"    </a>",
"    at times varying from two months to six years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/41\">",
"     41",
"    </a>",
"    ]. Six years later, an SBA titer &ge;8, which was the correlate of protection, was observed in 61 (25 percent) of 244 children. The proportion of children with an SBA titer &ge;8 increased with the age at initial vaccination, from 12 percent at a mean age of two months to 48 percent at a mean age of six years. One month after receiving a booster immunization, all children had an SBA titer &ge;8, which was sustained in 99.6 percent one year later.",
"   </p>",
"   <p>",
"    Although SBA titers following vaccination with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37316?source=see_link\">",
"     meningococcal serogroup C conjugate vaccine",
"    </a>",
"    wane fairly rapidly among infants and young children, they are more likely to persist among adolescents. An observational study from the United Kingdom assessed the persistence of SBA titers among 987 healthy adolescents 11 to 20 years of age, who had been vaccinated with one of three serogroup C conjugate vaccines between 6 and 15 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/42\">",
"     42",
"    </a>",
"    ]. Five years following immunization, 84 percent had SBA titers of &ge;1:8, which is considered a seroprotective titer. Higher geometric mean titers were observed in individuals immunized at age 10 or older compared with those who were immunized when they were younger than 10.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several countries have experienced substantial reductions in the incidence of serogroup C disease after large-scale vaccination campaigns with serogroup C meningococcal vaccines were implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/43\">",
"     43",
"    </a>",
"    ]. The efficacy of the serogroup C conjugate vaccine is illustrated by the following observations from different studies in the United Kingdom:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vaccine was effective at nine month follow-up in both toddlers (92 percent protection) and adolescents (97 percent protection) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among children who were routinely vaccinated in infancy at two, three, and four months, the effectiveness of the vaccine fell to very low levels after one year [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/45\">",
"       45",
"      </a>",
"      ]. The decline in efficacy was much less in infants who were vaccinated at five to eleven months. This observation has led to the recommendation for a booster dose at 12 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A follow-up study also demonstrated that there was no evidence of meningococcal capsular serogroup switches from serogroup C to serogroup A or B due to vaccine pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A reduction in serogroup C carriage (rate ratio 0.19) that lasted for at least two years was observed following the initiation of a mass vaccination campaign of individuals under 19 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/47\">",
"       47",
"      </a>",
"      ]. Vaccine efficacy against carriage was 75 percent.",
"     </li>",
"     <li>",
"      The incidence of meningococcal serogroup C disease declined by 67 and 35 percent in unvaccinated persons aged 1 to 17 years and &gt;25 years, respectively, which suggested that there was evidence of herd immunity [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaccine effectiveness in an outbreak setting was suggested by a population-based observational study in Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/49\">",
"     49",
"    </a>",
"    ]. Cases were identified from a registry of notifiable diseases and from the Quebec provincial reference laboratory from 1996 through 2002. A mass immunization campaign was initiated in 2001 to control an emerging epidemic. The incidence of invasive meningococcal disease was 7.8 per million before 2001 compared to 3.6 per million after the campaign. Vaccine effectiveness was 97 percent when vaccinees were compared with nonvaccinated individuals. In a follow-up study that evaluated the epidemiologic effect of the campaign between 2002 and 2008, the overall vaccine effectiveness was 87 percent, with lower protection in children who were vaccinated before two years of age and more pronounced waning of protection in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunologic response during vaccine failure, defined as a laboratory confirmed case of serogroup C meningococcal infection ten or more days after the last scheduled vaccine dose, was evaluated in a report of 53 children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/51\">",
"     51",
"    </a>",
"    ]. Serum bactericidal antibody titers were sixfold higher than in unvaccinated patients who were infected and the antibody response in the vaccinated patients was consistent with an anamnestic response. Thus, infection occurred even though the vaccine primed immune memory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dose and route",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serogroup C conjugate vaccine (Menjugate) is administered as a 0.5 mL intramuscular injection. The manufacturer recommends that infants between 2 and 12 months of age receive three doses with at least one month in between each dose. A single 0.5 mL intramuscular dose is recommended for children &ge;12 months, adolescents, and adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H937132\">",
"    <span class=\"h2\">",
"     Combination conjugate vaccine against meningococcus and Haemophilus influenzae type b",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination conjugate vaccine against meningococcus serogroups C and Y and Haemophilus influenzae type b (MenHibrix) was approved by the US Food and Drug Administration in June 2012 for infants and children 6 weeks to 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In prelicensure trials involving approximately 8000 children, this vaccine was safe, immunogenic, and did not interfere with immune responses to routine immunizations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H182642754\">",
"     'In infants and toddlers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182642906\">",
"    <span class=\"h2\">",
"     Serogroup A conjugate vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemics of meningococcal disease in the meningitis belt of sub-Saharan Africa are caused most commonly by serogroup A. In two trials that evaluated a meningococcal serogroup A conjugate vaccine (PsA-TT) compared with a quadrivalent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"     meningococcal polysaccharide vaccine",
"    </a>",
"    against serogroups A, C, W135, and Y (PsACWY) in children and adults in Africa, the conjugate vaccine had superior immunogenicity against group A meningococcus than the polysaccharide vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/57\">",
"     57",
"    </a>",
"    ]. In trial A, 601 children between the ages of 12 and 23 months were randomly assigned to receive either PsA-TT, PsACWY, or a control conjugate vaccine against Haemophilus influenzae type B (Hib-TT). Ten months later, participants were randomly assigned again to receive a booster immunization with a full dose of PsA-TT, a one-fifth dose of PsACWY, or a full dose of Hib-TT. In trial B, 900 individuals between 2 and 29 years of age were randomly assigned to receive a single injection of PsA-TT or PsACWY.",
"   </p>",
"   <p>",
"    The following results were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In trial A, four weeks after the primary immunization, 96 percent of individuals who received PsA-TT had serum bactericidal antibody (SBA) titers against serogroup A meningococcus that were at least four times as high as baseline titers, compared with 64 percent of those who received PsACWY, and 36 percent of those who received Hib-TT.",
"     </li>",
"     <li>",
"      In trial B, four weeks after immunization, 78 percent of the individuals who received PsA-TT had SBA titers that were at least four times as high as the baseline titers, compared with 46 percent of those who received PsACWY.",
"     </li>",
"     <li>",
"      In trial A, 10 months after the primary immunization, 82 percent of individuals who received PsA-TT still had SBA titers that were at least four times as high as baseline titers, compared with 38 percent of those who received PsACWY, and 38 percent of those who received Hib-TT.",
"     </li>",
"     <li>",
"      In trial A, seven days after the booster immunization, the highest geometric mean SBA titers occurred in those who had received PsA-TT for both the primary immunization and the booster (21,721 versus 8679 for those who received PsA-TT for the primary immunization and PsACWY for the booster, and 12,214 for those who received PsACWY for the primary immunization and PsA-TT for the booster).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials demonstrate that following a single injection, PsA-TT induces higher and longer lasting immune responses than PsACWY, and that PsA-TT is able to elicit greater immunologic memory than PsACWY.",
"   </p>",
"   <p>",
"    In 2010, Burkina Faso, a country in the meningitis belt of Africa, implemented a national prevention campaign in which individuals aged 1 to 29 years were targeted to receive PsA-TT; the target group represented 70 percent of the 16 million residents of the country [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/58\">",
"     58",
"    </a>",
"    ]. The vaccination campaign appears to have eliminated pharyngeal carriage of meningococcus serogroup A from both vaccinated and unvaccinated individuals for at least 13 months following mass vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, based on national population-based surveillance data, the vaccination campaign has substantially reduced the rate of meningitis in both individuals within the target group and in the general population (as a result of high coverage and herd immunity) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/60\">",
"     60",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the 14-year period before PsA&ndash;TT introduction, Burkina Faso had 148,603 cases of suspected meningitis with 17,965 deaths and 174 epidemics.",
"     </li>",
"     <li>",
"      After vaccine introduction, there was a 71 percent decline in the risk of meningitis (hazard ratio [HR] 0.29, 95% CI 0.28-0.30) and a 64 percent decline in the risk of fatal meningitis (HR 0.36, 95% CI 0.33-0.40).",
"     </li>",
"     <li>",
"      A statistically significant decline in the risk of probable meningococcal meningitis was observed across the age group targeted for vaccination (cumulative incidence ratio [CIR] 0.38, 95% CI 0.31-0.45). A significant decline was also observed among children aged less than 1 year (CIR 0.46, 95% CI 0.24-0.86) and among people aged 30 years and older (CIR 0.45, 95% CI 0.22-0.91); both of these age groups were ineligible for vaccination.",
"     </li>",
"     <li>",
"      No cases of serogroup A meningococcal meningitis occurred among vaccinated individuals and epidemics were eliminated.",
"     </li>",
"     <li>",
"      The incidence of laboratory-confirmed serogroup A meningococcal infection dropped significantly to 0.01 per 100,000 individuals per year, representing a 99.8 percent reduction in the risk of serogroup A meningococcal meningitis (CIR 0.002, 95% CI 0.0004-0.02).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POLYSACCHARIDE VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The capsular polysaccharides of serogroups A, C, Y, and W135 are the constituents of a safe and effective",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"     meningococcal polysaccharide vaccine",
"    </a>",
"    (Menomune, MPSV4) for adults and children older than two years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Immunogenicity and adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunogenicity and adverse effects of MPSV4 compared with the quadrivalent meningococcal conjugate vaccine, Menactra, are discussed above. Summarized briefly, MPSV4 is as immunogenic as Menactra in patients between the ages of 11 and 55, but is less immunogenic in children between the ages of 2 and 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Immunogenicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Another limitation of MPSV4 is that protection wanes after three to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. As a result, revaccination is required in selected patients. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Revaccination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With respect to adverse effects, MPSV4 is associated with a lower rate of local reactions than Menactra [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dose and route",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single 0.5 mL subcutaneous dose of MPSV4 is administered to both adults and children and will induce an antibody response in seven to 10 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454501268\">",
"    <span class=\"h1\">",
"     GROUP B MENINGOCOCCUS VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although group B meningococcus is one of the most common serotypes causing infection, no broadly effective vaccine preparation is licensed for use to prevent infection with this serogroup [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In January 2013, the European Commission approved a meningococcal serogroup B vaccine (Bexsero) for use in individuals over two months of age in the European Union [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major challenge in the development of a meningococcal serogroup B vaccine has been that the serogroup B polysaccharide is a very poor immunogen in humans probably due to the similarity of its immunochemical structure to human intracellular adhesion molecules. However, the sequencing of the complete genome of one strain of meningococcus serogroup B aided in vaccine development through the identification of antigenic determinants that could be used in a recombinant vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=see_link\">",
"     \"Microbiology and pathobiology of Neisseria meningitidis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An advance in the development of an effective serogroup B vaccine involved the production of a vaccine that used outer membrane vesicles (OMV) isolated from a specific strain of meningococci [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/64,65,67\">",
"     64,65,67",
"    </a>",
"    ]. In response to a long-standing epidemic of group B meningococcal infection in New Zealand, an OMV vaccine was administered to individuals between the ages of 2 and 20 from 2004 until 2008 as part of a national campaign [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Although the number of cases decreased following implementation, the effectiveness was unclear since the epidemic was already waning when the campaign was initiated. Furthermore, the overall utility of OMV vaccines appears to be limited since they elicit strain-specific immune responses against the PorA protein, which is highly variable among meningococcal strains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, a vaccine against group B meningococcus that includes three recombinant proteins (neisserial adhesin A, factor H binding protein, and neisserial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    binding antigen) with OMV from the New Zealand epidemic strain",
"    <span class=\"nowrap\">",
"     (NZ98/254)",
"    </span>",
"    was evaluated in a randomized trial of adolescents; 1631 vaccinees received one, two, or three doses of the vaccine at one month, two month, or six month intervals, and 128 controls received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/69\">",
"     69",
"    </a>",
"    ]. Immunogenicity was assessed as serum bactericidal activity (SBA) using human complement against three meningococcal serogroup B reference strains,",
"    <span class=\"nowrap\">",
"     44/76,",
"    </span>",
"    <span class=\"nowrap\">",
"     5/99,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     NZ98/254,",
"    </span>",
"    and by enzyme-linked immunosorbent assay against a fourth strain. No serious vaccine-related adverse effects were reported. The results of this study showed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One month after receiving a single dose of vaccine, 92 to 97 percent of individuals had bactericidal titers &ge;4 against the reference strains.",
"     </li>",
"     <li>",
"      One month after receiving two or three doses, 99 to 100 percent of individuals had bactericidal titers &ge;4 against the reference strains.",
"     </li>",
"     <li>",
"      In comparison, 29 to 50 percent of individuals who received placebo had bactericidal titers &ge;4 against the reference strains.",
"     </li>",
"     <li>",
"      Six months after the final injection, 73 to 76 percent of subjects who received one dose had bactericidal titers &ge;4, whereas 99 to 100 percent of the individuals who received two or three doses of vaccine had bactericidal titers &ge;4.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The vaccine against group B meningococcus described above was also immunogenic in several trials of healthy infants in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. In one trial, healthy two-month-old infants were randomly assigned to receive the group B meningococcal vaccine at two, four, and six months of age in combination with the routine vaccines (seven-valent pneumococcal vaccine, and combined diphtheria, tetanus, acellular pertussis, inactivated polio, hepatitis B, and Haemophilus influenzae type b vaccines); the group B meningococcal vaccine at two, four, and six months of age, with the routine vaccines administered at three, five, and seven months of age; the group B meningococcal vaccine in combination with the routine vaccines at two, three, and four months of age; or the routine vaccines alone at two, three, and four months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/71\">",
"     71",
"    </a>",
"    ]. Immunogenicity was assessed as SBA titers with human complement against three meningococcal reference strains,",
"    <span class=\"nowrap\">",
"     44/76-SL,",
"    </span>",
"    <span class=\"nowrap\">",
"     5/99,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     NZ98/254.",
"    </span>",
"    The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After three doses of the group B meningococcal vaccine, 99 percent or more of infants developed SBA titers &ge;5 against two of the three reference strains,",
"      <span class=\"nowrap\">",
"       44/76-SL",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       5/99.",
"      </span>",
"     </li>",
"     <li>",
"      For the third reference strain,",
"      <span class=\"nowrap\">",
"       NZ98/254,",
"      </span>",
"      the proportion of infants who developed SBA titers &ge;5 was 79 percent in the group that received the group B meningococcal vaccine in combination with routine vaccines at two, four, and six months of age; 86 percent in the group that received the group B meningococcal vaccine without routine vaccines at two, four, and six months; and 82 percent in the group that received the group B meningococcal vaccine in combination with routine vaccines at two, three, and four months of age.",
"     </li>",
"     <li>",
"      Responses to the routine vaccines given concurrently with the group B meningococcal vaccine were non-inferior to the responses to the routine vaccines given alone, except for the responses to pertactin (a correlate of immunity to pertussis) and serotype 6B pneumococcal polysaccharide.",
"     </li>",
"     <li>",
"      Fever was observed in 26 to 41 percent of infants who received the group B meningococcal vaccine alone, compared with 51 to 61 percent of infants who received the group B meningococcal vaccine in combination with the routine vaccines, and 23 to 36 percent of infants who received only the routine vaccines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Important limitations of this study are that only three reference strains were used to assess responses, and that the strains selected for SBA analysis could not be used to specifically evaluate the immunogenicity of the neisserial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    binding antigen because the only strain expressing this antigen also contained porin protein A homologous to the OMV component of the vaccine.",
"   </p>",
"   <p>",
"    In another trial, infants were randomly assigned to receive routine vaccines at two, four, and six months of age either alone or concomitantly with the group B or group C meningococcal vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/72\">",
"     72",
"    </a>",
"    ]. Among infants who received the group B meningococcal vaccine, 100 percent of infants developed SBA titers &ge;5 against strains selective for factor H binding protein and neisserial adhesin A, and 84 percent developed SBA titers &ge;5 against New Zealand outer membrane vesicle and Neisseria",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    binding antigen. At 12 months of age, waning titers were boosted by a fourth dose of vaccine, resulting in SBA titers &ge;5 for all antigens one month after the booster dose. Immune responses to routine childhood vaccines were similar regardless of whether meningococcal vaccination was administered concurrently, but reactogenicity was higher among infants who received the routine vaccines in combination with the group B meningococcal vaccine. Among infants who received the routine vaccines plus the group B meningococcal vaccine, 77 percent had a fever &ge;38.5, compared with 47 percent among those who received routine vaccines plus the group C meningococcal vaccine and 45 percent among those who received routine vaccines alone.",
"   </p>",
"   <p>",
"    The efficacy of the vaccine will not be known until vaccination programs have been implemented in countries where meningococcus serogroup B infection is common, such as the United Kingdom.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COUNTRY-SPECIFIC VACCINATION GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varying policies have been adopted in different countries based in part upon local attack rates of illness, available resources, and interpretation of the data on vaccine effectiveness and cost-effectiveness.",
"   </p>",
"   <p>",
"    Modeling studies have suggested that widespread vaccination programs could significantly reduce the incidence of disease and death from meningococcus, although they would be costly [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. The largest benefit may come from vaccinating toddlers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cost considerations may make widespread vaccination less feasible when the incidence of disease is low [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/75\">",
"     75",
"    </a>",
"    ]. However, as more experience with conjugate vaccination is gained, it is probable that recommendations for vaccination programs will alter in a number of parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/73,75\">",
"     73,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, either formulation of the quadrivalent meningococcal conjugate vaccine (Menactra or Menveo) is recommended for",
"    <strong>",
"     all",
"    </strong>",
"    individuals between 11 and 18 years of age, and for individuals between 19 and 55 years of age who are at increased risk for invasive meningococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/38,61,76,77\">",
"     38,61,76,77",
"    </a>",
"    ]. Menactra is recommended for children between 2 and 10 years of age who are at increased risk for invasive meningococcal disease. Adults greater than 55 years of age who require vaccination should receive the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"     meningococcal polysaccharide vaccine",
"    </a>",
"    (MPSV4, Menomune).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182642754\">",
"    <span class=\"h3\">",
"     In infants and toddlers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two meningococcal vaccines have been approved by the US Food and Drug Administration (FDA) and recommended by the Advisory Panel on Immunization Practices (ACIP) for infants and toddlers in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A",
"      <strong>",
"       combination conjugate vaccine against meningococcus serogroups C and Y and Haemophilus influenzae type B (MenHibrix, HibMenCY)",
"      </strong>",
"      was approved by the FDA in June 2012 for infants and toddlers aged 6 weeks to 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. In January 2013, the ACIP began recommending HibMenCY for certain infants and toddlers at increased risk for meningococcal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/78\">",
"       78",
"      </a>",
"      ]. The vaccination schedule is a four-dose series given at 2, 4, 6, and 12 to 15 months of age.",
"     </li>",
"     <li>",
"      A",
"      <strong>",
"       quadrivalent conjugate vaccine against meningococcus serogroups A, C, Y, and W135 (Menactra)",
"      </strong>",
"      was approved by the FDA in April 2011 for infants and children &ge;9 months of age, to be administered as a two-dose series at least eight weeks apart [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/79\">",
"       79",
"      </a>",
"      ]. In October 2011, the ACIP began recommending Menactra in children from 9 to 23 months of age who are at increased risk for meningococcal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The appropriate formulation depends on the age of the individual and on the indication for vaccination (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants with anatomic or functional asplenia (including sickle cell disease), we recommend a four-dose series of HibMenCY at 2, 4, 6, and 12 to 15 months of age.",
"     </li>",
"     <li>",
"      For infants and toddlers (aged 2 months through 18 months) with persistent complement pathway deficiency (properdin, Factor D, Factor H, and late complement components [C5 through C9]), we recommend",
"      <strong>",
"       either",
"      </strong>",
"      a four-dose infant series of HibMenCY at 2, 4, 6, and 12 to 15 months of age, or a two-dose series of Menactra starting at 9 months of age, with at least eight weeks between doses.",
"     </li>",
"     <li>",
"      For toddlers aged 19 through 23 months with persistent complement component pathway deficiency who have not received a complete series of HibMenCY or Menactra, we recommend a two-dose series of Menactra given at least 8 weeks apart.",
"     </li>",
"     <li>",
"      If Menactra is administered to a child with asplenia (including sickle cell disease), Menactra should not be administered until two years of age and for at least four weeks after the completion of all pneumococcal conjugate vaccine doses. When administered together, Menactra may interfere with the protection conferred by the pneumococcal conjugate vaccine. Until the clinical significance of this finding has been clarified and because pneumococcal disease is a more significant threat than meningococcal disease to children with sickle cell disease or anatomic asplenia, the ACIP is",
"      <strong>",
"       not",
"      </strong>",
"      recommending Menactra for children between 9 and 23 months of age who have either of these conditions.",
"     </li>",
"     <li>",
"      For infants and toddlers &ge;9 months of age who are residents of or travelers to countries in the African meningitis belt or to the Hajj, we recommend an age-appropriate formulation of a quadrivalent meningococcal conjugate vaccine to provide protection against serogroups A and W-135. Prior receipt of Hib-MenCY is",
"      <strong>",
"       not",
"      </strong>",
"      sufficient for children traveling to the meningitis belt (eg, for the Hajj) (",
"      <a class=\"graphic graphic_figure graphicRef63287 \" href=\"UTD.htm?16/45/17110\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For infants and toddlers who are present during an outbreak caused by a vaccine serogroup, administer or complete an age- and formulation-appropriate series of HibMenCY or Menactra.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     In children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP and the American Academy of Pediatrics recommend immunization with a quadrivalent meningococcal conjugate vaccine for children aged 2 to 10 years who are at increased risk of disease and for",
"    <strong>",
"     all",
"    </strong>",
"    adolescents aged 11 to 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/24,38,76,81,82\">",
"     24,38,76,81,82",
"    </a>",
"    ]. In early 2011, the FDA approved Menveo for use in children between ages 2 and 10 years of age who have an indication for vaccination; Menveo had previously been approved only for individuals between the ages of 11 and 55 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/83\">",
"     83",
"    </a>",
"    ]. The specific schedule indicated depends upon age, host factors (ie, type of immunodeficiency), and prior history of vaccination; recommendations are presented in the Table (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In late 2010, the ACIP recommendations for meningococcal vaccination were modified to recommend that adolescents be vaccinated ideally at age 11 or 12, with a booster at age 16 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, a two-dose primary series two months apart was recommended in individuals with persistent complement component deficiency or functional or anatomic asplenia, as well as for adolescents with HIV infection. The rationale for the booster at age 16 is that immunogenicity data have suggested that adolescents who received a single dose of Menactra might not be protected for more than five years. Importantly, individuals who are immunized at age 11 or 12 years might have decreased protective immunity by ages 16 through 21 years, when their risk for disease is greatest.",
"   </p>",
"   <p>",
"    Children at increased risk for invasive meningococcal disease include travelers to regions in which meningococcal disease is hyperendemic or epidemic and those with complement component (properdin, Factor D, Factor H, and late complement components [C5 through C9]) deficiencies or anatomic or functional asplenia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/38,61,82,84,85\">",
"     38,61,82,84,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology of Neisseria meningitidis infection\", section on 'Complement deficiency and meningococcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     In adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP recommends vaccination with Menactra or Menveo for the following groups of adults &le;55 years of age; MPSV4 (Menomune), is preferred in those over age 55 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/17,24,61,77\">",
"     17,24,61,77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Military recruits.",
"     </li>",
"     <li>",
"      Microbiologists exposed to N. meningitidis.",
"     </li>",
"     <li>",
"      Individuals with functional or surgical asplenia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"       \"Prevention of sepsis in the asplenic patient\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Individuals with complement component (properdin, Factor D, Factor H, and late complement components [C5 through C9]) deficiencies [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link&amp;anchor=H11#H11\">",
"       \"Inherited disorders of the complement system\", section on 'C5-C9 deficiency'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology of Neisseria meningitidis infection\", section on 'Complement deficiency and meningococcemia'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Travelers or persons living in areas of the world where meningococcal infection is hyperendemic or epidemic (eg, the meningitis belt of sub-Saharan Africa during the dry season [December through June]), particularly if contact with local populations will be prolonged; vaccination is required for all travelers to Mecca, Saudi Arabia, during the annual Hajj [",
"      <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adults who were immunized with the polysaccharide vaccine within the past three to five years and remain at risk for meningococcal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the current outbreak of meningococcal disease (in the fall of 2012) in men who have sex with men (MSM) in New York City, we recommend meningococcal vaccination for MSM, especially if HIV-infected, if their residence, travel, or social interactions have put them (or will put them) in close contact with other MSM from New York City since September 1, 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Close contact includes kissing, sexual contact, sharing water bottles, sharing eating or drinking utensils, sharing cigarettes, or being within a three-foot distance for eight hours or more. The appropriate formulation depends upon the age of the patient (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 1",
"    </a>",
"    ). HIV-infected individuals should receive two doses, with the second dose administered eight weeks or more after the first dose, plus booster doses every five years.",
"   </p>",
"   <p>",
"    In late 2010, the ACIP recommendations were modified to recommend that a two-dose primary series two months apart be given to individuals with persistent complement component deficiency or functional or anatomic asplenia, as well as for adolescents with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/24\">",
"     24",
"    </a>",
"    ]. The schedules for the primary series and for revaccination are presented in the Table (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    While not cost-effective on a population basis, the ACIP notes that the vaccine is well-tolerated and could be administered to any college student upon request. In addition, persons infected with HIV who wish to decrease their risk for meningococcal disease may elect to receive vaccine, although the efficacy of the vaccine in this population is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaccination has also been used during outbreaks of meningococcal infection to reduce the number of secondary cases, when there is an appropriate vaccine available for the outbreak serogroup [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine vaccination is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for healthy adults between 20 and 55 years of age. The incidence of meningococcal disease is low in this age group and not affected by routine immunization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Revaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals who were previously vaccinated with either the quadrivalent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"     meningococcal polysaccharide vaccine",
"    </a>",
"    conjugated to diphtheria toxoid (Menactra or Menveo) or the meningococcal polysaccharide vaccine (Menomune, MPSV4) who remain at increased risk for meningococcal disease should be revaccinated. The specific schedule indicated depends upon age, host factors (ie, type of immunodeficiency), and prior history of vaccination; recommendations are presented in the Table (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/24,85\">",
"     24,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Groups at increased risk for meningococcal disease are discussed above. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'In children and adolescents'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'In adults'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some schools, colleges, and universities require meningococcal vaccination prior to enrollment. Individuals 21 years of age or younger should have documentation of receipt of a dose of a quadrivalent meningococcal conjugate vaccine &le;5 years prior to enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/24\">",
"     24",
"    </a>",
"    ]. If the primary dose was given before the 16",
"    <sup>",
"     th",
"    </sup>",
"    birthday, a booster dose should be administered before enrollment in college. The minimum interval between doses of quadrivalent meningococcal conjugate vaccine is eight weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     United Kingdom and the European Union",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United Kingdom established a program in November 1999 for vaccinating all infants with a conjugate serogroup C vaccine. The vaccine is administered on a three-dose schedule at two, three, and four months of age with a catch-up single dose vaccination for toddlers and adolescents up to the age of 18 years. Evidence of the induction of immunologic memory after a single dose of vaccine in children over the age of one year provided support for the catch-up program [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/87\">",
"     87",
"    </a>",
"    ]. As noted above, there is some concern about long-term efficacy in infants vaccinated at two, three, and four months unless they receive a booster [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the United Kingdom, vaccination against meningococcal serogroups A, C, W135, and Y is recommended for travelers to Mecca, Saudi Arabia, for the religious festivals of Hajj or Umrah [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In January 2013, the European Commission approved a meningococcal serogroup B vaccine (Bexsero) for use in individuals over two months of age in the European Union [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) has endorsed a surveillance strategy in sub-Saharan Africa to predict meningococcal epidemics early and initiate vaccination drives. One study from Mali showed that detection of 5 cases per 100,000 population in one week was an appropriate threshold for alerting officials that vaccination might be required, and 10 cases per 100,000 in one week confirmed regional epidemic activity with few false positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several countries initiated mass serogroup C vaccination campaigns in specific areas with an increased incidence of infection. One such drive in Quebec, Canada, produced a reduction in serogroup C infection from 1.4 per 100,000 population in the years 1990 to 1992 to 0.3 per 100,000 in 1993 to 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/90\">",
"     90",
"    </a>",
"    ]. A shift in infection with other serogroups was not observed. The vaccine used was a polysaccharide vaccine, and as expected, vaccination was ineffective in children under the age of two years. A similar mass vaccination program in Catalonia, Spain resulted in a 68 percent decrease in cases two years after vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/32/23050/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"       \"Patient information: Vaccines for adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18547?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=see_link\">",
"       \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neisseria meningitidis can cause both endemic and epidemic infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several different meningococcal vaccines available in the United States:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"       meningococcal polysaccharide vaccine",
"      </a>",
"      (Menomune, MPSV4) has been available in the United States for several decades.",
"     </li>",
"     <li>",
"      A quadrivalent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"       meningococcal polysaccharide vaccine",
"      </a>",
"      conjugated to diphtheria toxoid (Menactra) became available in 2005.",
"     </li>",
"     <li>",
"      Another quadrivalent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"       meningococcal polysaccharide vaccine",
"      </a>",
"      conjugated to a mutant diphtheria toxin, CRM197 (Menveo), was approved in 2010.",
"     </li>",
"     <li>",
"      A combination vaccine against meningococcus serogroups C and Y and Haemophilus influenzae type b (MenHibrix) was approved in 2012 for infants and children aged 6 weeks to 18 months. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Available vaccines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, we recommend meningococcal vaccination for infants and children from 2 months to 10 years of age who are at increased risk for meningococcal disease. The specific schedule indicated depends upon age, host factors (ie, type of immunodeficiency), and prior history of vaccination; recommendations are presented in the Table (",
"      <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H182642754\">",
"       'In infants and toddlers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'In children and adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, we recommend either formulation of the quadrivalent meningococcal conjugate vaccine (Menactra or Menveo) for",
"      <strong>",
"       all",
"      </strong>",
"      individuals between 11 and 18 years of age, for individuals between 2 and 10 years of age who are at increased risk for invasive meningococcal disease, and for individuals between 19 and 55 years of age who are at increased risk for invasive meningococcal disease (",
"      <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'In children and adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults greater than 55 years of age in the United States who require vaccination, we recommend the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38965?source=see_link\">",
"       meningococcal polysaccharide vaccine",
"      </a>",
"      (MPSV4, Menomune) (",
"      <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'United States'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, individuals who remain at increased risk for meningococcal disease require revaccination; the schedule for revaccination depends upon age, host factors (ie, type of immunodeficiency), and prior vaccination history (",
"      <a class=\"graphic graphic_table graphicRef71265 \" href=\"UTD.htm?9/48/9999\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Revaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United Kingdom, all infants are vaccinated with the conjugate serogroup C vaccine. In November 2012, the European Medicines Agency approved a meningococcal serogroup B vaccine (Bexsero) for use in individuals over two months of age in the European Union. (See",
"      <a class=\"local\" href=\"#H454501268\">",
"       'Group B meningococcus vaccines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'United Kingdom and the European Union'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The World Health Organization has endorsed a surveillance strategy in sub-Saharan Africa to predict meningococcal epidemics early and initiate vaccination drives. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Other countries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several countries, including Canada and Spain, have initiated mass serogroup C vaccination campaigns in specific areas with an increased incidence of infection, which have resulted in a reduction in the incidence of meningococcal disease. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Other countries'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/1\">",
"      Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50 Suppl 2:S37.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report: Neisseria meningitidis, 2009. file://www.cdc.gov/abcs/reports-findings/survreports/mening09.html (Accessed on April 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/3\">",
"      Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/4\">",
"      Harrison LH, Pass MA, Mendelsohn AB, et al. Invasive meningococcal disease in adolescents and young adults. JAMA 2001; 286:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/5\">",
"      Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college students. JAMA 1999; 281:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/6\">",
"      Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in college students. JAMA 2001; 286:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/7\">",
"      Nelson SJ, Charlett A, Orr HJ, et al. Risk factors for meningococcal disease in university halls of residence. Epidemiol Infect 2001; 126:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/8\">",
"      Bhatt KM, Bhatt SM, Mirza NB. Meningococcal meningitis. East Afr Med J 1996; 73:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/9\">",
"      Hart CA, Cuevas LE. Meningococcal disease in Africa. Ann Trop Med Parasitol 1997; 91:777.",
"     </a>",
"    </li>",
"    <li>",
"     New York State Department of Health. New York State Department of Health expands vaccination recommendation in response to meningococcal disease outbreak among high risk HIV positive men in New York City. file://www.health.ny.gov/press/releases/2012/2012-10-05_meningitis.htm (Accessed on October 26, 2012).",
"    </li>",
"    <li>",
"     Commonwealth of Masschusetts Department of Public Health. Health Advisory: Meningococcal vaccine recommendations for men who have sex with men. October 25, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: serogroup C invasive meningococcal disease among men who have sex with men - New York City, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 61:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/13\">",
"      Ramsay M, Kaczmarski E, Rush M, et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev 1997; 7:R49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/14\">",
"      Kaczmarski EB. Meningococcal disease in England and Wales: 1995. Commun Dis Rep CDR Rev 1997; 7:R55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia--United States, 2000. MMWR Morb Mortal Wkly Rep 2000; 49:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/16\">",
"      Menactra: a meningococcal conjugate vaccine. Med Lett Drugs Ther 2005; 47:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:273.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. News &amp; Events. FDA approves new combination vaccine that protects children against two bacterial diseases. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308350.htm?utm_campaign=Google2&amp;utm_source=fdaSearch&amp;utm_medium=website&amp;utm_term=Menhibrix&amp;utm_content=1 (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     GSK receives FDA approval for MenHibrix. file://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1134059.htm (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     Novartis media releases. Novartis receives EU approval for Bexsero, first vaccine to prevent the leading cause of life-threatening meningitis across Europe. file://www.novartis.com/newsroom/media-releases/en/2013/1672036.shtml (Accessed on January 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/21\">",
"      Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Product approval information-licensing action, package insert: Meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine Menactra&reg;. Sanofi Pasteur. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005 www.fda.gov/cber/label/menactralb.pdf (Accessed on May 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/23\">",
"      Vu DM, Welsch JA, Zuno-Mitchell P, et al. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006; 193:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011; 60:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/25\">",
"      Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005; 24:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/26\">",
"      Pichichero M, Papa T, Blatter M, et al. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2006; 25:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/27\">",
"      Rennels M, King J Jr, Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/28\">",
"      Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/29\">",
"      Klein NP, Reisinger KS, Johnston W, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012; 31:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/30\">",
"      Halperin SA, Gupta A, Jeanfreau R, et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:7865.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Product approval information: package insert. Menveo (Meningococcal [Groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine). file://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201349.pdf (Accessed on May 25, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/32\">",
"      Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009; 28:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/33\">",
"      Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/34\">",
"      Macneil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J 2011; 30:451.",
"     </a>",
"    </li>",
"    <li>",
"     FDA News. FDA and CDC issue alert on Menactra meningococcal vaccine and Guillain Barre Syndrome. September 30, 2005. www.fda.gov/bbs/topics/NEWS/2005/NEW01238.html (Accessed on May 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/36\">",
"      Centers for Disease Control and Prevention (CDC). Guillain-Barr&eacute; syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Update: Guillain-Barr&eacute; syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep 2006; 55:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/38\">",
"      Centers for Disease Control and Prevention (CDC). Notice to readers: Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2--10 years at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2007; 56:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Inadvertent misadministration of meningococcal conjugate vaccine--United States, June-August 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/40\">",
"      MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. JAMA 2000; 283:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/41\">",
"      Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010; 50:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/42\">",
"      Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008; 336:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/43\">",
"      McIntyre PB, O'Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet 2012; 380:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/44\">",
"      Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/45\">",
"      Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/46\">",
"      Offit PA, Peter G. Meningococcal conjugate vaccine in the UK: an update. Lancet 2004; 364:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/47\">",
"      Maiden MC, Ibarz-Pav&oacute;n AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/48\">",
"      Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/49\">",
"      De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004; 292:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/50\">",
"      De Wals P, Deceuninck G, Lefebvre B, et al. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 2011; 30:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/51\">",
"      Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006; 194:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/52\">",
"      Bryant KA, Marshall GS. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev Vaccines 2011; 10:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/53\">",
"      Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010; 29:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/54\">",
"      Marshall GS, Marchant CD, Blatter M, et al. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States. Hum Vaccin 2011; 7:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/55\">",
"      Bryant K, McVernon J, Marchant C, et al. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials. Hum Vaccin Immunother 2012; 8:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/56\">",
"      Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics 2011; 127:e1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/57\">",
"      Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011; 364:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/58\">",
"      Centers for Disease Control and Prevention (CDC). Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/59\">",
"      Kristiansen PA, Diomand&eacute; F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013; 56:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/60\">",
"      Novak RT, Kambou JL, Diomand&eacute; FV, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012; 12:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/61\">",
"      Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/62\">",
"      Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/63\">",
"      Ball R, Braun MM, Mootrey GT, Vaccine Adverse Event Reporting System Working Group. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System. Clin Infect Dis 2001; 32:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/64\">",
"      Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010; 50 Suppl 2:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/65\">",
"      Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/66\">",
"      Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/67\">",
"      Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010; 10:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/68\">",
"      O'Hallahan J, McNicholas A, Galloway Y, et al. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 2009; 122:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/69\">",
"      Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/70\">",
"      Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/71\">",
"      Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/72\">",
"      Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/73\">",
"      Lingappa JR, Rosenstein N, Zell ER, et al. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine 2001; 19:4566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/74\">",
"      Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis 2008; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/75\">",
"      Skull SA, Butler JR, Robinson P, Carnie J. Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation. Int J Epidemiol 2001; 30:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/76\">",
"      Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine. MMWR Morb Mortal Wkly Rep 2007; 56:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/77\">",
"      ACIP Adult Immunization Work Group, Bridges CB, Woods L, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/78\">",
"      Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration news release. FDA approves the first vaccine to prevent meningococcal disease in infants and toddlers. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm252392.htm (Accessed on April 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/80\">",
"      Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011; 60:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/81\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/82\">",
"      Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics 2011; 128:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/83\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/84\">",
"      Morgan BP, Orren A. Vaccination against meningococcus in complement-deficient individuals. Clin Exp Immunol 1998; 114:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/85\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009; 58:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/86\">",
"      Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/87\">",
"      Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160.",
"     </a>",
"    </li>",
"    <li>",
"     Health Protection Agency. Vaccination for meningococcal disease. file://www.hpa.org.uk/web/HPAweb&amp;HPAwebStandard/HPAweb_C/1296682977081 (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/89\">",
"      Lewis R, Nathan N, Diarra L, et al. Timely detection of meningococcal meningitis epidemics in Africa. Lancet 2001; 358:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/90\">",
"      De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/32/23050/abstract/91\">",
"      Salleras L, Dom&iacute;nguez A, Prats G, et al. Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people. J Epidemiol Community Health 2001; 55:283.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3901 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23050=[""].join("\n");
var outline_f22_32_23050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AVAILABLE VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONJUGATE VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Quadrivalent conjugate vaccines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14308778\">",
"      Menactra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14308785\">",
"      Menveo",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Possible association with Guillain-Barr&eacute; syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dose and route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serogroup C conjugate vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dose and route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H937132\">",
"      Combination conjugate vaccine against meningococcus and Haemophilus influenzae type b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182642906\">",
"      Serogroup A conjugate vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POLYSACCHARIDE VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Immunogenicity and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dose and route",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H454501268\">",
"      GROUP B MENINGOCOCCUS VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COUNTRY-SPECIFIC VACCINATION GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182642754\">",
"      - In infants and toddlers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - In children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - In adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Revaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      United Kingdom and the European Union",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3901\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3901|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/51/26429\" title=\"figure 1\">",
"      US meningococcal disease incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/45/17110\" title=\"figure 2\">",
"      Meningitis belt map",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3901|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9999\" title=\"table 1\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=related_link\">",
"      Diagnosis of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=related_link\">",
"      Epidemiology of Neisseria meningitidis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=related_link\">",
"      Microbiology and pathobiology of Neisseria meningitidis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=related_link\">",
"      Overview of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/18/37156?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18547?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=related_link\">",
"      Treatment of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_32_23051="Modified Rankin scale";
var content_f22_32_23051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Rankin scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        No symptoms at all",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        No significant disability despite symptoms; able to carry out all usual duties and activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Moderate disability; requiring some help, but able to walk without assistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        Severe disability; bedridden, incontinent and requiring constant nursing care and attention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"       <td>",
"        Dead",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Van Swieten JC, Koudstaa PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19:604. Copyright &copy; 1988 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23051=[""].join("\n");
var outline_f22_32_23051=null;
var title_f22_32_23052="Expanded criteria kidney donor condition and age";
var content_f22_32_23052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expanded criteria kidney donor condition and age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Donor condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        &lt;10",
"       </td>",
"       <td class=\"subtitle1\">",
"        10-39",
"       </td>",
"       <td class=\"subtitle1\">",
"        40-49",
"       </td>",
"       <td class=\"subtitle1\">",
"        50-59",
"       </td>",
"       <td class=\"subtitle1\">",
"        &ge;60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CVA + HTN + Creat &gt;1.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CVA + HTN",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CVA + Creat &gt;1.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HTN + Creat &gt;1.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CVA",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HTN",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creat &gt;1.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None of the above",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     X: Expanded Criteria Donor; CVA: CVA was cause of death; HTN: history of hypertension at any time; Creat &gt; 1.5: creatinine &gt;1.5 mg/dL (133 &micro;mol/L).",
"    </div>",
"    <div class=\"reference\">",
"     UNOS Allocation of Deceased Kidneys Policy, 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23052=[""].join("\n");
var outline_f22_32_23052=null;
var title_f22_32_23053="Tx guidelines comorbidities";
var content_f22_32_23053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment regimen based on clinical practice guidelines for a hypothetical 79-year-old woman with hypertension, diabetes mellitus, osteoporosis, osteoarthritis, and COPD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medications*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7:00 AM",
"       </td>",
"       <td>",
"        <p>",
"         Ipratropium metered dose inhaler",
"        </p>",
"        <p>",
"         70 mg/wk of alendronate",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Check feet",
"        </p>",
"        <p>",
"         Sit upright for 30 min on day when alendronate is taken",
"        </p>",
"        <p>",
"         Check blood sugar",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        8:00 AM",
"       </td>",
"       <td>",
"        <p>",
"         500 mg of calcium and 200 IU of vitamin D",
"        </p>",
"        <p>",
"         12.5 mg of hydrochlorothiazide",
"        </p>",
"        <p>",
"         40 mg of lisinopril",
"        </p>",
"        <p>",
"         10 mg of glyburide",
"        </p>",
"        <p>",
"         81 mg of aspirin",
"        </p>",
"        <p>",
"         850 mg of metformin",
"        </p>",
"        <p>",
"         250 mg of naproxen",
"        </p>",
"        <p>",
"         20 mg of omeprazole",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Eat breakfast",
"        </p>",
"        <p>",
"         2.4 g/d of sodium",
"        </p>",
"        <p>",
"         90 mmol/d of potassium",
"        </p>",
"        <p>",
"         Low intake of dietary saturated fat and cholesterol",
"        </p>",
"        <p>",
"         Adequate intake of magnesium and calcium",
"        </p>",
"        <p>",
"         Medical nutrition therapy for diabetes",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         DASH",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        12:00 PM",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Eat lunch",
"        </p>",
"        <p>",
"         2.4 g/d of sodium",
"        </p>",
"        <p>",
"         90 mmol/d of potassium",
"        </p>",
"        <p>",
"         Low intake of dietary saturated fat and cholesterol",
"        </p>",
"        <p>",
"         Adequate intake of magnesium and calcium",
"        </p>",
"        <p>",
"         Medical nutrition therapy for diabetes",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         DASH",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        1:00 PM",
"       </td>",
"       <td>",
"        <p>",
"         Ipratropium metered dose inhaler",
"        </p>",
"        <p>",
"         500 mg of calcium and 200 IU of vitamin D",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        7:00 PM",
"       </td>",
"       <td>",
"        <p>",
"         Ipratropium metered dose inhaler",
"        </p>",
"        <p>",
"         850 mg of metformin",
"        </p>",
"        <p>",
"         500 mg of calcium and 200 IU of vitamin D",
"        </p>",
"        <p>",
"         40 mg of lovastatin",
"        </p>",
"        <p>",
"         250 mg of naproxen",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Eat dinner",
"        </p>",
"        <p>",
"         2.4 g/d of sodium",
"        </p>",
"        <p>",
"         90 mmol/d of potassium",
"        </p>",
"        <p>",
"         Low intake of dietary saturated fat and cholesterol",
"        </p>",
"        <p>",
"         Adequate intake of magnesium and calcium",
"        </p>",
"        <p>",
"         Medical nutrition therapy for diabetes",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         DASH",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        11:00 PM",
"       </td>",
"       <td>",
"        Ipratropium metered dose inhaler",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        As needed",
"       </td>",
"       <td>",
"        Albuterol metered dose inhaler",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADA: American Diabetes Association; COPD: chronic obstructive pulmonary disease; DASH: Dietary Approaches to Stop Hypertension.",
"     <br>",
"      * Taken orally unless otherwise indicated. The medication complexity score of the regimen for this hypothetical woman is 14, with 19 doses of medications per day, assuming 2 as needed doses of albuterol metered dose inhaler plus 70 mg/wk of alendronate.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       DASH and ADA dietary guidelines may be synthesized, but the help of a registered dietitian is specifically recommended. Eat foods containing carbohydrate from whole grains, fruits, vegetables, and low-fat milk. Avoid protein intake of more than 20 percent of total daily energy; lower protein intake to about 10 percent of daily calories if overt nephropathy is present. Limit intake of saturated fat (&lt;10 percent of total daily energy) and dietary cholesterol (&lt;200 to 300 mg). Limit intake of",
"       <em>",
"        trans",
"       </em>",
"       unsaturated fatty acids. Eat two to three servings of fish per week. Intake of polyunsaturated fat should be about 10 percent of total daily energy.",
"       <br/>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: Implications for pay for performance. JAMA 2005; 294:716. Copyright &copy; 2005 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23053=[""].join("\n");
var outline_f22_32_23053=null;
var title_f22_32_23054="Drugs for ADHD";
var content_f22_32_23054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs for ADHD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Duration of action",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Adult dosage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Typical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Stimulants*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Dexmethylphenidate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Focalin (Novartis)",
"       </td>",
"       <td>",
"        5-6 h",
"       </td>",
"       <td>",
"        5 mg AM",
"       </td>",
"       <td>",
"        20 mg AM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Focalin XR&bull;",
"       </td>",
"       <td>",
"        12 h",
"       </td>",
"       <td>",
"        5 mg AM",
"       </td>",
"       <td>",
"        20 mg AM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Methylphenidate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Short-acting",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        3-5 h",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        10 mg bid",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        20 mg tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Generic",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Ritalin (Novartis)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Methylin (Mallinckrodt)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Methylin chewable tablets (Alliant)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Methylin oral solution (Alliant)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Intermediate-acting",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        3-8 h",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Generic",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        20 mg AM",
"       </td>",
"       <td class=\"sublist_other\">",
"        80 mg AM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Ritalin SR (Novartis)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Metadate ER (Celltech)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        10 mg bid",
"       </td>",
"       <td class=\"sublist_other\">",
"        80 mg AM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Methylin ER (Mallinckrodt)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Long-acting",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        8-12 h",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Metadate CD (Celltech)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        20 mg AM",
"       </td>",
"       <td class=\"sublist_other\">",
"        80 mg AM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Ritalin LA&bull; (Novartis)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        10 mg AM",
"       </td>",
"       <td class=\"sublist_other\">",
"        80 mg AM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Concerta (Alza)",
"       </td>",
"       <td class=\"sublist_other\">",
"        10-12 h",
"       </td>",
"       <td class=\"sublist_other\">",
"        18 mg AM",
"       </td>",
"       <td class=\"sublist_other\">",
"        72 mg AM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Daytrana (Noven/Shire)",
"       </td>",
"       <td class=\"sublist_other\">",
"        10-12 h",
"       </td>",
"       <td class=\"sublist_other\">",
"        10 mg patch on 9 h, off 15 h",
"       </td>",
"       <td class=\"sublist_other\">",
"        60 mg patch on 9 h, off 15 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Dextroamphetamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Short-acting",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        4-6 h",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        5 mg bid",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        15 mg bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Generic&bull;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Dextrostat&bull; (Shire)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Dexedrine&bull; (GSK)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Long-acting",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        6-8 h",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        5 mg AM",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        30 mg AM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Generic&bull;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Dexedrine spansules&bull; (GSK)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Amphetamine mixed salts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Short-acting",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        4-6 h",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        5 mg bid",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        15 mg bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Generic&bull;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Adderall&bull; (Shire)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        5 mg bid",
"       </td>",
"       <td class=\"sublist_other\">",
"        10 mg bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Long-acting",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        8-10 h",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Adderall XR&bull; (Shire)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        5 mg AM",
"       </td>",
"       <td class=\"sublist_other\">",
"        60 mg AM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Non-stimulants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Atomoxetine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Strattera (Lilly)",
"       </td>",
"       <td>",
"        24 h",
"       </td>",
"       <td>",
"        40 mg once",
"       </td>",
"       <td>",
"        80 mg once or divided bid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All are classified by the DEA as Schedule II controlled substances.",
"     <br>",
"      &bull; Should not be taken with antacids or other drugs that decrease gastric acidity.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Treatment guidelines from The Medical Letter. 2006; 4:77. Copyright &copy;2006 The Medical Letter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23054=[""].join("\n");
var outline_f22_32_23054=null;
var title_f22_32_23055="Unicornuate uter and xtra hornC";
var content_f22_32_23055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unicornuate uterus with noncommunicating uterine horn (containing an endometrial cavity) fused to unicornuate uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_32_23055=[""].join("\n");
var outline_f22_32_23055=null;
